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Summary 
 
The global number of obese people has reached pandemic proportions. High caloric diets and 
reduced physical exercise are to blame for this growing epidemic. Obesity has a very complex 
association with several other metabolic disorders, such as insulin resistance (IR), diabetes 
mellitus type 2 (DMT2) and cardiovascular disease. This puts a huge burden on health care 
systems world wide and claims many lives. Sutherlandia frutescens is a traditionally used 
herb, which is known to have anti-diabetic properties. However, the direct mode of action of 
S. frutescens still remains to be elucidated.  
 
The aim of this study was to investigate the developmental stages of high fat diet (HFD)-
induced IR, to illuminate the pathogenesis of IR with a focal point on modifications in the 
lipid metabolism. Furthermore, the effects of S. frutescens as a treatment or prevention drug 
for IR and associated metabolic changes were examined. 
 
Two sets of experiments were conducted on male Wistar rats. In the first experiment rats, one 
week post weaning received a low fat diet (LFD), high fat diet (HFD) or HFD supplemented 
with S. frutescens (50mg/kg BW/d). Rats were sacrificed at week 0, 1, 2, 4, 8 and 12 in the 
feeding regime. In a second experiment rats were fed with a LFD or a HFD for 12 weeks and 
treated thereafter with S. frutescens (50mg/kg BW/d), metformin (13mg/kg BW/d) or water 
(control) for 28 days. Rats in the second experiment were sacrificed at week 12 to confirm IR 
while concurrently run rats were sacrificed after 28 days of treatment. For all the experiments 
rats were anaesthetized, blood was removed and rats were dissected. Plasma samples were 
analyzed for insulin, glucose, blood lipid parameters and cytokines. Liver, muscle and adipose 
tissue were analyzed for glucose uptake, total lipid content, lipid profile and fatty acid profile.  
 
It was shown that the intake of HFD caused IR and hyperinsulinaemia. The developmental 
stages in experiment one confirmed that an increase in plasma free fatty acids preceeded the 
onset of IR. Plasma and tissue lipid parameters (free fatty acid-, triglyceride- and cholesterol 
concentrations) showed pathological modifications in the HFD group. An ectopic 
accumulation of fat was observed in muscle and liver, as well as a change in membrane fatty 
acid profile. The results for circulating cytokines were somewhat inconclusive. Rats 
 XII 
supplemented with S. frutescens did not develop HFD-induced IR (study one) or IR was 
reversed (study two). S. frutescens treatment also resulted in positive changes in plasma and 
tissue lipid parameters.  
 
In summary, an animal model for HFD-induced IR was established and the detrimental effect 
of elevated plasma FFA on glucose and lipid metabolism was observed. A novel discovery 
suggests that the anti-diabetic mode of action of S. frutescens is through modulation of lipid 
metabolism. It was also established that S. frutescens has the potential to prevent IR in vivo.   
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Chapter 1 
 
Review of Literature 
 - 2 - 
1.1. Epidemiology of obesity, insulin resistance & diabetes mellitus type 2 
 
1.1.1. Introduction & definitions 
 
The global health care system is burdened by the pandemic of obesity, insulin resistance and 
their associated diseases. It has been estimated that the direct medical costs of obesity in the 
US were more than $92 billion in 2002 [1].  
Obesity is generally defined as excess body fat, however the definition of “excess” is not 
clear-cut and it is difficult to measure the exact amount of body fat in human patients [2].  
Therefore, the level of human body fatness is commonly described by the body mass index 
(BMI), which is calculated by dividing the body weight (kg) by the square of height (m2). The 
BMI has been found to correlate well with the amount of total body fat [3,4]. Different 
categories for body mass have been proposed (table 1.1).  
 
Table 1.1: Categories of obesity in adults (reviewed in [2-4]) 
BMI 18.5-25 kg/m2 normal weight 
BMI 25-30 kg/m2 overweight 
BMI 30-40 kg/m2 obese 
BMI 40-50 kg/m2 morbidly obese 
BMI >50 kg/m2 extremely obese 
 
 
The association of obesity and insulin resistance can be observed in all ethnic groups and all 
categories of obesity. Insulin resistance (IR) is defined as the decreased effect of insulin on 
glucose uptake, metabolism and storage [5]. 
 
Diabetes mellitus type 2 (DMT2), accounts for 90–95% of all cases of adult diabetes, and is 
also known as non-insulin dependent diabetes or adult-onset diabetes. DMT2 refers to 
individuals who display IR and insulin levels that are either normal or elevated but are 
insufficient to compensate for the IR, thus resulting in high blood glucose levels [5]. In late 
stages of DMT2 the pancreas fails to secrete the insulin needed and blood insulin levels drop 
below normal [3].  
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1.1.2. Prevalence of obesity, insulin resistance & diabetes mellitus type 2 
 
In the US one in three adults are obese [6]. There has been a huge increase in the prevalence of 
adult obesity, especially since 1980 (table 1.2). In the period from 1980 to 2004 the 
prevalence of obese adults has more than doubled and the number of adults with a BMI 
>40kg/m2 has increased 3.6 fold. Similar trends have been also observed among children and 
adolescents (2-19 years old) [2]. Due to the ongoing pandemic of obesity and related 
metabolic disorders, the average US life expectancy is predicted to plateau or even drop in the 
first half of this century [7]. 
 
Table 1.2: Prevalence of overweight and obesity among adults ages 20–74 years in the US 1960–2004  
          (reviewed in [2]) 
Survey year 
Overweight  
(BMI 25-30kg/m2) 
Obese  
(BMI  30-40 kg/m2) 
Extremely or morbidly obese  
(BMI >40kg/m2) 
 % % % 
1960–1962 31.5 13.3 0.9 
1971–1974 32.7 14.5 1.3 
1976–1980 32.1 15 1.4 
1988–1994 32.6 23.2 3.0 
1999–2000 33.6 30.9 5.0 
2001–2002 34.4 31.3 5.4 
2003–2004 33.4 32.9 5.1 
 
However, the United States is only one of many countries in the world where obesity has risen 
in the last decades. Developed and developing countries experience the same problem. The 
WHO’s latest projections from 2005 indicate that globally approximately 1.6 billion adults 
(age 15 years and older) were overweight and at least 400 million adults were obese. 
Staggeringly, globally at least 20 million children under the age of 5 years were overweight in 
2005. The WHO further predicts that by 2015, approximately 2.3 billion adults will be 
overweight and more than 700 million will be obese [8].  
 
There is very little information on the prevalence of IR in the population. Generally, IR is 
associated with an increased BMI, therefore most overweight and obese individuals display IR 
to varying degrees. However, it is also known that lean individuals can present with IR, and on 
the other hand, some obese patients have normal insulin sensitivity [9]. A study on 888 normal 
weight and obese subjects found that 85% of individuals with a metabolic condition (DMT2, 
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hypertriglyceridaemia or low HDL-cholesterol) also displayed IR. Among overweight subjects 
with no other metabolic disorders, approximately 40% were insulin resistant. Interestingly, 
5.1% of the general population consisted of normal-weight subjects who had no metabolic 
disorders but showed insulin resistance [10].  
 
The WHO projection of the global diabetes prevalence was 171 million in 2000. The 
estimation for the year 2030 predicts a doubling of this number to 366 million [11].   
 
 
1.1.3. Prevalence of diabetes and diabetes management in South Africa 
 
The WHO predicts an increase in the prevalence of diabetes from 0.81 million in 2000 to 1.3 
million cases in 2030 in South Africa [11]. South African females in the age groups 45-54 and 
65-100 show much higher prevalence for diabetes than males of the same age group. This 
trend is very likely associated with the higher mean BMI observed in females of all age groups 
compared to males (figure 1.1 a,b).  
 
 
Figure 1.1: Mean body mass index (a.) and prevalence of diabetes mellitus (b.) in the rural black population in 
South Africa. Data from demographic health survey 1998. [12] 
 
Another survey conducted in rural clinics found that about 75% of the treated diabetes 
patients were female.  Half of the patients reporting to the clinic knew that weight, nutrition 
and physical activity have an influence on their diabetes mellitus. However, only 18% of the 
patients had a fasting blood glucose level ≤7mmol/l, the target for good control. This poor 
diabetes management appears to be due to  
1. a lack of knowledge regarding the disease;  
2. inadequate and inaccurate dietary counselling; and  
a
 
b
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3. poor compliance with dietary advice given.  
Difficulties in the implementation of nutritional therapy for South African patients arise due to 
prescripted diet not relating to the patients cultural, environmental and economic situation. 
Also patients with a low level of school education show the worst diabetes management. 
[13,14] 
Traditional treatments and the use of medicinal plants and herbs are still prevalent in South 
Africa, especially in remote and rural areas, where access to clinics and pharmacies is 
difficult.   
 
 
1.2. A detrimental causal chain – from high fat diet to diabetes 
 
1.2.1. Disaster in the making – living on high fat diet and its consequences  
 
The dietary recommendation for fat intake is 30 kcal% or less, with less than 10 kcal% 
deriving from saturated fatty acids (SFA). Compared to the recommended intake of 10% or 
less from saturated fat, young people with diabetes reported intakes of about 13% saturated fat 
(reviewed in [15]). 
 
Several studies on animals have observed that prolonged excessive intake of almost any kind 
of fat results in obesity and IR. Saturated (lard, butter), monounsaturated (olive oil) or 
polyunsaturated (safflower oil) high fat diets (HFD) lead to the same detrimental effects in 
vivo [16,17]. Diets rich in trans fatty acids also have been shown to cause obesity and IR in 
humans and rodents [18,19]. Only high fat diets rich in omega-3 poly-unsaturated fatty acids 
(n3-PUFA) have been found to have beneficial metabolic effects [20-22]. Interestingly, a 
study comparing iso-caloric diets found that whilst a Western-style diet (high fat 40kcal%, 
animal protein) resulted in insulin resistance, an Asian-style diet (low fat 10kcal%, plant 
protein) did not [23].   
 
The human body has a genetically built-in weight set-point, which is tightly regulated by an 
energetic homeostatic mechanism [3,24]. Insulin, secreted from pancreatic β-cells, and leptin, 
secreted from adipocytes, are both released in proportion to the total body fat content. With 
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increased adipose mass, insulin and leptin bind to receptors in the hypothalamus to induce the 
reduction of body weight. The resulting anorexic pathway leads to increased energy 
expenditure and thermogenesis, as well as diminished appetite. In a state of low body weight 
(low adipose tissue mass) the decrease in insulin and leptin levels results in activation of the 
orexic pathway with low metabolic rate and enhanced appetite. Other factors secreted by the 
gastrointestinal tract, for example ghrelin, motilin and cholecystokinin (CCK), can also exert 
short term regulation of the food intake [3,24]. However, this theoretical mechanism to keep a 
set body weight does not function fully in reality. The theory of a “thrifty genotype”, in which 
alleles for weight gain and fat storage were selectively passed to the next generation, might 
explain the higher incidences of obesity seen worldwide due to constant food availability and 
sedentary lifestyles [3]. Studies with identical twins suggest that inheritance accounts for up to 
70% and environmental factors (diet, physical inactivity) account for the rest of the variation 
in body weight [25]. 
 
 
1.2.2. Insulin resistance - a multifaceted disease  
 
The exact causal chain by which a high fat diet leads to obesity and IR is still not fully 
understood. However, it has become increasingly clear in recent years that IR does not only 
occur in obese individuals, but can also develop before, or synchronously with obesity [26]. 
The metabolic changes during the development of HFD-induced IR are complex and many 
different factors and tissues are involved in the pathogenesis. This section will address 
important key factors and events responsible for HFD-induced obesity and IR.  
In recent years the focus of research has shifted from a “glyco-centric” to a “lipo-centric” 
approach to try to understand the complete pathogenesis of IR and the metabolic syndrome. 
The involvement of the adipose tissue, plasma free fatty acids (FFA) and ectopic fat stores has 
been increasingly emphasized [27].  
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1.2.2.1. The effects of high fat diet on the development of insulin resistance 
 
After the ingestion of a high fat meal, fatty acids (FA) are absorbed into the mucosal epithelial 
cells of the small intestine, where they are reassembled to triglycerides (TG) and incorporated 
together with cholesterol into chylomicrons for release via the lymph into venous blood [28]. 
Lipoprotein lipase (LPL), an enzyme located in the capillary beds of adipose tissue and 
skeletal muscle, hydrolyses the TG in the circulating chylomicrons. The resulting FFA are 
taken up by the tissues and used for storage (adipose tissue) or energy production (muscle) 
[29]. However, it has been found that not all of the FFA are taken up. Some remain in the 
plasma, where they significantly contribute to increased postprandial and fasting FFA levels 
[30,31]. This leads to the exposure of non-adipose tissue to FFA. Additionally, circulating TG 
can also be directly extracted into non-adipose tissues, such as skeletal muscle, heart and liver, 
contributing to increased exposure of these tissues to FFA [30].     
The caloric overload and high availability of FFA leads to an increased TG storage in the 
adipocytes. In the early stages of caloric excess, adipocytes continue to store TG in the 
postprandial state and display normal lipolysis during the fasting state, while the muscle tissue 
still remains insulin sensitive (figure1.2 a). However, as the adipocyte size increases (figure 
1.2 b), more monocyte chemoattractant protein-1 (MCP-1) is secreted by the adipose tissue, 
which in turn leads to macrophage infiltration [32] (figure 1.2 c,d). As observed in obese 
patients, macrophage numbers can contribute up to 50% of the total cell numbers in the 
adipose tissue [33]. Together adipocytes and macrophages secrete several pro-inflammatory 
cytokines (e.g. TNF-α, IL-1β), which in turn increase the lipolysis in the adipose tissue (figure 
1.2 d). With further increased FFA levels in the blood, non-adipose tissues (e.g. muscle, liver, 
and pancreas) start to accumulate TG and other FA metabolites, which in turn disrupt the 
normal insulin signalling, metabolic processes and physiological function of these tissues [32]. 
The elevation in plasma FFA and the onset of a pro-inflammatory state appear to be the 
starting point of IR. The exact mechanism of the inflammatory processes and altered insulin 
signalling will be described below.  
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Figure 1.2: Chronic inflammation in adipose tissue triggers insulin resistance in skeletal muscle. [32] 
a) In the lean state, small adipocytes efficiently store fatty acids as triglyceride (TG input, arrow), which can be 
mobilized and used to generate ATP through the mitochondrial β-oxidation pathway in muscle during periods of 
caloric need. Insulin-stimulated glucose uptake under these conditions is normal. b) Excess caloric intake leads to 
metabolic overload, increased TG input and adipocyte enlargement. Nonetheless, in non-diabetic overweight 
individuals, TG storage by adipose cells and β-oxidation in muscle can often be maintained to prevent insulin 
resistance. c) On further overloading with TG, hypertrophy of adipocytes and increased secretion of macrophage 
chemoattractants occurs, including the secretion of monocyte chemoattractant protein-1 (MCP-1; arrows), which 
recruits additional macrophages. d) Macrophage recruitment in turn results in a pro-inflammatory state in obese 
adipose tissue. Infiltrating macrophages secrete large amounts of tumour necrosis factor-α (TNFα), which results 
in a chronic inflammatory state with impaired TG deposition and increased lipolysis. (arrow and plus signal). The 
excess of circulating TG and free fatty acids results in the accumulation of activated lipids in the muscle (dots), 
disrupting functions such as mitochondrial oxidative phosphorylation and insulin-stimulated glucose transport, 
thus triggering insulin resistance. 
 
1.2.2.2. The role of free fatty acids in the development of insulin resistance 
 
Already in 1963 Randle and co-workers [34] proposed “the glucose-fatty acid cycle”, in which 
the increased availability of FFAs leads to more β-oxidation of FFA and elevated amounts of 
acetyl-CoA in the muscle. Subsequently acetyl-CoA inhibits pyruvate dehydrogenase which 
results in a decrease in glucose oxidation and less glucose uptake in the cell [34] (figure 1.3 
a). However, this concept has since been modified and many other metabolic effects of FFA 
recognized. Long-chain CoA (LC-CoA), metabolized from FFA, enter the mitochondria via 
carnitine palmitoyl transferase 1 (CPT-1) to be oxidized and form acetyl-CoA, but can also be 
metabolized in different pathways. It is now known that LC-CoA can also be re-esterified to 
TG and other FA-metabolites (e.g. diacylglycerol (DAG), ceramides, and phosphatidic acid 
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(PA)) [35]. These metabolites and LC-CoA can modulate the activity of pyruvate kinase C and 
peroxisome proliferator-activated receptors (PPARs), also leading to a diminished glucose 
uptake. With progressing IR, the citrate produced from acetyl CoA can leave the mitochondria 
and gives rise to malonyl-CoA in the cytosol. Malonyl-CoA then inhibits CPT-1, thus 
decreasing the transport of LC-CoA and β-oxidation in the mitochondria [35] (figure 1.3 b).  
 
 
Figure 1.3: Metabolic effects of myocellular FFA. [35] 
a. Metabolic events in the “glucose-fatty acid cycle.” Increased FFA oxidation leads to reduced glucose 
utilization through the inhibition of pyruvate dehydrogenase by acetyl-CoA and of phosphofructokinase by 
citrate. b. Reciprocal inhibitory effects between the metabolism of glucose and FFA. FFA availability and β-
oxidation lead to inhibition of glucose oxidation (through the effect of acetyl-CoA on pyruvate dehydrogenase) 
and of nonoxidative glucose utilization (through the complex effects of LC-CoA). Glucose utilization leads to 
formation of malonyl-CoA which, by inhibiting carnitine palmitoyl transferase 1, reduces FFA b-oxidation and 
increases LCCoA concentration. Dotted arrows indicate the regulatory effects. 
 
Fatty acids and FA-metabolites can activate several protein kinases, such as protein kinase C 
(PKC), Jun kinase (JNK) and the inhibitor of nuclear factor-κB (NFκB) kinase-β (Ikkb), which 
in turn increases serine phosphorylation of insulin receptor substrates (IRS). Serine 
phosphorylation of IRS inhibits the downstream cascade of insulin signalling and therefore 
leads to decreased glucose uptake [36,37] (figures 1.4 D,G). 
Free fatty acids not only affect metabolic processes in the muscle, but also in the liver. For 
example, FFA are an important regulator of endogenous glucose production (EPG) in the 
liver. It has been shown that FFA attenuate the inhibitory effects of insulin on EPG, which 
leads to increased gluconeogenesis and glycogenolysis in the liver [38]. This increases the 
glucose “burden” adding to higher plasma glucose levels and the need of more insulin to 
reduce the plasma glucose.   
a. b. 
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The physiological processes in the β-cells can also be altered by higher levels of FFA 
arriving at the pancreas. Long term exposure of rat islets to FFA resulted in increased insulin 
secretion at low glucose concentrations. Additionally, proinsulin was synthesized in higher 
amounts, insulin stores were reduced in the pancreas, and there was an impaired ability to 
respond to high glucose concentrations (reviewed in [39]). 
The reviewed literature suggests strongly that increased circulating FFA levels are one of the 
earliest and most influential factors leading to obesity and IR. Therefore, targeting the 
increased plasma FFA concentrations should be a central objective to prevent or treat IR.  
 
1.2.2.3. The role of macrophages and inflammatory processes in the development of insulin 
resistance 
 
As already mentioned, TNF-α and MCP-1 are released from expanding adipose tissue and 
infiltrating macrophages, and act as early pro-inflammatory factors. Additionally, it has been 
shown that a chronic low grade inflammation provides a strong link between obesity and IR 
[40].  
Liver and adipose tissue contain a substantial number of residing macrophages (in the liver 
named Kupffer cells), lymphocytes, natural killer T-cells, neutrophils and dendritic cells. 
These cells are part of the innate immune system and have physiological functions. However, 
in the obese state their numbers and activation status has been observed to change [41]. In the 
lean body the tissue resident macrophages are alternatively activated M2-macrophages and 
have the role of tissue repair and remodelling. The M2-macrophages are activated by type 2 T-
helper (TH2) cytokines (IL-4, IL-13) and activation is sustained by PPAR-γ and –β/δ action. 
The M2-macrophages secrete only low amounts of pro-inflammatory TNF-α, IL-6 and IL-12. 
Additionally, the enzyme arginase 1 is activated in the M2-macrophages, which changes 
arginine metabolism away from the formation of nitric oxide (NO) [41]. Nitric oxide acts as a 
signal transduction molecule, which can inhibit several pathways of the insulin signalling 
cascade [42]. In contrast, macrophages that are newly recruited into the adipose tissue, display 
the classical activation profile of M1-macrophages. Classical activation is usually induced by 
TH1 cytokine interferon-γ (IFN-γ) and lipopolysaccharides (LPS) during bacterial infection. It 
has also been shown that during obesity saturated FA can also activate the M1 profile in 
macrophages. The classically activated macrophages secrete pro-inflammatory cytokines and 
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arginine is metabolized via inducible nitric oxide synthase (iNOS), resulting in high amounts 
of NO and reactive oxygen species (ROS) [41]. These pro-inflammatory cytokines, NO and 
ROS play an important role in the development of IR.  
 
 
Figure 1.4: Endocrine, inflammatory, and neuronal pathways link obesity to insulin resistance. [36] 
(A) The obesity-associated increase in FAs can trigger insulin resistance through intracellular metabolites that 
activate PKC, leading to the activation of serine/threonine kinases that inhibit insulin signaling. (B) Obesity-
associated changes in secretion of adipokines that modulate insulin signaling. (C) Obesity-associated 
inflammatory factors. Obesity is characterized by an increase in the accumulation of ATMs, which increase the 
adipose tissue production of inflammatory cytokines that inhibit insulin signaling. (D) Endocrine and 
inflammatory mediators converging on serine/threonine kinases that inhibit insulin signaling. (E) Obesity-
associated activation of NF-κB heightens inflammatory responses that exacerbate insulin resistance. (F) SOCS 
family proteins, induced by adipokines, induce insulin resistance either by interfering with IRS-1 and IRS-2 
tyrosine phosphorylation or by targeting IRS-1 and IRS-2 for proteosomal degradation. (G) FAs also trigger 
insulin resistance by direct activation of TLR4 and the innate immune response. (H) Obesity-related alteration in 
the central response to hormonal and nutrient signals alters peripheral insulin sensitivity. 
 
 
The events activating the innate immune system and the following signalling cascades induced 
by inflammatory cytokines are as follows (figures 1.4 D-G and 1.5). Circulating FFA bind to 
the Toll-like receptor 4 (Tlr4), which is a pattern recognition receptor for bacterial and viral 
components (e.g. LPS) and activates the innate immune response. With the binding to Tlr4, 
FFA activates IkkB and also JNK signalling. In detail, the activation of IkkB results in the 
translocation of NFκB, which induces gene expression for the pro-inflammatory cytokines IL-
6 and TNF-α. These are then secreted from the immune cells and can act on target tissues. 
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Activation of JNK, as well as PKC, inhibits the insulin signalling cascade due to serine 
phosphorylation of IRS, leading to decreased glucose uptake. The secreted TNF-α binds to 
TNF-receptor and also activates JNK, leading to already described metabolic changes. 
Interleukin-6 activates suppressor of cytokine signalling 3 (SOCS3), which also leads to 
insulin resistance in peripheral organs. [36,42,43] 
 
Figure 1.5: TLR4 mediates FFA-induced activation of inflammatory and metabolic signalling in IR. [43] 
FFAs bind to TLR4 to activate IkB-kinase (IKK), which causes degradation of IkBa and stimulates nuclear 
translocation and expression of NF-kB associated genes such as IL-6 and tumor necrosis factor (TNF)-a. 
Activated IKK, c-Jun amino-terminal kinase (JNK), and protein kinase C (PKC) directly increase serine 
phosphorylation of insulin receptor substrate (IRS) that down-regulates insulin signalling associated with IRS 
tyrosine phosphorylation, PI 3-kinase (PI3K), PDK, and Akt, resulting in reduced glucose transport into cells 
(insulin resistance). FFA-induced activation of TLR4/IKK/NF-kB and production of IL-6 and TNF-a further 
down-regulate insulin signalling via suppressor of cytokine signalling 3 (SOCS3) and JNK and indirectly cause 
insulin resistance in peripheral organs. 
 
New publications also suggest a Tlr2 and Tlr4 mediated induction of muscle and endothelial 
IR by palmitate (C16:0) [44].   
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1.2.3. Final destination: Diabetes mellitus type 2  
 
Diabetes mellitus type 2 is a complication of IR. Approximately 80–85% of patients with 
DMT2 have IR as a major contributory factor in the development of their disease [45]. When 
β-cells fail to secrete the large amounts of insulin needed for IR tissues to dispose glucose, 
DMT2 sets in [3]. Features of DMT2 are impaired glucose stimulated insulin secretion (GSIS) 
and hyperglycaemia. Circulating FFA have a lipotoxic effect on the β-cell function, as 
described above, but the precise hierarchy of events leading to FA-induced β-cell failure is  
currently poorly understood.  Interestingly, it has been suggested that all prevalent long-chain 
FA (SFA, MUFA or PUFA) have a diabetic effect when sufficient overexposure occurs [44]. 
It has been found that the dietary fat intake in adolescents ranged from 36.9kcal% to 
38.2kcal% in youths with diabetes, compared to the recommended less than 30kcal%. 
Compared to the recommended intake of 10kcal% or less from SFA, youths with diabetes 
reported intakes of about 13kcal% (reviewed in [15]). 
 
Figure 1.6: A model for the development of type 2 diabetes. [47] 
Diabetes and the metabolic syndrome develop when environmental trigger factors, such as obesity, 
cause insulin resistance and impaired insulin secretion in genetically or otherwise susceptible people. 
Note that type 2 diabetes is associated with many additional clinical and biochemical features in 
addition to hyperglycaemia. The described triggers impinge on susceptibility. The arrow from 
metabolic syndrome to other features denotes the inter-relationship of these factors once metabolic 
syndrome develops.  
Key: IGT/ IFG, impaired glucose tolerance/impaired fasting glucose. CRP, C-reactive protein 
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However, it was suggested that the events in IR only result in DMT2, if an additional genetic 
susceptibility to β-cell failure is present [46] (figure 1.6).  
A possible mechanism for the β-cell dysfunction might be the up-regulation of iNOS activity 
and resulting over-production of NO, as well as the cytotoxic effects of pro-inflammatory 
cytokines (IL-1) [39] 
It has been found that the decline of insulin secretion during the development of DMT2 is 
associated with a reduction of β-cell mass, which was related to increased apoptosis. The 
continued loss of functional β-cell mass eventually leads to overt diabetes, and subsequent 
progressive worsening of glycaemic control [48]. It was observed that obese individuals with 
impaired fasting glucose and DMT2 had a 50% and 63% reduction in β-cell mass, compared 
to patients with no diabetes [49].  
This review of factors leading to β-cell dysfunction clearly shows that circulating FFA, pro-
inflammatory cytokines and oxidative stress (via NO) are not only key elements in the 
development of IR, but also in the onset of DMT2.  
  
 
1.2.4. Other factors leading to insulin resistance & diabetes mellitus type 2 
 
Factors leading to IR and DMT2 already reviewed are genetic predisposition, diet, lack of 
excercise and obesity. However, there are other elements that play a role in the pathogenesis 
of both diseases (figure 1. 6). 
Some medical disorders, e.g. pancreatitis and acromegaly, can lead to secondary diabetes. 
Additionally, various medications can also increase the risk of DMT2. For example, 
glucocorticoids, which enhance liver glucose output and increase IR [49]. Also of great 
concern is the observation of increased IR and diabetes in HIV-patients treated with protease 
inhibitors [50]. Antipsychotic drugs have been associated with an increased incidence of 
weight gain and DMT2 [51,52]. Smoking and psychological stress have also been identified as 
risk factors for the development of IR and DMT2 [47].  
Age, sex, ethnicity, educational and social status have also been found to have an effect on 
the prevalence of IR and DMT2 [2,53].   
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1.2.5. Risk factors associated with insulin resistance & diabetes mellitus type 2 
 
Insulin resistance is associated with several other metabolic diseases, which are often easier 
detected in clinical evaluations of patients. The entirety of these diseases is called “metabolic 
syndrome” (figure 1. 6). In recent years there have been many different approaches to define 
the metabolic syndrome (also “Syndrome X” [54]), as well as to give clear guidelines for its 
clinical diagnosis [55].  The WHO defines the metabolic syndrome as follows: 
 
 
 
Figure 1.7: Definition of the metabolic syndrome. [49,56] 
 
The main features of the metabolic syndrome are IR, abdominal obesity, atherogenic 
dyslipidaemia, hypertension, pro-inflammatory and pro-thrombotic states. These pathological 
profiles in turn are strong risk factors for the development of DMT2, cardiovascular disease, 
fatty liver, polycystic ovarian syndrome, cholesterol gallstones and certain types of cancers 
(kidney, colon, rectum, breast, ovary, pancreas and prostate) [5,57]. Interestingly, it was found 
in a US study that 92% of young people with DMT2 had the metabolic syndrome, defined as 
having two or more cardiovascular disease risk factors in addition to diabetes [58]. 
The increased mortality in obese patients and individuals with the metabolic syndrome 
should not be forgotten. The higher mortality rate is due to complications from associated 
pathologies of the metabolic syndrome, and also sudden death, which is predominantly seen in 
patients with a BMI >40kg/m2 [59]. 
 
 
 - 16 - 
1.3. Current treatments for insulin resistance & metabolic syndrome 
 
Obesity and IR have been identified as inducers of several other metabolic conditions, 
including DMT2, cardiovascular diseases, fatty liver and cancer [5,57]. In recent years 
increased efforts have been made to find suitable approaches to treat the root causes of those 
metabolic conditions, rather than the resulting diseases. The two major non-pharmacological 
approaches to increase insulin sensitivity include weight loss and increased exercise, whilst 
different pharmacological therapies are given according the metabolic needs of the patient. 
This section will give a review of the major pharmaceutical treatments and relevant lifestyle 
changes for the improvement of insulin sensitivity.  
 
1.3.1. Pharmacotherapy 
 
1.3.1.1. Biguanides 
 
Metformin (a biguanide) is a chemical analogue of the naturally occurring guanidine, which 
was used from medieval times to treat diabetes. The major anti-hyperglycaemic effect of 
metformin results from suppression of endogenous hepatic glucose production. This reduces 
fasting plasma glucose levels [60]. Metformin treatment has also been shown to cause weight 
loss, although it was most effective in obese patients in decreasing body weight and adipose 
tissue mass. The observed weight loss could account for an increase in insulin sensitivity by 
20-25% [61]. However, recent studies have found evidence that metformin not only acts 
directly on glucose metabolism, but also has indirect effects through the improvement of 
plasma lipid parameters [62-64] and the attenuation of ectopic fat accumulations in non-
adipose tissues [65,66].  
Many studies in the last decade have successfully elucidated the mode of action of 
metformin, although the molecular target for metformin still remains unidentified. 
Nevertheless, a probable target is complex I of the respiratory chain, which has been shown to 
be inhibited by metformin [67].  With the inhibition of complex I intracellular ATP levels drop 
and the AMP/ATP ratio rises. ATP normally acts as an antagonist for the binding of AMP to 
AMP kinase (AMPK), however this antagonistic effect is diminished with decreasing ATP 
levels. AMPK with bound AMP is a better substrate for the upstream kinase LKB1, and 
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AMPK activation is achieved. This inhibition of the respiratory chain can also lead to a side 
effect very rarely seen with metformin treatment: lactic acidosis (reviewed in [68]). The AMP 
kinase is a regulator for several metabolic pathways, which will be reviewed in section 1.6.1.   
 
1.3.1.2. Sulfonylurea 
 
Sulfonylurea drugs are used to treat DMT2 by increasing insulin secretion in the pancreas. 
They target and inhibit the ATP-sensitive K+ channels in the β-cell membrane and cause a 
depolarization to occur. This, in turn, opens Ca2+ channels and an intracellular Ca2+ influx 
takes place, which stimulates the exocytosis of secretory granules containing insulin [69,70]. 
Recently, it was also observed that sulfonylurea (glimepiride) can increase adiponectin levels 
in DMT2 patients, as well as adiponectin expression and secretion from 3T3-adipocytes. It has 
also been suggested that sulfonylureas might have PPAR-γ like properties [71]. A side effect 
of some of the sulfonylurea drugs (containing a benzamido group) can be binding to ATP-
sensitive K+ channels in the heart, resulting in deleterious effects during acute cardiac 
ischaemia [72]. The use of sulfonylureas is also associated with weight gain [73].  
 
1.3.1.3. DDP-4 inhibitors 
 
Dipeptidyl peptidase-4 (DPP-4) is an enzyme responsible for the break down of the hormone 
glucagon-like peptide 1 (GLP-1). GLP-1 is released by cells in the small intestine after the 
ingestion of food. It has been shown to stimulate glucose dependent insulin release from the 
pancreas, increase pancreatic β-cell mass, and also causes satiety. Patients with DMT2 display 
low levels of GLP-1 in the blood. DPP-4 inhibitors have been developed to reduce the 
catabolism of the GLP-1 and improve the pathophysiological features seen in DMT2 patients. 
For example, studies showed a decrease in blood glucose levels and glycated haemoglobin 
(HbA1c) in DMT2 patients. [74-76] 
 
1.3.1.4. Thiazolidinediones 
 
Pioglitazone and rosiglitazone are clinically used members of the TZDs. Both have been found 
to have glucose-lowering, anti-inflammatory and insulin sensitizing effects [77,78]. 
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Rosiglitazone has been shown to increase insulin-stimulated glucose metabolism by 20%, 
while pioglitazone was able to elevate insulin-stimulated glucose metabolism by 40–70% 
[79,80]. TZDs are known agonists for the peroxisome proliferator-activated receptor-γ (PPAR-
γ), a member of the superfamily of nuclear hormone receptors that function as ligand-activated 
transcription factors (reviewed in [78]). PPAR-γ agonists induce adipocyte differentiation, 
which in turn take up FFA to store as triglycerides and therefore decrease circulating FFA [81-
83]. With lower FFA levels the detrimental metabolic effects described in section 1.2.2.2 are 
ameliorated and also inflammatory processes are not activated. The primary effects of these 
drugs are on adipose tissue, followed by secondary beneficial effects on other insulin target 
tissues. It is also known that PPAR-γ agonists lead to increased synthesis and circulating 
levels of adiponectin. Adiponectin is a protein derived from adipocytes, which leads to AMPK 
activation in skeletal muscle and liver, increasing FA oxidation and insulin sensitivity in these 
tissues [84,85]. However, the increase in insulin sensitivity by TZDs also comes with a 
concerning side effect – an increase in adipose tissue mass and body weight [86]. The exact 
mechanisms of PPAR-γ activation and resulting metabolic effects will be reviewed in section 
1.6.2.  
 
1.3.1.5. PPAR – duel and pan agonists 
 
It has been found that dual and pan-agonists of PPAR-α, -δ and -γ can have more beneficial 
effects on insulin resistance than PPAR-γ activators alone. PPAR-α and -δ are very important 
regulators of lipid metabolism. Activation by antagonists results in increased β- and ω-
oxidation of fatty acids and less synthesis of triglycerides and LDL cholesterol. Furthermore, 
PPAR-δ agonists have been shown to induce weight loss [87-92]. Several novel PPAR pan-
agonistic drugs have been developed and tested for the treatment of IR in recent years  [93-
96]. The metabolic effects controlled by PPARs will be reviewed in more detail in section 
1.6.2.  
 
1.3.1.6. α-Lipoic acid 
 
Lipoic acid is a 8-carbon fatty acid and a cofactor for several mitochondrial enzyme 
complexes responsible for cellular energy production and oxidative glucose metabolism. It 
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also functions as a potent antioxidant and insulin sensitizer. The exact mechanism by which 
lipoic acid exerts its action is not known. However, it can be speculated that it preserves the 
intracellular redox balance, thereby blocking the activation of Ikkb and pro-inflammatory 
pathways. Alternatively, α-lipoic acid might increase insulin sensitivity through tissue-specific 
effects on AMPK. [78,97]  
 
1.3.1.7. Acarbose 
 
Acarbose is a known α-glucosidase inhibitor which directly targets postprandial 
hyperglycaemia. Acarbose is not absorbed into the body, but exerts its effects in the gut. It 
binds specifically to the brush border enzyme α-glucosidase and inhibits the break down of 
complex carbohydrates to monosaccharides, thus decreasing glucose uptake from the gut. 
When given to patients with established IR, it decreases the incidence rate of DMT2, 
hypertension and cardiovascular events. Acarbose treatment results in lower HbA1c levels and 
normalized glucose tolerance, but has only a limited effect on lipid parameters [73,98]. 
Additionally, α-glucosidase inhibitors are associated with gastro-intestinal side effects [73].  
 
A summary of four groups of antidiabetic drugs is given in table 1.3.  
 
Table 1.3: The effects of four groups of oral hypoglycaemic drugs. [73] 
 
Key: ↔ no effect; ↓ reduced; ↑ increased; ? = unknown; HbA1C = glycosylated haemoglobin; TG = triglycerides; TC = total 
cholesterol; LDL = low-density lipoprotein cholesterol; HDL = high-density lipoprotein cholesterol; SUs = sulphonylureas; 
TZDs = thiazolidinediones; AGIs = α-glucosidase inhibitors 
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1.3.2. Lifestyle changes 
 
Sustained weight loss in obese patients is a universally accepted approach to combat IR and 
the metabolic syndrome. While bariatric surgery [78] is one of the last resorts to decrease body 
weight, a change in diet (less calories, total fat and saturated fat) and increase in physical 
activity can be a suitable initial approache to achieve weight loss. Epidemiological data 
suggest that lifestyle changes can at least partially prevent DMT2.  
Two separate prevention studies conducted in the US and Finland illustrated that after three 
years of exercise regime (150 and 210min/week, respectively) in addition to reduced daily 
energy intake resulted in a 58% reduced incidence rate of DMT2 in patients who were 
overweight or obese [49].  
However, a healthy diet should not only be low in total fat and SFA, but also rich in n3-
PUFA. A diet rich in n3-PUFA has markedly beneficial effects on IR and associated diseases 
[20-22,99]. The effects are likely to be exerted through activation of PPARs, as PUFA are 
natural pan PPAR agonists [100].  
 
 
1.4. Metabolic changes in high fat diet-induced insulin resistance 
 
1.4.1. Changes in lipid metabolism 
 
Intake of HFD causes an increase in circulating TG-rich chylomicrons, which are hydrolyzed 
by LPL and therefore increase the availability of FFA to adipose tissue and muscle. With 
increasing storage of TG in the adipose tissue, macrophages are recruited, which secrete TNF-
α. This increases lipolysis in the adipose tissue and produces even higher levels of circulating 
FFA. This mechanism appears to be the key factor in the development of IR and is reviewed in 
detail in section 1.2.2.1. However, several other pathological changes in lipid metabolism are 
apparent in fully developed IR.  
A diet rich in fat results in large amounts of circulating chylomicrons which are rich in TG 
(80-95% of total chylomicron lipids) [29] (table 1.4).  
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Table 1.4: Characteristics of the major lipoprotein classes. [29] 
 
 
Lipid% 
Lipoprotein Density MW Diameter TG CHOL PL 
Chylomicrons 0.95 400 75–1200 80–95 2–7 3–9 
VLDL 0.95–1.006 10–80 30–80 55–80 5–15 10–20 
IDL 1.006–1.019 5–10 25–35 20–50 20–40 15–25 
LDL 1.019–1.063 2.3 18–25 5–15 40–50 20–25 
HDL 1.063–1.21 1.7–3.6 5–12 5–10 15–25 20–30 
 
Density, g/dL; MW, daltons; diameter, nm; lipids (%), percent composition of lipids; apolipoproteins make up the rest. 
 
The chylomicrons usually interact with lipoprotein lipase (LPL), an enzyme synthesized by 
adipose tissue and muscle, and secreted into the capillary beds of these tissues. LPL 
hydrolyzes the chylomicron-TG, and fatty acids are then taken up into muscle or adipose 
tissue, or are circulated back to the liver. The resulting chylomicron remnants are removed 
from the blood by binding to the LDL-receptor in the liver [101]. In the IR-state LPL synthesis 
and secretion is reduced [102], which leads to chylomicron remnants high in TG circulating 
back to the liver. Furthermore, clearance of those TG-rich chylomicron particles is affected in 
IR because of a decreased expression of LDL-receptors in the liver [103]. In addition to the 
prolonged circulation of TG-rich chylomicrons, the liver synthesizes vast amounts of TG-rich 
VLDL (55-80% TG of total lipids, table 1.4) in the IR-state. Increased amounts of VLDL are 
assembled due to increased influx of FFA from adipose tissue, TG-rich remnants taken up by 
the liver, and increased de novo lipogenesis due to the diminished effects of insulin on the 
liver. VLDL is secreted into the circulation and competes with chylomicrons for LPL 
hydrolysation in the endothelium and the LDL-receptor in the liver [29] (figure 1.8).  
Insulin, as a major regulator not only of glucose metabolism but also fat metabolism, 
directly triggers the synthesis of VLDL-TG in the liver and decreases the TG catabolism by 
modulating lipoprotein lipase activity [104,105]. These effects are potentiated in the 
hyperinsulinemic state [104]. 
The plasma concentrations of HDL-cholesterol are often decreased in patients with IR or 
DMT2 [29]. HDL-precursors are synthesized in the liver and small intestine. At the precursor 
stage they contain apolipoproteins (apoA1), cholesterylester transfer protein (CETP) and 
lecithin-cholesterol acyl transferase (LCAT), but are free of cholesterylesters. Circulating 
HDL-precursors can act on chylomicrons and VLDLs, converting free cholesterol to 
cholesterylesters via LCAT and exchanging the newly synthesized cholesterylester for TG 
from apoB containing lipoproteins via CETP. The mature HDL particle, containing 
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cholesterylesters and TG, then returns to the liver, where the lipids are disposed and HDL 
remnants return to the circulation.  HDL remnants are also able to take up cholesterol from 
non-hepatic tissues via the ABC1 transporter to dispose excess cholesterol through the reverse 
cholesterol transport pathway [29,106,107]. It has been found that the catabolism of apoA1 is 
increased in IR, leading to reduced synthesis of HDL-precursors. Furthermore, modifications 
in ABC1, LCAT and CEPT appear to be responsible for the low HDL-levels found in IR [29].  
 
Figure 1.8: Substrate driving forces for the assembly and secretion of VLDL.[29] 
There are three major sources of TG, the main substrate regulating apoB secretion as VLDL. They are 
FA from peripheral tissues, particularly adipose tissue; chylomicron and VLDL remnants; de novo 
hepatic lipogenesis. In insulin resistance, FA flux through the plasma to the liver is increased, peripheral 
removal (by lipolysis) of chylomicron and VLDL TG is reduced, leaving TG-enriched remnants for 
hepatic uptake, de novo lipogenesis can be increased. All of these sources of TG may contribute to the 
increased VLDL secretion present in insulin resistant people. 
 
 Increased accumulation of lipids in non-adipose tissue is often associated with IR and 
DMT2. The high availability of FFA and decreased β-oxidation in liver and muscle in the fully 
developed IR-state leads to this ectopic fat storage. Insulin normally suppresses lipogenesis in 
liver but in IR this inhibitory effect is not produced. The intracellular uptake of FFA leads to 
production of long-chain FA, which can be used as a substrate for the production of fatty acid 
metabolites (e.g. DAG, ceramides, LC-CoA) and TG [108-111]. 
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1.4.2. Changes in glucose metabolism 
 
As already reviewed in section 1.2.2.2., the changes in the lipid metabolism are very closely 
intertwined with alterations in glucose metabolism.  
The increased intracellular production of acetyl-CoA and citrate subsequent to FA β-
oxidization, inhibits the enzymes pyruvate dehydrogenase (PDH) and phosphofructokinase 
(PFK), therefore attenuating the oxidative utilization of glucose. Additionally, non-oxidative 
glucose utilization in the form of glycogen synthesis is also diminished. This decrease in 
glycogen synthesis is an effect of lower glycogen mobilization due to decreased glucose 
oxidation. The glycogen stores become saturated and the synthesis of new glycogen is 
inhibited. [34,35]. Gene expression of the key gluconeogenic enzyme in the liver, 
phosphoenoylpyruvate carboxykinase, is elevated and leads to endogenous glucose production 
[35,112].  
 
 
1.5 Signalling cascades and receptors of importance  
 
1.5.1. Insulin  
 
Insulin was discovered in 1921 by Banting and Best and since then many publications have 
elucidated the action of this hormone on glucose, lipid and protein metabolism. Insulin is a 
protein with two polypeptide chains, which are combined by sulphide bonds. It is synthesized 
by the pancreatic β-cells as preproinsulin. Preproinsulin contains an amino-terminal sequence, 
which directs its passage into secretory vesicles. The amino-sequence is removed by 
proteolytic enzymes and three disulfide bonds are formed between the polypeptide chains, 
producing proinsulin. Proinsulin is stored in secretory granules until elevated blood glucose 
levels induce secretion. Further proteolytic enzymes remove the C-peptide from proinsulin to 
produce mature insulin. [106] 
Circulating insulin arrives rapidly at its target organs, where it binds to the insulin receptor. 
The insulin receptor is a trans-membrane tyrosine (Tyr) kinase that forms a heterotetramer in 
the cell membrane [113].  
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After inducing a cascade of downstream signals (described in section 1.5.1.1) insulin is 
either released back into circulation, or is internalized via receptor mediation, or pinocytosis. 
Inside the cell, insulin becomes a substrate for the insulin degrading enzyme, present in the 
endosomes. Liver and kidneys are the major clearance sites for insulin, but all insulin sensitive 
tissues are capable of insulin degradation [114].    
 
1.5.1.1. Insulin signalling pathways 
 
Binding of insulin to its receptor leads to auto-phosphorylation of tyrosine residues on the 
intracellular region of the receptor. This in turn induces the tyrosine kinase activity of the 
receptor. Insulin receptor substrates (IRS 1-4), Shc, and Gab-1 are then phosphorylated by the 
tyrosine kinase and downstream activation diverges into three major pathways (figure 1.9) 
[3,113].  
Firstly, phosphorylated tyrosine from the IRS molecules interacts with phosphoinositide-3-
kinase (PI3K), which leads to transformation of phosphatidyl inositol-4,5-diphosphate (PIP2) 
to phosphatidyl inositol-3,4,5-triiphosphate (PIP3) via phosphorylation. PIP3 activates 
phosphoinositide-dependent kinase 1 (PDK-1), which phosphorylates protein kinase B (PKB, 
also known as Akt) and atypical protein kinase C (aPKC). Phosphorylated PKB/Akt has 
several different downstream effects, it: 
- inactivates glycogen synthase kinase 3 (GSK-3), resulting in glycogen synthesis and 
suppression of gluconeogenesis 
- up-regulates the fatty acid synthase gene expression  
- down-regulates the expression of phosphoenolpyruvate carboxykinase (PEPCK) 
- mediates the translocation of glucose transporter 4 (GLUT4) to the cell surface 
together with aPKC 
- activates protein synthesis mediated by the mammalian target of rapamycin (mTOR). 
Secondly, the adapter protein CAP recruits the proto-oncogene Cb1 to the phosphorylated 
insulin receptor, which can also mediate the translocation of GLUT4, independent of PI3K 
activation. 
The third pathway downstream of IRS phosphorylation involves several proteins (Grb2, 
Shp2, SOS, Ras, Mek) and results ultimately in the activation of mitogen-activated protein 
kinase (MAPK). The protein Grb2, which is pre-bound to SOS, binds either to the tyrosine-
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phosphorylated Shc or IRS, and SOS becomes activated. SOS then mediates the activation of 
Ras. Ras, in turn, phosphorylates Raf by a number of Serine/Threonine kinases, thus inducing 
active RAF and MEK kinase and ultimately MAPK. The activation ofMAPK regulates the 
transcription of several genes, which play an important role in cellular proliferation and 
differentiation [3,42,113,115]. 
 
 
 
Figure 1.9: Insulin signal transduction [3].  
After autophosphorylation of insulin receptor Tyr, Tyr phosphorylation in insulin receptor substrates 1-4 (IRS 1-
4) takes place and subsequently three different pathways transduce the signal: the PI3K-dependent pathway 
mediating metabolic responses, including glucose/lipid/protein metabolism and insulin-stimulated glucose 
uptake, the CAP/Cbl pathway which is additionally required for glucose transporter-4 (GLUT4) translocation, 
and the mitogen-activated protein kinase (MAP kinase) pathway that results in cell proliferation and 
differentiation.  
Key: Solid line: stimulation, dashed line: inhibition. IRS - insulin receptor substrate; PI3K - phosphoinositide-3-kinase; PDK-
1 - phosphoinositide-dependent kinase 1; PKB - protein kinase B; aPKC - atypical protein kinases C; mTOR - mammalian 
target of rapamycin; p70S6K - p70 ribosomal S6 kinase; PEPCK - phosphoenolpyruvate carboxykinase; GSK3 - glycogen 
synthase kinase 3. 
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1.5.1.2. Insulin signalling in insulin resistance 
 
In the IR-state the target cells respond to insulin in abnormal manner. Four major defects 
could be the cause of impaired insulin signalling: a) mutations or post-translation alterations of 
the insulin receptor or its downstream effector molecules, b) increased degradation of the 
insulin receptor, c) a defect in the binding of insulin to its receptor, or d) a post-binding defect 
in one or more places of the downstream signalling cascade. The latter defect is the most 
common cause of the pathological effects in IR [3,113].  
The insulin receptor, which is physiologically phosphorylated on its intracellular tyrosine 
residues, can also be phosphorylated on serine/threonine residues, which inhibits the tyrosine 
kinase activity of the receptor. The downstream signalling cascades are therefore decreased in 
proportion to the defect in insulin receptor tyrosine kinase activity. PKCs and MAP kinases 
are thought to be responsible for the serine/threonine phosphorylation. The serine 
phosphorylated IRS can become subject to enhanced proteosomal degradation, which also 
diminishes the insulin downstream signalling.   Decreased Tyr phosphorylation of IRS 
proteins and a decrease in their associated PI3K activity was observed in skeletal muscle and 
adipocytes both in obesity and DMT2. The pro-inflammatory processes occurring in obesity 
and IR are directly associated with modifications in insulin signalling. It has been shown that 
TNF-α increases the serine phosphorylation of IRS-1 and -2. Serine phosphorylation of the 
IRS results in a reduction in both insulin-receptor tyrosine auto-phosphorylation and tyrosine 
kinase activity of the receptor, as well as reducing the ability of the IRS molecules to bind to 
the receptor and induce downstream pathways, such as PI3-K and glucose transport 
[3,113,116]. 
The activation of suppressor of cytokine signalling (SOCS) in the pro-inflammatory state 
(described in section 1.2.2.3), results in modifications in the insulin signalling cascade. SOCS 
can compete with IRS-1 for binding to the insulin receptor, disabling the tyrosine 
phosphorylation and downstream effects of IRS-1. Furthermore SOCS can also increase the 
degradation of IRS. Metabolites (DAG, acyl-CoA) derived from excess intracellular FFA and 
FFA themselves, are also able to increase the serine phosphorylation of IRS by activating 
several protein kinases (PKC, JNK, IkkB) (figures 1.4 D.G) [36,37]. In animal experiments 
with elevated myocellular FFA concentrations, decreased activities of IRS, PI3K, PKB, PKC 
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and GSK were found, which was the reason for the low insulin sensitivity seen in the skeletal 
muscle tissue [3,32,42,117].  
 
 
1.5.2. Adenosine monophosphate activated protein kinase (AMPK) 
 
AMPK is a 200kDa enzyme, consisting of three subunits and highly conserved in the cytosol 
and nuclei of eukaryotic cells [62]. The involvement of metformin in the activation of AMPK 
was first observed by Zhou et al. [63].  As already reviewed in section 1.3.1.1, metformin 
inhibits the respiratory chain and therefore decreases the ATP levels in the cell. The resulting 
activation of AMPK via LKB1 then tries to counteract these low ATP levels by increasing 
catabolic pathways (e.g. glucose uptake and glycolysis, FA oxidation) and decreasing anabolic 
processes, such as glycogen-, protein- and TG-synthesis, as well as gluconeogenesis [62]. In 
recent years it has become more and more evident that AMPK is a metabolic gauge regulating 
energy homeostatsis at the whole-body level (table 1.5, figure 5.2) [118].   
 
Table 1.5: Targets of AMPK and their biologic effects.  [118] 
 
Key: ↑, stimulation; ↓, inhibition. a The role of AMPK in the regulation is complex and recent data have challenged the idea 
that AMPK inhibits lipolysis through direct phosphorylation of hormone-sensitive lipase (HSL) and by the blocking of protein 
kinase A (PKA)-induced HSL activation 
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1.5.2.1. AMPK regulation of lipid metabolism 
 
The activation of AMPK has several effects on lipid metabolism in liver and hypothalamus. 
Firstly, AMPK inhibits acetyl-CoA carboxylase (ACC) activity, as well as fatty acid synthase 
(FAS), therefore inhibiting two enzymes in the fatty acid anabolic pathway. Additionally, it 
also decreases the substrate for fatty acid synthesis by decreasing the levels of malonyl-CoA 
by activating the malonyl-CoA decarboxylase. Secondly, by reducing the levels of malonyl-
CoA it ameliorates the allosteric inhibitory effects of malonyl-CoA on carnitine palmitoyl 
transferase 1 (CPT1). This enables the entry of long chain fatty acyl-CoA into the 
mitochondria, facilitated by CPT1, where β-oxidation takes place [118,119]. 
AMPK is also involved in the regulation of TG-lipolysis in the adipose tissue. It has been 
shown that AMPK is able to phosphorylate and inhibit hormone-sensitive lipase (HSL). 
However, some studies have found an opposite effect, increasing lipolysis in adipocytes [118]. 
The simultaneous inactivation of ACC and hydroxyl-methyl-3-glutaryl-CoA (HMG-CoA) 
reductase by AMPK in hepatocytes inhibits the conversion of HMG-CoA to mevalonate, and 
therefore cholesterol synthesis [118,119]. 
 
1.5.2.2. AMPK regulation of glucose metabolism 
 
During physical exercise AMPK is activated in the skeletal muscle, which leads to increased 
synthesis and translocation of GLUT4 via  two transcription regulators MEF2 and GEF [120]. 
Once GLUT4 is located on the cell surface, glucose can be taken up by the myocytes.  
AMPK activation also increases the expression of hexokinases, enzymes involved in the first 
step of glycogen synthesis by converting glucose to glucose 6-phosphate.  
With chronic energy deprivation in the skeletal muscle, increased expression of nuclear 
respiratory factor 1 (NRF-1) and peroxisomal proliferator-activated receptor γ coactivator 1 
(PGC-1) is achieved via AMPK, which leads to mitochondrial biogenesis.  
Hepatic gluconeogenesis is inhibited by AMPK via the decreased transcription of PEPCK 
and glucose-6-phosphatase (G6Pase). The production of glycogen in skeletal muscle is 
decreased by AMPK-induced phosphorylation of glycogen synthase (GS).  
AMPK activation also appears to have a regulatory effect on β-cell mass in the pancreas. 
Although the exact mechanisms are not fully elucidated, AMPK activation has a pro-apoptotic 
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effect on β-cells. Most studies on the influence of AMPK on insulin secretion found a decrease 
in insulin secretion, which could alleviate hyperinsulinaemia in the IR state [119,121]. 
 
1.5.3. Peroxisome proliferator-activated receptors (PPARs) 
 
The PPARs are members of a nuclear hormone receptor family, which are activated by small 
lipophilic compounds. PPARs play a central role in the regulation of lipid metabolism, but 
also have several other functions [82,94,100] which are reviewed in detail below.  
 
 
Figure 1.10: The peroxisome proliferators-activated receptors (PPARs) as transcription factor. [94] 
As members of the steroid hormone nuclear receptor family, PPARs are thought to control gene expression 
through a heterodimeric complex with the retinoid X nuclear receptor (RXR). Both PPAR and RXR activation 
are controlled by binding to specific ligands. The ultimate transcriptional response is determined by the 
association or release of specific co-activators and corepressors. This complex binds to certain PPAR response 
elements (PPRE) in the promoter regions of target genes controlling their expression, either inducing or 
repressing the transcriptional response.  
Key: L=ligand; RA=9-cis-retinoic acid. (NCoR=Nuclear receptor co-repressors, SMRT=Silencing mediator for retinoid and 
thyroid-hormone receptor, HAT=Histone acetylase transferase, CBP=CREB binding protein, SRC-I=Steroid receptor co-
activator, LPL=Lipoprotein lipase, PEPCK=Phosphenolpyruvate carboxykinase). 
 
PPARs have four functional domains:  
- A/B domain, which contains a ligand-independent activation function 1 (AF-1) and is 
responsible for the phosphorylation of PPAR 
- DNA binding domain (DBD) promotes the binding of PPAR to the peroxisome 
proliferator response element (PPRE) in the promoter region of target genes 
- docking domain for cofactors, and 
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- ligand-binding domain (LBD), responsible for ligand specificity and activation of 
PPAR binding to the PPRE. [100]  
PPARs form a heterodimer with retinoid X nuclear receptor (RXR) and bind certain cofactors 
(either activators or repressors) before binding to PPRE in the promoter region of target genes 
to achieve activation or inhibition of gene transcription (figure 1.10). [94,100,122] 
Three subtypes of PPARs have been identified – PPAR-α, PPAR-β/δ and PPAR-γ. The three 
isoforms share a 60-80% homology in their ligand- and DNA-binding domain [122], but have 
an individual pattern of ligand binding and tissue distribution (table 1.6). PPARs have a wide 
variety of regulatory effects in the body. However, only the regulation of genes involved in 
glucose- and fat-metabolism, and inflammatory processes will be reviewed in this section.   
 
Table 1.6: Tissue distribution and ligands of PPARs. (modified from [94,100,123]) 
 PPAR-α PPAR-β/δ PPAR-γ 
Liver ++ + + 
Brown adipose +++ + +++ 
White adipose + + +++ 
Muscle ++ ++  
Pancrease + ++  
Brain + ++ + 
Heart +++ +++ + 
Intestine + +++ + 
Kidney +++ ++ + 
Spleen  ++ ++ 
Endothelial cells ++  ++ 
Monocytes/macrophages ++  ++ 
Vascular smooth muscle cells ++  ++ 
    
Endogenous ligands Palmitic acid saturated fatty acids Linoleic acid 
 Stearic acid unsaturated fatty acids Arachidonic acid 
 Palmitoleic acid  Prostaglandins 
 Oleic acid  Oxidized lipids  
 Linoleic acid         (HODE,HETE) 
 Arachidonic acid   
 Eicosapentaenoic acid   
 Eicosanoids (LTB4)   
Exogenous ligands WY-14.643 L-165041 TZDs 
 Clofibrate GW-501516 JTT-501  
 Gemfibrozil GW-0742     (isoxazolidinedione) 
 Nafenopin NSAIDs (antagonist) GW-7845 
 Bezafibrate   
 Fenofibrate   
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1.5.3.1. PPAR-α 
 
PPAR-α is mainly expressed in tissues with high rate of FA oxidation, such as liver, skeletal 
muscle and heart. PPAR-α controls the transcription rate of genes encoding key enzymes 
(CoA oxidase, CPT1) for fatty acid β- and ω-oxidation in peroxisomes and mitochondria. It 
stimulates the cellular uptake of fatty acids by increasing the expression of fatty acid transport 
protein (FATP) and fatty acid translocase (FAT). Some of the exogenous ligands promote the 
expression of cytochrome P450-4A (CYP4A) enzymes, which catalyze the ω-hydroxylation of 
FA, thus reducing TG synthesis in tissues expressing PPAR-α. Additionally, PPAR-α 
activation decreases plasma TG levels by amplifying the expression of lipoprotein lipase 
(LPL) in the capillary beds of adipose tissue and muscle. Agonists of PPAR-α have been 
found to inhibit apolipoprotein (apo) C-III synthesis and to increase apoA1 production in the 
liver [100,124]. This results in the production of VLDL containing no apoCIII, which can 
therefore be easily lipolyzed by LPL. ApoA1 is the major protein in HDL, and activation of 
PPAR-α consequently leads to higher circulating HDL levels [29]. 
In addition to the lipid regulatory mechanisms, PPAR-α agonists have anti-inflammatory 
effects in vascular cells leading to reduced plasma concentrations of IL-6. These effects are 
brought about by the inhibition of IL-1 mediated expression of IL-6 and cyclooxygenase-2 
(COX-2) by repressing the NFκB signalling pathway. It has also been shown, that certain pro-
inflammatory eicosanoids (leukotriene B4, LTB4) bind and activate PPAR-α and induce their 
own degradation via β- and ω-oxidation, therefore controlling the length of inflammatory 
processes [82,100].  
 
1.5.3.2. PPAR-γ 
 
The major effect of PPAR-γ activation is the promotion of pre-adipocyte precursor cell 
differentiation into adipocytes (adipogenesis). PPAR-γ also induces apoptosis in mature lipid-
filled large adipocytes. This shift from large, more insulin resistant adipocytes to an increment 
number of small, relatively insulin-sensitive adipocytes, is one of the reasons why PPAR-γ 
agonists (TZDs) are used for IR treatment. The newly differentiated adipocytes are capable of 
taking up plasma FFA, thus ameliorating the FFA burden on other tissues. The FA uptake is a 
result of increased expression of cell surface receptors such as fatty acid protein transporter 
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(FATP) induced by PPAR-γ. The FA are then used for the synthesis TG, a process also 
influenced by PPAR-γ by increasing the expression levels of phosphenolpyruvate 
carboxykinase (PEPCK), glycerol kinase [38,82,94,100]. 
PPAR-γ agonists also lead to an increase of GLUT4 and GLUT2 expression in adipose 
tissue and increased PI3-kinase activity in the skeletal muscle, therefore improving insulin 
resistance. In vitro studies have also shown that PPAR-γ activation represses the synthesis of 
IL-6 and TNF-α in macrophages. PPAR-γ inhibits the expression of the iNOS, by 
antagonizing the activities of STAT and NFκB in macrophages.  
 
1.5.3.3. PPAR-β/δ 
 
PPAR-β/δ is the least known of the PPAR members. However, in recent years many positive 
metabolic effects have been discovered to be associated with PPAR-β/δ. Animal studies on 
PPAR-δ agonists have shown an increase in HDL-cholesterol levels, while LDL-cholesterol, 
TG and insulin levels decreased.  Furthermore, PPAR-β/δ activates heat-producing uncoupling 
enzymes in brown adipose tissue (UCP1 and 3) and muscle (UCP2). This could be an 
explanation for weight loss seen after PPAR-β/δ agonist treatment. [94,100]. Both, PPAR-β/δ 
and -γ, are important regulators in macrophage differentiation, and their activation is essential 
for the phenotypic switch from M1 to M2 macrophages [41,125]. 
 
 
1.5.4. Sterol regulatory element–binding proteins (SREBPs) 
 
SREBPs are transcription factors, which control the expression of more than 30 genes for the 
synthesis and uptake of cholesterol, fatty acids, triglycerides, and phospholipids (figure 1.11). 
There are three known isoforms of sterol regulatory element–binding proteins, SREBP-1a, 
SREBP-1c, and SREBP-2. SREBP-1a activates all SREBP-responsive genes, including those 
that mediate the synthesis of cholesterol, FA, and TG. SREBP-1c preferentially activates the 
transcription of genes required for FA synthesis and SREBP-2 only activates cholesterol 
synthesis. SREBPs are expressed in several tissues, for example, skeletal muscle, liver and 
adipose tissue [126,127]. 
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The expression of SREBP-1c is regulated by insulin. Hence, SREBP-1c is possibly a link for 
several features of obesity-associated IR. SREBPs have been implicated in the development of 
several metabolic diseases. For example, the development of ectopic TG accumulations in 
liver and skeletal muscle of IR-individuals with hyperinsulinaemia is very likely due to 
insulin-induced activation of SREPB-1c [126,127]. This leads to enhanced FA-synthesis and 
TG-accumulation in these individuals. Studies in animals over-expressing SREBP-1c in 
adipose tissue observed the development of IR, fatty liver and elevated plasma TG levels 
[128]. Interestingly, SREBP expression is not only regulated by insulin, but also by other 
hormones, metabolites and nutrients. It has been found that polyunsaturated fatty acids can 
suppress SREBP-1c expression [126,127]. 
 
 
 
Figure 1.11: Genes regulated by SREBPs. [126] 
The diagram shows the major metabolic intermediates in the pathways for synthesis of cholesterol, fatty acids, 
and triglycerides. In vivo, SREBP-2 preferentially activates genes of cholesterol metabolism, whereas SREBP-1c 
preferentially activates genes of fatty acid and triglyceride metabolism.  
Key: DHCR, 7-dehydrocholesterol reductase; FPP, farnesyl diphosphate; GPP, geranylgeranyl pyrophosphate synthase; 
CYP51, lanosterol 14α-demethylase; G6PD, glucose-6-phosphate dehydrogenase; PGDH, 6-phosphogluconate 
dehydrogenase; GPAT, glycerol-3-phosphate acyltransferase. 
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1.6. Sutherlandia: taxonomy, botanical information, traditional use, active 
compounds, pharmacological properties & toxicology  
 
1.6.1. Taxonomy & botanical information of Sutherlandia  
 
The genus Sutherlandia belongs to the family of Fabaceae (Leguminosa) and is closely 
related to Astragalus L. and Lessertia DC [129]. The genus can be divided in two species as 
proposed by Moshe [130] – Sutherlandia tomentosa and Sutherlandia frutescens. The species 
S. frutescens can be further subdivided into subsp. 
frutescens, subsp. speciosa and subsp. microphylla.  
S. frutescens is endemic to southern Africa occurring 
in the western, central and eastern parts of South 
Africa, most of Lesotho, southern parts of Namibia and 
the southeastern corner of Botswana [129]. S. 
frutescens is a perennial shrub (0.2-2.5m in height) 
with red flowers and large bladdery pots containing 
numerous seeds.  
Local names used for S. frutescens are cancer bush, 
balloon pea, and turkey flower in English, as well as 
kankerbos, gansies, wildekeur, and belbos in Afrikaans 
(reviewed in [129]).  
 
 
1.6.2. Traditional uses of Sutherlandia 
 
S. frutescens is one of the most widely used medicinal plants in southern Africa. The 
traditional form of medication is to use “two or three leafy twigs” infused in boiling water. 
This tea containing approximately 2.5-5g of dry material is traditionally given as a daily 
dosage [129].  
Traditionally S. frutescens is used for a wide range of conditions, including cancer, diabetes, 
inflammation, back pain, stomach pain, eye diseases, skin diseases, influenza, HIV/AIDS and 
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many more  [129,131,132]. The use of S. frutescens in traditional medicine exceeds by far the 
use of S. tomentosa. This is due to the limited localized distribution of S. tomentosa on coastal 
dunes in the Western Cape area of South Africa.  
 
 
1.6.3. Active compounds, pharmacological properties & toxicology of Sutherlandia 
 
Several biologically active compounds have been isolated and identified from S. frutescens, 
although many questions still remain about its mode of action. Studies conducted in the last 
decade were mainly focused on anti-diabetic, anti-cancer, anti-HIV, anti-inflammatory and 
anti-oxidant effects of S. frutescens, as well as toxicological safety. This section briefly gives 
an overview of known active compounds and effects of S. frutescens in vivo and in vitro.  
 
1.6.3.1. Pinitol 
 
Pinitol is a cyclitol and is contained in quantities of up to 14mg/g dry weight in S. frutescens 
leaves. Pintol was patented in the US in 1996 for its anti-diabetic properties and has 
applications in treating wasting in cancer and AIDS (reviewed in [129]). Studies on 
streptozotocin diabetic rats and diabetic humans showed glucose lowering effects after pinitol 
administration [133-135]. Pinitol appears to mimic the effects of insulin by acting downstream 
in the insulin signalling pathway [134].  Pinitol also has been shown to increase the retention 
of creatinine by human myocytes [136]. It was previously proposed that S. frutescens may 
display anti-diabetic properties either due to direct action of pinitol or indirectly by improving 
inflammation [137]. However, a clinical study showed no positive effects of pinitol in type 2 
diabetes patients [138]. Chadwick et al. [139] and Ojewole [140] both noted anti-diabetic 
effects of S. frutescens in rat models but the active compound(s) and mode of action still need 
to be elucidated.  
 
1.6.3.2. L-Canavanine  
 
L-canavanine is a non-protein amino acid found in substantial amounts of up to 14.5 mg/g in S. 
frutescens leaves [129]. Canavanine has been previously found to have anti-cancer properties 
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[141,142]. Studies using S. frutescens extracts published anti-proliferative and pro-apoptotic 
effects in vitro [143,144]. However, it remains uncertain if L-canavanine is the only active 
compound responsible for the anti-cancer property of S. frutescens.  
It is also known that L-canavanine can compete with L-arginine for the binding site of 
inducible nitric oxide synthase (iNOS) at the cellular level [145], therefore reducing the 
production of nitric oxide (NO). This could be an explanation for the anti-inflammatory 
properties of S. frutescens.   
Another free amino acid found in S. frutescens leaves, L-arginine, is a competitive inhibitor 
of L-canavanine [129] and should therefore attenuate the effects brought about by L-
canavanine. Furthermore, L-canavanine not only competes with L-arginine for binding sites, 
but also replaces arginine in structural and functional proteins, resulting in aberrant canavanyl 
proteins in vivo [146]. These proteins can disrupt enzymatic activity and persistent presence of 
L-canavanine can result in apoptotic cell death and auto-immunity [145,146].  
 
1.6.3.3. Triterpenoid glycosides 
 
There are at least 56 triterpenoid glycosides contained in S. frutescens leaves, with the 
cycloartane-type triterpene glycoside SU1 being the major terpene (reviewed in [129]). A 
recent publication showed the chemical structure of another four novel triterpenoids isolated 
from S. frutescens [147]. Kikuchi et al. [148] noted the cancer chemotherapeutic  activity of 
astragalosides isolated from the related genus Astragalus. These are structurally closely related 
to cycloartane-type triterpenoids. Triterpenoids and diterpenoids are contained in many herbs 
and have been found to have agonistic properties for PPAR-α and -γ, resulting in anti-
inflammatory effects and improvements in lipid metabolism [149,150].   
 
1.6.3.4. Other biological active compounds of S. frutescens  
 
There are other minor active compounds contained in S. frutescens. Gamma-aminobutyric acid 
(GABA), another non-protein amino acid, can be found in quantities up to 0.85mg/g [129]. 
GABA is an inhibitory neurotransmitter and might be responsible for the observed 
improvements in the mood of patients, as well as having anti-stress effects [129]. GABA has 
also been found to inhibit tumor cell migration [151].  
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At least six flavonol glycosides have been determined in S. frutescens, although their 
chemical structure still needs to be elucidated [129]. Flavonoids are plant pigments and have 
been found to have a wide range of pharmacological effects and medicinal applications. For 
example, flavonoids can act as immune-modulators, radical scavengers and enzyme inhibitors. 
They are frequently used in the treatment of inflammation, cancer, hypertension, gastric ulcers 
and rheumatic disease (reviewed in [152]).  
Van Wyk and Albrecht [129] reported very high levels of polysaccharides in S. frutescens, 
which still need to be further identified. Tai et al. [144] also noted the presence of palmitic 
acid (hexadecanoic acid, C16:0), three other long chain alcohols, γ-sitosterol and stigmast-4-
en-one. Beta-sitosterol has been previously shown to have positive effects on glucose and lipid 
metabolism [153].   
 
1.6.3.5. Toxicity of S. frutescens  
 
Sutherlandia is a traditional medicine used for centuries and no toxic effects have been 
reported in the long history of its use. Occasionally some mild side effects have been noted, 
for example, dryness of the mouth, mild diarrhea, diuresis and dizziness (reviewed in 
[129,154]. 
Several studies on animals have shown no toxic effects of S. frutescens. Ojewole [140] 
determined the median lethal dose (LD50) for mice to be 1280mg S. frutescens extract/kg BW 
and concluded that S. frutescens can be used safely in mammals. A study on vervet monkeys, 
as well as a clinical trial on healthy human subjects, did not show any toxic side effects 
(reviewed in [129]).   
The only compound with possible toxic properties isolated from S. frutescens is L-
canavanine. L-Canavanine has been reported to alter enzyme activities, causing cell death and 
auto-immunity due to its incorporation into proteins instead of L-arginine [145,146]. However, 
no such side effects have been seen after S. frutescens administration, which might be due to 
the competitive effects of L-arginine with L-canavanine, a free amino acid also contained in S. 
frutescens leaves [129].  
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2.1. Motivation 
 
Obesity has been declared by the WHO as a global pandemic. At present over 2 billion adults 
are overweight or obese worldwide and the incidence of childhood obesity is growing at an 
alarming rate. Due to its association with other metabolic disorders, obesity puts a huge 
burden on the global health care system. Genes evolved over thousands of years to protect the 
body from starvation are now proving to be fatal. The intake of highly refined and high caloric 
food in association with a sedentary lifestyle leads to obesity and associated diseases in a 
staggeringly short period of time.   
 
One disorder closely connected to obesity is insulin resistance, which is a central factor for the 
development of dyslipidaemia, cardiovascular diseases, cancer, fatty liver, polycystic ovarian 
syndrome, gallstones and diabetes mellitus type 2. Although it is difficult to estimate the 
global number of people suffering from IR, it can be estimated that approximately 85% of 
patients presenting with a metabolic condition are also suffering from IR. Therefore, IR 
appears to be an appropriate target to prevent or cure several metabolic disorders. 
 
In recent years the pathogenesis of IR as a pre-diabetic state has become the focal point for 
investigations. Also, the focus in diabetes research has changed from a gluco-centric to a more 
lipo-centric approach. Free fatty acids (FFA) are now known to be the key element to induce 
high fat diet-induced IR. The overload of important metabolic tissues, like liver, skeletal 
muscle and adipose tissue, with FFA has been shown to have detrimental effects. However the 
interplay between the different tissues is very complex and not all the molecular mechanisms 
are fully understood. Therefore there is a need for further research to obtain a complete picture 
of the pathogenesis of HFD-induced IR.  
 
A change in lifestyle, including a healthy diet, appropriate caloric intake and physical exercise 
can ease or even cure IR and most associated disorders. However, very few patients make to 
the necessary lifestyle alterations. Therefore, it is usually necessary in clinical practise to 
intervene with pharmaceuticals. Novel and well established drugs are available for the 
treatment of IR and DMT2. However, these drugs can be expensive and most of them are 
associated with side effects. It is therefore necessary to find alternative treatments for IR.  
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Developing countries present a major challenge to the aim to reduce the global prevalence of 
metabolic disorders associated with obesity and IR. Epidemiological data on obesity and 
diabetes indicates similar trends in those countries to developed countries. However, limited 
health care systems and financial limitations often prohibit efficient treatment of patients. 
Additionally, patients are often uneducated and reluctant to use modern medicine. Traditional, 
cultural and religious beliefs are still a major influence in the choice of treatment. It is 
therefore important to obtain scientific evidence on traditional herbal remedies.  
 
South Africa faces these above mentioned challenges. The number of obese and diabetic 
patients is increasing steadily and modern medical care is often rejected or poorly accessible in 
rural areas. Sutherlandia frutescens is one of many medicinal plants, used for various ailments 
by the indigenous people of South Africa. The use of S. frutescens is predominantly for the 
treatment of diabetes. Previous studies have confirmed the anti-diabetic properties of S. 
frutescens. However, the active compounds and mode of action are not clear at present. Also, 
very little data is available for possible positive effects on other metabolic disorders connected 
with IR and diabetes.  
 
 
2.2. Introduction to the present study 
 
The present study aimed to obtain insight into the developmental stages of HFD-induced IR 
in an animal model. In addition, the pathological changes in lipid metabolism received special 
attention. Dyslipidaemia is a common feature in IR-individuals; however, pathological 
changes in blood lipid parameters rarely have been analysed in connection with tissue lipid 
changes. This study obtained insight into the lipid composition of key metabolic tissues in 
association with the development of dyslipidaemia and excess circulating free fatty acids. 
Furthermore, the alterations in the fatty acid profile of membrane and storage lipids were 
assessed.  
Chronic low grade inflammation is thought to be an important factor for the decrease of 
insulin sensitivity in several tissues. Therefore, this study assessed alterations in circulating 
cytokine levels.  
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S. frutescens is known to have anti-diabetic properties. Much research is currently   undertaken 
to identify the active compounds and the mode of action of this remarkable medicinal plant. 
Recent studies mainly focused on its anti-inflammatory, anti-cancer and anti-diabetic effects. 
However, nothing is known about the effects of S. frutescens in the complex interactions 
between glucose and lipid metabolism in IR. This study therefore tried to elucidate the effects 
of S. frutescens on the combined pathology of lipid and glucose metabolism. Additionally, an 
assessment was done on the anti-inflammatory properties of S. frutescens in vivo by measuring 
circulating cytokine levels. Furthermore, the present study aimed to obtained detailed 
information about the mode of action of S. frutescens, not only as a treatment for IR, but also 
as a possible treatment to prevent IR.  
 
To obtain data for these aims, two separate studies were conducted with the use of an animal 
model. Male Wistar rats have previously been shown to be a good model for obesity and IR. 
 
1. In the first study Wistar rats were divided into three groups. The first group received a low 
fat diet to simulate a healthy, low caloric diet and to prevent the onset of IR. The second 
group received a high fat diet to simulate a Westernized, high caloric diet and to induce IR. 
The third group received the same high fat diet as the first group and additional treatment 
with S. frutescens extract to assess potential preventative effects of this plant on the 
development of IR. The rats were sacrificed at different time points in the feeding regime 
to obtain information about developmental stages of IR and associated metabolic changes, 
as well as about early and prolonged metabolic effects of S. frutescens. It was also of 
interest to analyze to what extent S. frutescens ameliorates the metabolic effects of the 
high fat diet.  
 
2. In the second study male Wistar rats were fed with high fat diet for three months to achieve 
IR. Insulin resistant rats were then treated with S. frutescens or metformin for 28 days and 
the improvements in IR and other parameters were assessed. A group of rats fed on low fat 
diet ran concurrently as a control group.  
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Metformin was used as positive treatment control for IR. Metformin is widely used in the 
clinical practise in patients with IR and early stages of diabetes mellitus type 2. This study was 
not trying to determinate the mode of action of metformin, but to use it as reference point for 
comparison of the metabolic effects and mode of action of S. frutescens. Metformin was not 
used in the prevention study as the low fat diet group was considered as a negative control 
group for IR. 
 
The analytical approach for this present study included the assessment of IR via determination 
of fasting plasma insulin and glucose, as well as glucose uptake into tissues and glucose 
clearance rate from the blood. Changes in lipid metabolism were determined at plasma level 
by analysing FFA, TG, total cholesterol, HDL-cholesterol and LDL-cholesterol. Alterations in 
lipid content, lipid profile and FA profile in tissues where then associated with the changes 
seen in the plasma. The assessment of the onset of a low grade pro-inflammatory stage was 
done via the analysis of circulating cytokine levels, including TNF-α, MCP-1 and interleukins.  
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3.1. Animals and experimental design 
 
All animal experiments were approved by the Animal Ethics Committee of the Nelson 
Mandela Metropolitan University (approval number A06BM-004). Male Wistar rats were 
obtained as three week old weanlings from the MRC animal unit in Cape Town. Rats were left 
to acclimatise for several days before starting feeding regimes and treatment.    
The rats were housed in an environmental room with controlled temperature (22 ± 2 °C) and a 
12h/12h light-dark cycle. A maximum of four rats were housed per cage. The rats had ad 
libitum access to food and water.  
Two long term studies were undertaken. The aim of the first study was to determine the time 
course of the development of insulin resistance, the sequence of biochemical and 
physiological changes associated with IR, the effects of S. frutescens upon these parameters 
and the capacity of the plant extract to prevent insulin resistance. 
In the second study, rats were made insulin resistant and the action of S. frutescens extract as a 
potential treatment of IR was assessed.  
 
3.1.1. Prevention study 
 
A total of 112 rats were used in the prevention study. Weanlings were left to acclimatise for 
seven days before seven rats were sacrificed prior to starting the study (day 0). The remaining 
one hundred and five rats were divided randomly into three groups, with each group consisting 
of thirty five animals. The rats in the three groups received low fat diet (LFD group), high fat 
diet (HFD group) or high fat diet supplemented with Sutherlandia frutescens (HFD+S.f. 
group). To observe developmental stages of IR and preventative effects of S. frutescens, seven 
rats from each group were sacrificed after seven days (week one), fourteen days (week two), 
twenty eight days (week four), fifty six days (week eight) and eighty four days (week twelve) 
(Table 3.1).  
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Table 3.1: Prevention study – experimental animal setup. 
 
 
3.1.2. Treatment study 
 
In this study seventy eight rats were randomly divided into two groups after a two week 
acclimatisation period. The first group consisted of twenty two rats and was fed low fat diet 
(LFD group). Group two consisted of forty four rats that were fed high fat diet (HFD group). 
The rats were fed the diets for twelve weeks with the aim of causing insulin resistance in the 
HFD group. Eleven rats from each group were sacrificed at this point to confirm insulin 
resistance. The remaining thirty three rats in the HFD group were divided into three groups, 
each consisting of eleven rats. Insulin resistant rats in the HFD group were then either treated 
with S. frutescens extract or metformin for twenty eight days (for dosages see 3.3 below) or 
water as a control. The remaining eleven rats in the LFD group continued on low fat diet and 
were also given water as a control (Table 3.2). 
On the day of sacrifice four of the eleven rats were used to measure glucose clearance from 
the blood and the glucose uptake into tissues. The remaining seven rats were used for blood 
and tissue analysis.  
 
 
 
 
Day (week) of sacrifice LFD HFD HFD+S.f. 
0    (0) 7 - - 
7    (1) 7 7 7 
14   (2) 7 7 7 
28   (4) 7 7 7 
56   (8) 7 7 7 
84 (12) 7 7 7 
Number of rats/ group 42 35 35 
Number of rats total   112 
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Table 3.2: Treatment study – experimental animal setup. 
 LFD HFD 
Number of rats/group 26 52 
Number of rats sacrificed after 12 weeks diet 13 13 
Number of rats remaining  13 39 
Treatment for 28 days  water water S. frutescens metformin 
Number of rats sacrificed after treatment  13 13 13 13 
 
 
3.2. Diets  
 
3.2.1. Prevention study 
 
A commercial low fat diet consisting of 20.7% protein, 69.8% carbohydrates and 9.5% fat 
(expressed as % energy per 100g wet matter) (Harlan Teklad, TD.06683, Wisconsin, USA) 
was fed to the rats in the LFD group. A commercial high fat diet consisting of 18.8% protein, 
41.4% carbohydrates and 39.8% fat (expressed as % energy per 100g wet matter) (Harlan 
Teklad, TD.95217, Wisconsin, USA) was fed to the rats in the HFD group. This high fat diet 
had been reported to cause obesity in a previous study [155]. See table 3.3 for detailed 
nutritional information of the diets.  
 
3.2.2. Treatment study 
 
In this study a different low fat diet was given to the rats. This diet consisted of 21.3% protein, 
72.4% carbohydrates and 6.3% fat (expressed as % energy per 100g wet matter) (mice cubes, 
EPOL, South Africa). 
The diet fed to the rats in the HFD group, was a self prepared mixture of 1kg mice cubes 
(EPOL, South Africa), 110g condensed milk (SPAR), 95g brick margarine (Wooden spoon) 
and 65g white margarine (Holsum). The mice cubes were crushed and mixed with 500ml 
boiling water, condensed milk and melted margarine was added. The dough was mixed 
thoroughly, rolled onto baking trays and dried in an oven at 90 ºC for 6 hours. The HFD 
consisted of 15.8% protein, 45.3% carbohydrates and 38.9% fat (expressed as % energy per 
100g wet matter). For detailed nutrition information see table 3.3. 
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Table 3.3: Nutritional values of rat diets for prevention and treatment study. 
  
Prevention study Treatment study 
LFD HFD LFD HFD 
g/100g wet matter 
moisture 6.75 4.53 9.77 12.92 
fibre 6.53 7.25 7.72 5.25 
ash 3.72 4.92 6.30 7.14 
protein 18.10 20.10 16.82 15.10 
carbohydrate 61.20 44.30 57.17 43.12 
fat 3.70 18.90 2.22 16.47 
kcal/100g wet matter 350.5 427.7 315.9 381.1 
% of total energy 
protein 20.66 18.79 21.3 15.84 
carbohydrate 69.84 41.43 72.38 45.26 
fat 9.50 39.77 6.32 38.9 
% of total fatty acids 
C6:0 - 0.1 - - 
C8:0 - 0.2 - - 
C10:0 - 0.5 - 0.6 
C11:0 - - - - 
C12:0 - 0.6 - 5.1 
C14:0 0.1 2.5 0.9 2.8 
C14:1 - 0.5 - - 
C15:0 0.1 0.3 0.3 0.1 
C15:1 - 0.1 - - 
C16:0 10.8 19.3 13.5 40.9 
C16:1 0.3 0.9 1.3 0.4 
C17:0 0.1 0.3 - 0.1 
C17:1 - 0.2 - - 
C18:0 3.8 8.6 2.2 4.5 
C18:1 n9 trans - 19.8 - - 
C18:1 n9 cis 20.5 22.2 24.1 29.8 
C18:2 n6 55.5 20.6 45.3 13.7 
C18:3 n3 7.5 2.1 2.1 0.6 
C20:0 0.6 0.6 0.3 0.3 
C20:1 0.2 0.2 1.0 0.1 
C20:2 0.1 - 0.1 - 
C20:4 n6 - - 0.2 - 
C22:0 0.3 0.2 0.2 0.1 
C22:1 - - 0.4 - 
C20:5 n3 - - 2.5 0.2 
C24:0 0.1 0.1 0.3 0.1 
C24:1 - - 0.2 - 
C22:5 n3 - - 0.6 0.1 
C22:6 n3 - - 4.5 0.3 
SFA 15.9 33.3 17.8 54.7 
MUFA 21.0 43.8 27.0 30.3 
PUFA 63.0 22.8 55.2 14.9 
Trans FA - 19.8 - - 
n3-FA 7.5 2.1 5.1 1.2 
n6-FA 55.5 20.6 45.5 13.7 
n6/n3 ratio 7.4 9.8 8.9 11.4 
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3.3. Medication 
 
3.3.1. Sutherlandia frutescens 
 
A commercially available aqueous S. frutescens extract (Pinosundia®, Value Added Life 
Health Products (Pty) Ltd., South Africa, batch 671) was used in both studies. Rats received a 
dose of 50mg S. frutescens extract/kg BW/d. A previous study conducted at NMMU [52] 
showed anti-diabetic activity for S. frutescens at this concentration. Chadwick et al. [139] used 
2.5g leaves in 100ml water and treated the rats with 0.01ml concoction/g rat. Following 
calculation was applied to determine the amount of extract given to the rats: 
 The extract yield of S. frutescens leaves is approximately 20% (data not shown). 
 Therefore 2.5g leaves yields 0.5g extract diluted in 100ml water. 
 Rats were given 0.01ml/g BW (=10ml/kg) hence received 0.05g extract/kg BW/d. 
For the prevention study S. frutescens extract was added to the drinking water. Consumption 
of water was measured daily and medication was adjusted according to the body weights of 
the rats which were measured weekly. 
Rats in the treatment study were gavaged once per day for 28 days with S. frutescens extract 
diluted in water to obtain a 25mg/ml solution. The volume of extract solution was then 
gavaged into the rat’s stomach according to its weight.  
 
3.3.2. Metformin 
 
Metformin (Glucophage®, Merck) is a known treatment for insulin resistance, and was given 
in a similar dosage recommended for humans, calculated as follows: 
1g metformin/75kg BW/day (human recommendation) = 13.3 mg/kg BW/d. 
One 500mg tablet weighs 600mg = 83.3% active ingredient.  
Therefore 16mg of metformin tablet/kg BW (rat) was used. 
Rats in the treatment study were gavaged once per day for 28 days with metformin diluted in 
water to obtain a 25mg/ml solution. The volume of extract solution was then gavaged into the 
rat’s stomach according to its weight. A slightly lower dosage was used for the animals 
compared to the recommendations for humans (850mg twice daily or 500mg three times daily 
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[156]). The rats were gavaged only once per day to avoid excessive stress, and a maximum of 
13.3mg metformin/kg BW (equivalent to 1g/day) was used to avoid gastrointestinal side 
effects in the animals.    
 
3.4. Sacrifice and sampling 
 
Prior to the sacrifice, animals were starved overnight and anaesthetized by an intramuscular 
injection of 3µl ketamine/g BW (Centaur Labs, 100mg ketamine hydrochloride/ml). Blood 
was removed via heart puncture with a 22 gauge needle without dissecting the animal. The 
blood was collected in blood collection tubes containing potassium EDTA (Sigma Aldrich) 
and centrifuged at 2000xg for 20 min. Plasma was removed and snap frozen in liquid nitrogen 
and stored at -80 °C for further analysis. The animal was then dissected and tissues (pancreas, 
liver, hind limb muscle, kidneys, heart, spleen, epididymal fat, and colon) were snap frozen in 
liquid nitrogen and stored at -80°C for further analysis.  
 
3.5. Glucose clearance and glucose uptake  
 
The rate of glucose clearance from the blood and glucose uptake into muscle, liver and 
epididymal adipose tissue was analysed in rats from the treatment study. Six rats per group 
were starved overnight and anaesthetized by an intramuscular injection of 3µl ketamine/g BW. 
The method used was previously described [139]. The femoral vein was laid open and one 
millilitre of 0.9% saline, containing 0.4g/kg glucose and 2µCi/kg 2-deoxy-D-[2,6-3H]-glucose 
(53 Ci/mmol specific activity, Amersham Bioscience) was slowly injected with an insulin 
syringe (30G). One drop of blood was then taken from the femoral vein and analyzed with a 
glucometer before (0 min) and after injection (5, 10, 15 and 20 min). The rate of glucose 
clearance from the blood was expressed as the slope of the clearance curve.  
To measure the glucose uptake into the tissues, rats from the glucose clearance experiment 
were left for a further 40 min. After a total of one hour incubation time, rats were sacrificed by 
injecting 0.5 ml of ketamine into the heart. Liver, epididymal fat and hind limb muscles were 
removed. Potassium hydroxide (KOH, 30% (m/v), 1ml) was added to 1g of muscle or liver or 
500 mg of fat tissue. The tissues were then degraded by leaving the samples in a boiling water 
bath for 20 minutes. The tissue extract (100µl) was added to 3ml of Packard Ultima Gold 
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scintillation cocktail and was counted for 15 min in a Packard tri-carb 2300TR liquid 
scintillation analyzer (reading 1). One hundred µl of 30% KOH in 3ml of scintillation cocktail 
was used as blank. To check for quenching of the readings due to blood in the tissue samples, 
a known amount of 2-deoxy-D-[2,6-3H]-glucose (10000dpm, equals 100%) was added and 
vials were counted again in the scintillation analyzer (reading 2). The readings were then 
recalculated as follows to obtain the values without quenching: 
 
%quenching = (sample reading 2 – sample reading 1) x100/ (blank reading 2 – blank reading 1) 
Count without quenching = ((reading 1 – blank) x100)/ %quenching) 
 
 
3.6. Fasting plasma insulin  
 
Fasting plasma insulin levels were determined using a radio labelled immunoassay for rat 
insulin (LINCO). 
Principle 
A fixed concentration of [125I] labeled tracer antigen (insulin), was incubated with a constant 
amount of antiserum such that the concentration of antigen binding sites on the rat insulin 
antibody was limited. Addition of unlabeled antigen (rat plasma with insulin) to the system 
causes competition between labeled tracer and unlabeled antigen for the limited and constant 
number of binding sites on the antibody. Thus, the amount of [125I]-tracer bound to the 
antibody decreased as the amount of unlabeled antigen increased. After separating the free 
tracer from antibody bound tracer, the latter was determined using a scintillation counter. A 
standard curve with increasing concentrations of standard unlabelled antigen was used to 
determine the amount of antigen in the plasma samples. 
 
The following protocol was used to determine insulin levels in the rat plasma samples: 
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Plasma samples that had insulin levels higher than 5ng/ml were diluted 1:1 with assay buffer 
to obtain a more accurate reading. 
The plasma insulin values were calculated as follows:  
The reading for non-specific binding was subtracted from all other counts, except total count. 
The percentage of tracer bound, normally 35-50%, was calculated as: 
%B = (total binding/total count) x100.  
The percentage of total binding (%B/Bo) for each standard or sample was calculated using the 
formula: %B/Bo = (sample or standard/total binding) x100. 
The %B/Bo and concentrations for each standard were plotted on a log-log scatter diagram to 
obtain a standard curve. Insulin values for the rat plasma were then read of the standard curve. 
 
3.7. Fasting plasma glucose  
 
Plasma glucose levels were determined using a glucose oxidase assay (Bayer, Sera-Pak).  
 
Principle 
Glucose oxidase converted glucose to gluconic acid and hydrogen peroxide. The latter 
oxidized 4-aminoantipyine and phenol to quinoneimine (a red dye) in the presence of 
peroxidase. Quinoneimine was then  measuered at an absorbance of 492nm. 
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Non-specific 
binding 
200µl - 100µl - 1ml 
Total binding 100µl 100µl 0.1ng/ml 100µl 100µl 1ml 
STD 1 - 100µl 0.2ng/ml 100µl 100µl 1ml 
STD 2 - 100µl 0.5ng/ml 100µl 100µl 1ml 
STD 3 - 100µl 1.0ng/ml 100µl 100µl 1ml 
STD 4 - 100µl 2.0ng/ml 100µl 100µl 1ml 
STD 5 - 100µl 5.0ng/ml 100µl 100µl 1ml 
STD 6 - 100µl 10.0ng/ml 100µl 100µl 1ml 
samples - 100µl of rat plasma 100µl 100µl 1ml 
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Plasma samples were diluted 1:1 with destilled water. Five µl of diluted plasma sample was 
added to each well (96-well plate) and 150µl of glucose oxidase reagent mix was added. Plate 
was left at 37°C for full colour development (approx. 20min) and read in an absorbance plate 
reader at 492nm. Absorbance readings for the blank were subtracted from the sample readings, 
which were then plotted onto a linear standard curve to obtain the glucose concentrations in 
the plasma. A 8-point standard curve was used ranging from 0-8mM glucose. 
 
3.8. Assessment of insulin resistance 
 
To evaluate if the animals were insulin resistant the quantitative insulin sensitivity check index 
(QUICKI) [157] and homeostasis model assessment for insulin resistance (HOMA–IR) [158] 
were calculated as follows: 
 
QUICKI = 1/(log INSfasting [mU/l] + log GLUfasting [mg/dl]) 
HOMA-IR = (INSfasting [mU/l] x GLUfasting [mmol/l]) / 22.5 
 
While the QUICK-index, as a measurement of insulin sensitivity is decreased in subjects with 
insulin resistance, the HOMA-IR as a direct measurement of insulin resistance will be 
increased.  
 
 
3.9. Plasma free fatty acids 
 
The total plasma free fatty acid (FFA) levels were analyzed using an enzymatic colorimetric 
half-micro assay (Roche, Germany). 
 
Principle 
Acyl-CoA synthetase and ATP (reagent mix A) converted free fatty acids into acyl-CoA. In 
presence of acyl-CoA oxidase (also in reagent mix A) acyl-CoA reacted with oxygen to form 
2,3-enoyl-CoA and hydrogen peroxide. Hydrogen peroxide was used as a substrate for 
peroxidase to convert any 2,4,6-tribromo-3-hydroxy-benzoic acid and 4-aminoantipyrine 
(reagent mix B) present to a red dye. The dye was then measured at a wavelength of 546nm. 
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The manufacturer’s instructions were followed but scaled down to use in a microtiter plate. 
One hundred µl of reagent mix A was added to five µl sample, standard or blank (distilled 
water) and left for 10 min at 25°C. Then five µl of N-ethyl-maleinimide-solution was added to 
remove any excess CoA and the microtiter plate was read at 546nm (reading A). Reagent B 
was added in the amount of five µl to each well and left for 15min at 25°C until red color had 
fully developed. Plate was then read again at 546nm (reading B). 
 
To prepare standard dilutions of free fatty acids, 36mg of palmitic acid (Sigma-Aldrich) was 
dissolved in 24ml warm ethanol (1.4mM FFA). This solution was then diluted with 6% Triton 
X-100 to obtain following concentrations: 
mM FFA 6% Triton X-100 (µl) 1.4mM FFA (µl) 
0 1000 - 
0.0875 937.5 62.5 
0.175 875 125 
0.35 750 250 
0.525 625 375 
0.7 500 500 
 
The following formula was applied to calculate FFA levels: 
FFA (mM) = (standard reading B-blank reading B) - (standard reading A-blank reading A).  
 
Absorbance values for the blank were also subtracted from the absorbance values for the 
samples and then plotted onto the standard curve. 
 
3.10. Plasma triglyceride 
 
The plasma triglyceride (TG) levels were analyzed using a colorimetric enzymatic assay 
(KAT, South Africa). 
 
Principle 
Plasma triglycerides were hydrolyzed by lipoprotein lipases to glycerol and free fatty acids. 
The glycerol was then converted by glycerol kinase to glycerol-3-phosphate (G3P) and G3P-
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oxidase to dihydroxyacetone phosphate and hydrogen peroxide. The hydrogen peroxide was 
then able to convert 4-chlorophenol and 4-aminoantipyrine to red quinone which could be 
read at 510nm. 
 
The supplied reagent mix contained all the necessary enzymes and pre-dye. The protocol 
supplied by the manufacturer was used but scaled down to microtiter plate size.  
Ten microliter of standard or sample was incubated at 37°C with 250µl of reagent mix until 
the colour had fully developed (approx.15min). The absorbance values were read at 510nm on 
a plate reader and the absorbance value for the blank was subtracted. The standard supplied by 
the manufacturer (2.29mmol/l) was diluted with water to obtain a 5-point standard curve. The 
absorbance values of the plasma samples were then calculated using the linear standard curve.  
 
3.11. Plasma cholesterol (total) 
 
The plasma total cholesterol content was analyzed using a colorimetric enzymatic assay 
(KAT, South Africa). Free and esterified cholesterol can be measured with this assay.  
 
Principle  
Cholesterol esters were split into free cholesterol and fatty acids by cholesterol esterase. The 
free cholesterol could then be oxidized by a cholesterol oxidase to cholestene-3-one and 
hydrogen peroxide. Present phenol and 4-aminoantipyren were then converted by the peroxide 
to quinoneimine (red dye). The red dye was measured at 500nm.  
 
The enzymes and pre-dyes necessary for the colour reaction were supplied in a reagent mix of 
which 250µl was added to either five µl of plasma sample or standard. This was scaled down 
to suit a 96-plate well. Absorbance values for the blank were subtracted from the values for 
standard and plasma samples. The standard supplied by the manufacturer (5.2mmol/l) was 
diluted with water in a dilution series to obtain a 5-point standard curve.  
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3.12. Plasma HDL-cholesterol 
 
High density lipoprotein (HDL)-cholestrol was determined by using an enzymatic colorimetric 
assay (Shanghai Rongsheng Biotech). 
 
Principle 
Lipoproteins contained in the plasma were stabilized and coated by a polymer and anion 
under the action of a surfactant (reagent mix A). Reagent mix B contained an elimination 
reagent and enzymes, the former rapidly released HDL-cholesterol which was then hydrolized 
and oxidized to obtain hydrogen peroxide. The peroxide then reacted with a pre-dye (also 
contained in reagent mix B) to form a red colour which was measured at 546nm.  
 
Three µl of plasma, standard or blank were added to 240µl reagent mix A in a 96-well plate. 
This was kept at 37°C for 5 min before reading the absorbance values at 546nm with a plate 
reader. Reagent mix B was then added in a quantity of 80µl to each well and incubated for 
another 5 min at 37°C. After the colour had fully developed the plate was read again at 
546nm. The standard supplied by the manufacturer (1.05mmol/l) was used for a serial dilution 
to obtain a 5 point standard curve on which the sample absorbance values were plotted. To 
calculate the HDL-cholesterol levels following formula was used:  
 
HDL-cholesterol (mM) = (reading B - blank reading B) - (reading A - blank reading A).  
 
 
3.13. Plasma LDL-cholesterol 
 
Low-density lipoprotein (LDL)-cholesterol concentrations in the rat plasma were calculated 
according to the equation of Friedewald et al. [159]. 
 
LDL = total cholesterol – HDL-cholesterol – (Triglyceride/ 5) 
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3.14. Plasma cytokines  
 
To detect levels of circulating cytokines in the plasma a rat cytokine 6-plex flow cytomix was 
used (Bender MedSystems, Austria). This bead based fluorescent immunoassay was suitable 
for quantitative detection of rat granulocyte macrophage colony stimulating factor (GM-CSF), 
interferon-γ (INF- γ), interleukin-1α (IL-1α), interleukin-4 (IL-4), monocyte chemoattractant 
protein-1 (MCP-1) and tumor necrosis factor-α (TNF- α) by flow cytometry. 
 
Principle 
Two sets of different size fluorescent beads were coated with antibodies specific to the 
analytes. The beads were incubated with standard or sample and the analyte present bound to 
the surface antibody on the beads. A biotin-conjugated secondary antibody mixture is added 
and bound to the analyte attached to the bead. Strepavidin was added which bound to the 
biotin conjugates and emitted fluorescent signals. The beads were then sorted by flow 
cytometry on a basis of their different sizes and fluorescence intensities.  
 
Supplied standards were reconstituted by adding distilled water and 7-point serial dilution of 
each analyte was obtained by adding assay buffer. 
Twenty five µl of bead mixture was needed for each test (Vfinal = number of tests x 25µl). The 
supplied bead sets were vortexed and 1/20 of final volume of each bead added to new vial. 
Assay buffer was added to obtain Vfinal. Bead mixtures were centrifuged at 3000 x g for 5 
minutes and the supernatant discarded and fresh assay buffer added. 
Fifty µl of biotin-conjugate mixture was required for each test (Vfinal = number of test x 50µl). 
A 1/20 of Vfinal was pipetted for each biotin conjugate and diluted to the final volume with 
assay buffer. 
To complete the test 25µl of either standard, blank or rat plasma was placed in flow cytometry 
tubes and 25µl of bead mixture and 50µl of biotin-conjugate mixture added. The contents were 
mixed and incubated at room temperature for 2 h. One ml of assay buffer was then added and 
tubes were centrifuged at 200x g for 5 min. The supernatant was discarded and the washing 
process was repeated. Fifty µl of Streptavidin solution was added to all the tubes and 
incubated for 1 h at room temperature. The tubes were washed twice with assay buffer and a 
final 500µl of buffer was added to the tubes. The tubes were vortexed and analyzed on a flow 
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cytometer (FC 500, Beckman Coulter). Flow cytometer settings according to manufacturer’s 
instructions were applied for the analysis.  
 
 
3.15. Total tissue fat content  
 
Crude fat was extracted from liver, muscle and adipose tissue using the method described by 
Folch et al. [160]. The method was modified for extraction from tissues as well as cell 
cultures. The organic solvents used for this experiment met the quality standard for gas 
chromatography (SupraSolv, Merck, Germany). BHT (Sigma) was added to all steps in the 
extraction process to protect the fatty acids from oxidation. Liver (300-400mg), muscle (800-
1000mg) and adipose tissue (200-300mg) were weighed and homogenized. Muscle tissue was 
crushed with a metal pestle on a cold metal plate and transferred into a metal container 
containing small metal beads and 2ml of chloroform/methanol (2:1; plus 0.01% BHT). The 
metal  container was placed into a grinder (Retsch) and shaken at 30 Hz for 10min. Liver and 
adipose tissues were placed into a glass grinder and 1ml of chloroform/methanol (2:1; plus 
0.01% BHT) added. The tissues were then manually ground until a homogenous solution was 
obtained. Homogenized tissues were filtered through a glass fiber filter (GF/A, Whatman) into 
a glass vial, and the grinder and filter were washed with chloroform/methanol (2:1; plus 0.01% 
BHT). The final volume of chloroform/methanol used to extract the crude fat was at least 
twenty times that of the tissue (e.g. 200mg tissue was extracted with a final amount of 4ml 
chloroform/methanol). To remove any non-lipid components in the extract, saline (0.9% NaCl; 
saturated with cloroform/methanol) was added to the chloroform/methanol extract solution 
(20% v/v) and  vials were flushed with nitrogen gas (UHP Nitrogen, AFROX) before sealing 
and gently inverting them ten times. The vials were centrifuged at 500xG for 5 minutes to 
achieve a complete separation of the water/methanol layer, the chloroform layer and protein 
disc. The water/methanol layer and the protein disc contained the non-lipid components which 
were removed and discarded. The chloroform layer was filtered through anhydrous sodium 
sulfate to remove any remaining water in the solution. The filtrate was collected in a new and 
weight glass vial which was then placed into a block heater (40ºC) and the chloroform was 
removed to total dryness with a stream of nitrogen gas. The glass vial was weighed to 
determine the total amount of crude fat extracted. The fat extracts were dissolved in 
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chloroform/methanol (2:1; plus 0.01% BHT), flushed with nitrogen gas and stored for up to 2 
weeks at -20 ºC. 
 
3.16. Tissue lipid fractions 
 
The crude fat extracts obtained from liver, muscle and adipose tissue were analyzed for 
triglyceride, total cholesterol and free fatty acid concentrations. The protocols described in 
sections 3.9, 3.10, and 3.11 were used to analyze the different lipid fractions. 
 
Crude fat extracts were diluted in 6% Triton X-100 as follows prior to analysis: 
  
  
analysis for 
Triglyceride Total cholesterol Free fatty acids 
Liver fat 25 mg/ml 50 mg/ml 50 mg/ml 
Muscle fat 5 mg/ml 25 mg/ml 10 mg/ml 
Adipose fat 1 mg/ml 250 mg/ml 250 mg/ml 
 
 
3.17. Tissue fatty acid profile 
 
3.17.1. Thin layer chromatography (TLC) 
 
To be able to differentiate between membrane lipids and storage lipids the crude fat extract 
was separated into different lipid fractions via TLC. Crude fat extracts (3mg) and TLC 
standards were spotted onto a glass-backed Silica 60 plates (Merck). The mobile phase 
consisted of n-hexane – diethyl ether – acidic acid (70:30:1). Plates were placed into a TLC 
glass chamber and the mobile phase left to run for 20 minutes. Plates were then dried under a 
stream of nitrogen gas and placed in a glass chamber with iodine crystals for 15 minutes. 
Samples were covered with a glass plate and only standards were subjected to the iodine 
fumes. After the development of the lipid bands, the areas corresponding to phospholipids and 
triglycerides were scraped of the plates and put into separate screw cap vials. 
Chloroform/methanol (2:1; plus 0.01% BHT; 300-500µl) was added to dissolve lipids.  
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3.17.2. Methylation of fatty acids 
 
To prepare the lipids for gas chromatography the fatty acids need to be unbound and volatile. 
Sodium methoxide (sodium methylate, methanolic base, CH3NaO) is a base catalyst for very 
rapid trans-esterification of triglycerides and phospholipids. The following reaction occurs: 
    
  -OCH3 
RCOOR’ + CH3 → RCOOCH3 + R’OH 
 
Sodium methoxide (0.5N; 200µl) was added to the TLC scrapings and left at room 
temperature for 5 minutes. Hexane and distilled water (2ml and 1ml respectively) were added 
and vials flushed with nitrogen gas, sealed and inverted ten times. For complete separation of 
the different layers the vials were centrifuged for 5 minutes at 500xG. The upper hexane layer 
was then transferred into a new vial containing anhydrous sodium sulfate to remove any water 
residues. The hexane containing the free fatty acid methyl esters (FAME) was transferred into 
a new vial and solvent was removed completely with a stream of nitrogen gas and 50µl hexane 
was added to the samples. FAME were then analyzed within 2 days of preparation via gas 
chromatography.  
 
3.17.3. Gas chromatography (GC) 
 
The FAME were analyzed using a Focus GC, Thermo Finnegan with a very polar column 
(BPX 70, 30m length, 0.32 mm inner diameter, 0.25µm film thickness) and flame ionization 
detector (FID). 
GC settings were as follows: the oven starting temperature was 125 ºC; ramp 1: 15 ºC/min to 
184 ºC; ramp 2: 1.5 ºC/min to 193 ºC; ramp 3: 10 ºC/min to 230 ºC; giving a total run time of 
13.63 min. The inlet temperature was 250 ºC, with a 1:80 split and a split flow of 104ml/min. 
The column flow was 1.3ml/min and the FID temperature was 280 ºC with a range of 1. 
 
The standards used were SupelcoTM 37 component FAME mix (Sigma Aldrich, Germany); 
Linoleic acid methyl ester isomer mix (Sigma Aldrich, Germany); Methyle arachidonate 
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(Sigma Aldrich, Germany); GLC 481B (trans FAME mix) (Nu-Chek-Prep, MN, USA); and 
Methyl Docosapentaenoate (Nu-Chek-Prep, MN, USA). 
 
To identify the peaks, retention times of the sample FAME were compared to the retention 
times of the standard FAME and the area under the peak was calculated using ChromQuest 
software.  
 
3.18. Yield and fatty acid composition of aqueous S. frutescens extract 
 
To analyze the fatty acid composition of the commercial S. frutescens extract and compare the 
data to other S. frutescens extracts, we used two self prepared aqueous extracts. 
Whole plants were collected in the Uitenhage area (Eastern Cape, South Africa) and left to dry 
at room temperature for either 3 or 14 days before stripping the leaves from the stems. One 
hundred ml of distilled water was boiled and added to 2.5g leaves. Concoction was left 
overnight and filtered (Whatman filter, No1) and tea placed into weighed tubes. The samples 
were placed onto a freeze drier (Virtis, SP-Industries) and the obtained extracts were weighed 
immediately. The respective yields of extracts were 24.7% and 23.9% for the three and 
fourteen days dried leafs, respectively.  
 
To obtain the lipids from the S. frutescens extracts 10ml of chloroform/methanol (2:1; plus 
0.01% BHT) was added to 500mg of plant extract and left on a shaker for 2h.  
The protocols described in sections 3.15. 3.16. and 3.17. were followed for lipid extraction, 
lipid fractioning and fatty acid analysis.  
 
 3.19. Statistical Analysis 
 
Values were reported as mean ± SEM. Comparisons between groups were analyzed for 
statistical significance using the unpaired student t-test for several independent observations. P 
values less than 0.05 were considered significant. Outliers were excluded using Grubbs-test 
(GraphPad).  
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The following symbols were used to show statistical significance: 
*p<0.05  **p<0.01  ***p<0.001  compared to the HFD group 
†p<0.05  ††p<0.01  †††p<0.001  compared to the LFD group 
#p<0.05  ##p<0.01  ###p<0.001  compared to the HFD+Met group. 
 
For the statistical analysis of the fatty acid profile in rat tissues no comparison was made 
between the LFD group and any of the other groups. The differences seen in the LFD group 
were mainly influenced by the fatty acid profile of the diet and differences in the tissue fatty 
acid profile were not necessarily related to insulin resistance. Also, fatty acids that were lower 
than 0.5% of total fatty acids were not compared between the groups. The accuracy of the 
detection of values under 0.5% was not given due to noises in the GC base line. 
 
High variations for cytokine values were detected within the groups. This was mostly due to 
zero values detected in several rats. To be still able to display changes in plasma cytokine 
levels, the median values were calculated (n=7 rats/group). One rat per group that was furthest 
away from the median value for all of the cytokines was not considered for the calculation of 
mean ± SEM (n=6/group). 
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Chapter 4 
 
Results 
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4.1. Prevention study 
 
Rats in the prevention study were fed low fat diet (LFD), high fat diet (HFD) or HFD 
supplemented with S. frutescens (HFD+S.f.) and were sacrificed at different time points. The 
metabolic and physiological changes in the HFD group were compared to the control rats 
(LFD group). To determine if medication with S. frutescens was able to prevent the 
pathological changes caused by HFD, results from the HFD+S.f. group were compared to the 
HFD group and LFD group.  
 
 
4.1.1. Body weight of rats 
 
Rats were randomly divided into 3 groups at the beginning of the feeding and treatment 
regime. Care was taken, that there was no difference in weight between the LFD group, HFD 
group and HFD+S.f. group at the start of the experiment (figure 4.1).  
Rats fed with high fat diet developed significantly increased body weights by week twelve in 
comparison to the control group (556.6 ± 19.0g vs. 505.0 ± 21.9g p<0.05).  
At week four a significant increase in body weight was observed in the rats medicated with 
S. frutescens compared to the LFD and HFD group. Later in the experiment the weight gain in 
this group slowed down and at week twelve the average weight in the HFD+S.f. group was 
significantly lower compared to the HFD group (519.3 ± 39.8g vs. 556.6 ± 19.0g p<0.05).  
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Figure 4.1: Body weight of rats from day 0 to day 84 (week 12) of the feeding scheme. 
Values are expressed as mean ± SEM (n=7 per group).  *p<0.05 compared to HFD group, †† p<0.01 
compared to LFD group 
 
 
4.1.2. Food and water intake  
 
The exact consumption of food and water could not be determined accurately due to the 
housing of the rats in non-metabolic cages. The water intake was measured daily in the 
HFD+S.f. group to determine the amount of plant extract taken in. No comparison between the 
three groups was made. The different levels of moisture in the diets (6.75% in LFD and 4.53% 
in HFD) made the water intake too variable. The slightly bitter taste of S. frutescens did not 
appear to influence the amount of drinking water consumed by the rats. For example at week 
two rats in the HFD group consumed on average 115.4ml water/kg BW/d while rats in the 
HFD+S.f. group consumed 114.8ml water/kg BW/d (including spillage).   
 
4.1.3. Fasting plasma glucose levels 
 
There was no significant change in fasting plasma glucose values between the three groups at 
any time point (figure 4.2 a). Rats did not become diabetic after feeding for twelve weeks on 
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high fat diet and treatment with S. frutescens extract also did not alter fasting plasma glucose 
levels. 
   
4.1.4. Fasting plasma insulin levels  
 
The corresponding fasting insulin values in the rat plasma are shown in  figure 4.2 b. Rats that 
were fed HFD displayed significantly higher insulin levels from week eight compared to the 
lean control group (2.71 ± 0.30ng/ml vs. 1.91 ± 0.17ng/ml p<0.05). This significant difference 
was maintained at week twelve (2.21 ± 0.20ng/ml vs. 1.48 ± 0.23ng/ml p<0.05).  
These results clearly indicate that prolonged intake of high caloric food resulted in higher 
levels of insulin, which are needed in order to maintain normal blood glucose levels. 
Unexpectedly, there were significantly elevated insulin levels in the LFD group at week four 
compared to the HFD group (p<0.01). The possible reasons for this finding will be discussed 
in section 5.  
Comparing the group of rats medicated with S. frutescens with the HFD only group, 
significantly lower insulin levels were found at weeks two (p<0.01), eight (p<0.05) and twelve 
(p<0.001). This suggests that S. frutescens achieved higher insulin sensitivity in the body, such 
that normal blood glucose levels could be maintained with lower amounts of insulin. The 
assessment of insulin resistance (see section 4.1.5.) supports this hypothesis.   
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Figure 4.2: Fasting plasma glucose (a) and insulin (b). 
Values are expressed as mean ± SEM (n=7 per group).  *p<0.05 **p<0.01 ***p<0.001 compared to HFD group 
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4.1.5. Assessment of insulin resistance 
 
To verify if rats fed with high fat diet had indeed developed IR and if S. frutescens had 
prevented the pathogenesis, the homeostatic model assessment for insulin resistance (HOMA-
IR) [158] and quantitative insulin sensitivity check index (QUICKI) [157] were applied.   
 
4.1.5.1. HOMA-IR 
 
From week eight the rats in the HFD group displayed insulin resistance. This was seen as a 
significantly increased HOMA-IR in the HFD group compared to the control group (24.34 ± 
1.33 vs. 10.72 ± 0.98 p<0.001 at week 8 and 18.03 ± 1.44 vs. 9.60 ± 1.58 p<0.01 at week 12) 
(Figure 4.3 a). 
In contrast rats medicated with S. frutescens displayed similar low HOMA-IR values to those 
of rats in the LFD group at week two, eight and twelve. The rats in the HFD+S.f. group did 
not become insulin resistant. 
 
4.1.5.2. QUICKI 
 
The results for the quantitative insulin sensitivity check index (QUICKI) also confirmed that 
S. frutescens counteracts the effects of high fat diet in regards to insulin sensitivity (figure 4.3 
b). Rats fed with high caloric food showed a significant decrease in insulin sensitivity at week 
eight (p<0.05) and twelve (p<0.01), whereas rats medicated with S. frutescens had 
significantly (p<0.05) higher sensitivity compared to the HFD only group at the same time as 
well as at week two (p<0.05).  
 
Both models, HOMA-IR and QUICK-index, demonstrate that prolonged intake of HFD 
caused insulin resistance in male Wistar rats after eight weeks. Rats in the control group 
displayed IR at week four due to the significantly increased insulin levels (see 4.1.4). This 
finding will be discussed in section 5.  
S. frutescens, given as a supplement to the high fat diet, prevented these pathological 
changes and kept the insulin sensitivity at similar levels to that of the control rats (LFD 
group).  
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Figure 4.3: Assessment of insulin resistance via HOMA-IR (a) and QUICK-index (b). 
Values are expressed as mean ± SEM (n=7 per group).  *p<0.05 **p<0.01 ***p<0.001 compared to HFD group. 
 
 
 
4.1.6. Plasma lipids  
 
4.1.6.1. Plasma free fatty acids 
 
The feeding of high fat diet increased the levels of circulating free fatty acids. As depicted in 
figure 4.4 a the elevation in the HFD group in comparison to the control group was already 
noticeable at week one, although not quite significant (78.4 ± 7.3µmol/l vs. 54.3 ± 8.9µmol/l 
p=0.058). This difference became significant at week eight (95.0 ± 5.6µmol/l vs. 70.7 
±5.3µmol/l p<0.05) and remained elevated at week twelve (89.5 ± 5.3µmol/l vs. 72.7 ± 
2.5µmol/l p<0.05). 
Supplementing the high fat diet with S. frutescens lowered the plasma FFA levels 
throughout the experiment. Already at week one the FFA levels in the HFD+S.f. group were 
significantly lower than the HFD group (50.6 ± 6.0µmol/l vs. 78.4 ± 7.3µmol/l p<0.05) and 
the same pattern was still evident at week twelve (53.0 ± 6.7µmol/l vs. 89.5 ± 5.3µmol/l 
p<0.01). Rats in HFD+S.f. group displayed even lower levels of circulating FFA than the 
control rats (LFD group). This difference was apparent from week one and became significant 
from week eight (p<0.05). 
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4.1.6.2. Plasma triglycerides 
 
The levels of plasma triglycerides in the rats are shown in figure 4.4 b. Comparing rats fed 
with high caloric food to the lean control rats, the TG values in the HFD group were 
significantly elevated at week one (0.75 ± 0.08mmol/l vs. 0.51 ± 0.06mmol/l p<0.05). This 
difference was not seen at any of the later time points in the experiment. 
Plasma TG levels in the HFD+S.f. group remained unchanged compared to the HFD group, 
except at week two when a significant increase was observed (p<0.05). Unexpectedly S. 
frutescens increased the TG levels in comparison to the control rats. This elevation was 
significant at weeks one, eight and twelve (p<0.05). 
 
4.1.6.3. Total plasma cholesterol 
 
The effects of high fat diet on the plasma cholesterol levels can be seen in figure 4.4 c. In the 
HFD group a clear trend towards elevated cholesterol concentrations was seen compared to 
the LFD group. This increase was significant at weeks four and eight (p<0.05).  
Supplementing the HFD with S. frutescens resulted in significantly decreased cholesterol 
levels at weeks four (p<0.01) and twelve (p<0.05) when compared to the HFD only group. 
However, comparing the results of the HFD+S.f. group to the LFD rats, a significant increase 
was observed at weeks one and eight (p<0.05). 
  
4.1.6.4. Plasma HDL cholesterol 
 
As shown in figure 4.4 d, there was no significant change in HDL cholesterol levels between 
the HFD and LFD group at any of the time points. 
An initial decrease in HDL-cholesterol was observed in the HFD+S.f. group compared to the 
HFD group (p<0.01). However, this changed during the course of the experiment when the 
HFD+S.f. rats displayed a clear trend of elevated HDL cholesterol concentrations. The HDL-
cholesterol concentrations were significantly higher compared to the HFD group at week eight 
(p<0.01) and also compared to the LFD group at weeks eight and twelve (p<0.05).  
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4.1.6.5. Plasma LDL cholesterol  
 
Feeding a high caloric diet to the rats had no effects on the LDL cholesterol levels compared 
to the control rats. There were no significant changes between those two groups (figure 4.4 e).  
In spite of this, giving S. frutescens daily to the high fat diet resulted in an initial increase in 
LDL cholesterol, but only compared to the LFD group (p<0.01). However, longer S. 
frutescens intake resulted in significantly lower levels of LDL-cholesterol at weeks four and 
twelve compared to both LFD and HFD groups (p<0.05). 
 
4.1.6.6. LDL/HDL ratio 
 
Looking at the LDL/HDL-cholesterol ratio in figure 4.4.f, there was only a significant 
difference between LFD and HFD group at week two (p<0.05), otherwise the high fat diet had 
no effect on the ratio.  
At week one S. frutescens significantly increased the LDL/HDL cholesterol ratio compared to 
the LFD and HFD group (p<0.001). This is due to the increased LDL cholesterol and 
decreased HDL-cholesterol at this time point as noted in 4.1.6.4 and 4.1.6.5, respectively. At 
week two the ratio was still increased in comparison to the HFD group (p<0.05). However, at 
the last two time points (week eight and twelve) the LDL/HDL-cholesterol ratio dropped 
significantly compared to the HFD group (p<0.01) and was even lower than in the LFD group 
(p<0.001). Therefore S. frutescens had a beneficial influenced the LDL/HDL cholesterol ratio 
after long term supplementation. 
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Figure 4.4: Plasma lipid parameters: Free fatty acids (a), triglycerides (b), total cholesterol (c), high 
density lipoprotein (HDL)-cholesterol (d), low density lipoprotein (LDL)-cholesterol (e), and 
LDL/HDL-cholesterol ratio (f).  
Values are expressed as mean ± SEM (n=7 per group).  *p<0.05 **p<0.01 ***p<0.001 compared to 
HFD group; † p<0.05 ††p<0.01 †††p<0.001 compared to LFD group. 
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4.1.7. Plasma cytokines 
 
4.1.7.1. Tumor necrosis factor-alpha (TNF- α) 
 
According to the results shown in figure 4.5 a & b, there were no significant changes in 
circulating TNF-α levels at any time point between the three groups. Continuous exposure to 
high fat diet appeared to elevate circulating TNF-α level after eight weeks compared to the 
lean control (73.4 ± 21.2pg/ml vs. 47.9 ± 10.2pg/ml), which were decreased in the HFD+S.f. 
group (62.7 ± 9.0pg/ml). However, these differences were not significant, due to the high 
variations within the groups.  
 
4.1.7.2. Interleukin-1α (IL-1 α) 
 
IL-1α levels, as shown in figure 4.5 c, were higher in the rats fed with HFD from week two 
compared to the control rats. However, this difference was only significant at week four (20.1 
± 5.4pg/ml vs. 53.5 ± 5.3pg/ml p<0.01).  
Rats in the HFD+S.f. group displayed very low levels of IL-1α when compared to both, LFD 
and HFD group. At week four IL-1α plasma concentrations in the HFD+S.f. group were 
significantly lower than in the HFD group (11.2 ± 4.7pg/ml vs. 53.5 ± 5.3pg/ml p<0.001). At 
week twelve IL-1α levels in the HFD+S.f. group were lower compared to the lean control rats 
(2.9 ± 2.9pg/ml vs. 27.5 ± 3.0pg/ml <0.001) but not compared to the HFD group (62.0 ± 
29.5pg/ml), due to a high variation within the HFD group. The median values for the 
HFD+S.f. group were zero at week eight and twelve, indicating that no circulating IL-1α was 
detectable in this group (figure 4.5 d).  
. 
4.1.7.3. Interleukin-4 (IL-4) 
 
IL-4 levels were noticeably increased by high fat diet from week four. As figure 4.5 e 
illustrates this increase of IL-4 in the HFD group (1.4 ± 0.2pg/ml) was only significant at week 
four compared to the lean controls (0.6 ± 0.3pg/ml) and the HFD+S.f. (0.1 ± 0.1pg/ml) group 
(p<0.05 and <0.001, respectively).  
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As with IL-1α, S. frutescens lowered the IL-4 levels in HFD fed rats. This clear trend was seen 
from week four. The median values in figure 4.5 f confirmed the finding that S. frutescens 
appeared to have a lowering effect on circulating IL-4. Due to high variations within the HFD 
group this decrease in circulating IL-4 was only significant at week four. 
 
4.1.7.4. Monocyte chemo-attractant protein-1 (MCP-1) 
 
It is clear from figures 4.5 g & h that there were no significant differences in circulating 
MCP-1 levels between the three groups at any time point, although the amounts of circulating 
MCP-1 generally decreased in all groups over time. 
 
4.1.7.5. Granulocyte macrophage colony stimulating factor (GM-CSF) 
 
Long term intake of high fat diet did not elevate the GM-CSF levels in the plasma. No 
significant differences were found between the lean control and the HFD group at any of the 
time points (figures 4.5 i & j).  
Supplementing the high fat diet with S. frutescens had only a significant effect at week twelve 
compared to the lean control group, the circulating level of GM-CSF was reduced from 2.4 ± 
1.3pg/ml in the lean controls to 15.9 ± 1.2 pg/ml in the HFD+S.f. group (p<0.001). 
  
 
4.1.7.6. Interferon-γ (IFN-γ) 
 
No circulating IFN-γ could be measured in any of the plasma samples (data not shown). 
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Figure 4.5: Plasma cytokines: TNF-α (a,b), IL-1α (c,d), IL-4 (e,f), MCP-1 (g,h), and GM-CSF (i,j),. 
Values in the left hand figures (a,c,e,g,i) are expressed as mean ± SEM (n=6 per group).  
Values in the right hand figures (b,d,f,h,j) are expressed as median (n=7 per group).  *p<0.05 **p<0.01 
***p<0.001 compared to HFD group; †††p<0.001 compared to LFD group. 
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4.2. Treatment study 
 
Rats in the treatment study were fed for twelve weeks with a HFD to induce IR and a second 
set of rats were fed a LFD as control. After twelve weeks some of the rats were sacrificed to 
confirm IR and the remaining HFD rats were treated with water (negative control), S. 
frutescens extract (test) or metformin (positive control) for 28 days.  
 
4.2.1. Body weight of rats 
 
Male Wistar rats were randomly divided into two groups at the beginning of the feeding 
regime. The first weighing of the rats on day five showed that rats on low fat diet had 
significantly higher weights than the rats fed with high fat diet (274.4 ± 10.4g vs. 246.4 ± 5.7g 
p<0.05) (figure 4.6). This difference in weight remained significant until day 26 of the feeding 
regime when the difference in weight between the groups started to reduce.  
At the start of the treatment regime, when rats in both groups were gavaged with water as 
control, the average weights in both groups were almost identical (503.8 ± 13.9g LFD vs. 
511.4 ± 14.7g HFD). Rats that were fed on LFD reached a plateau at 60 days and did not pick 
up more weight until the end of the experiment. In contrast, rats in the HFD group started to 
overtake the rats in the lean control group from day 80 and continued to increase in weight till 
the end of the experiment. At day 95 the difference in body weight between the groups was 
significant with average weights of 510.6 ± 11.7g for the LFD group and 571.0 ± 20.3g for the 
HFD group (p<0.05). At the end of the experiment the rats in the LFD and HFD group 
weighed 509.0 ± 10.0g and 591.8 ± 20.9g, respectively (p<0.01). 
Comparing the weight changes in the treatment study with the prevention study, confirmed 
that male Wistar rats only become overweight after a long term intake of HFD.  
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Figure 4.6: Body weight of rats from the start of the feeding regime to the end of the treatment (112 
days in total).  
The arrow indicates the start of the gavaging with water as a control. Values are expressed as mean ± 
SEM (n=11 per group).  *p<0.05 **p<0.01 compared to HFD group. 
 
 
To display the changes in weight after the start of the treatment regime, the average weights of 
all four groups (LFD, HFD, HFD+S.f, and HFD+Met) were plotted onto a new graph (figure 
4.7). 
As mentioned above, rats in the HFD group started the treatment with similar body weights 
to the lean control group but had gained significantly (p<0.01) more weight by the end of the 
experiment.  
Medicating the high fat fed rats daily with 50mg S. frutescens extract/kg BW resulted in a 
decrease in weight gain from the start of the treatment period, which became significant by the 
end of the experiment. On day 28 of the treatment rats medicated with S. frutescens still 
displayed a significantly higher weight than the lean control rats (547.3 ± 8.1g vs. 509.0 ± 
10.0g p<0.01) but their body weight had significantly declined compared to the rats fed with 
high fat diet only (547.3 ± 8.1g vs. 591.8 ± 20.9g p<0.05). 
Treating high fat fed rats daily with 13.3 mg metformin/kg BW resulted in no significant 
difference in weight within 28 days compared to the HFD group, although the mean weight 
appeared to decline from day 100 (day 16 of treatment). Body weights in the HFD+Met group 
remained significantly higher than in the LFD group until the end of the treatment period. 
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Figure 4.7: Body weight of rats from the start to the end of the treatment (28 days in total).  
The rats were gavaged with either water as a control (LFD and HFD group), S. frutescens extract 
(HFD+S.f.) or metformin (HFD+Met). Values are expressed as mean ± SEM (n=11 per group). *p<0.05 
**p<0.01 compared to HFD group; † p<0.05 ††p<0.01 compared to LFD group. 
 
4.2.2. Food and water intake 
 
The intake of food could not be determined accurately due to the brittle consistency of the 
self-made high fat diet patties and the housing of the rats in non-metabolic cages. The amount 
of water taken in by the rats is not shown as the moisture in the two different diets varied 
(9.77% in LFD and 12.92% in HFD) and therefore influenced the intake of drinking water.  
 
4.2.3. Confirmation of insulin resistance before treatment 
 
It was important to determine if the rats in the HFD group had become insulin resistant before 
the start of the treatment regimes. Fasting plasma insulin and glucose levels were measured 
and the insulin resistance was assessed (see section 3.8). 
In agreement with the results from the prevention study (see section 4.1.3), the fasting 
glucose levels did not change after twelve weeks of high fat diet intake. Glucose levels were 
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slightly, but not significantly increased in the HFD group (6.60 ± 0.40mmol/l vs. 6.99 ± 
0.40mmol/l) (figure 4.8 a).  
Also in agreement with the findings in the prevention study (see section 4.3.2), the 
prolonged intake of high caloric food led to a significantly increased fasting insulin level (0.70 
± 0.19ng/ml vs. 1.75 ± 0.56ng/ml p<0.001) (figure 4.8 b). 
The assessment of insulin resistance via HOMA-IR and QUICK-index (figures 4.8 c & d) 
showed that rats in the HFD group had a significantly higher HOMA-IR (p<0.001) and 
significantly lower QUICK-index (p<0.01) compared to the lean control rats. This confirmed 
that the rats were indeed insulin resistant before the start of the treatments. 
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Figure 4.8: Analysis of fasting plasma glucose and insulin levels (a,b) and assessment of insulin 
resistance (c,d) on rats fed for 12 weeks on either low or high fat diet.  
The onset of insulin resistance in the HFD group was confirmed. Values are expressed as mean ± SEM 
(n=7 per group).  **p<0.01 ***p<0.001 compared to HFD group. 
 
 
Another method to evaluate the body’s sensitivity or resistance to insulin is to measure the 
actual glucose uptake into tissues. The amount of tritium-labeled glucose that was taken up by 
liver, skeletal muscle and adipose tissue within one hour after intravenous infusion of 0.4g/kg 
glucose and 2µCi/kg 2-deoxy-D-[2,6-3H]-glucose into liver, muscle and adipose tissue is 
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depicted in figure 4.9. The results showed that high caloric food intake for twelve weeks had 
no significant effect on the glucose uptake into muscle tissue. However, the adipose tissue and 
liver took up significantly less glucose (p<0.05 and p<0.01, respectively) in the HFD rats.  
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Figure 4.9: Glucose uptake (measured as 3H counts) in liver, muscle and adipose tissue 1h after an 
intravenous glucose load with 2-deoxy-D-[2,6-3H]-glucose in rats fed for 12 weeks with LFD or HFD. 
Values are expressed as mean ± SEM (n=6 per group).  *p<0.05 **p<0.01 compared to HFD group. 
 
 
The rate at which glucose was cleared from the blood is depicted in figure 4.10.  The glucose 
is cleared at a significantly slower rate in the HFD group compared to the low fat control rats. 
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Figure 4.10: Glucose clearance rate in rats fed for 12 weeks on either low or high fat diet.  
Values are expressed as mean ± SEM (n=6 per group).  *p<0.05 compared to HFD group. 
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4.2.4. Fasting plasma glucose levels after treatment 
 
After feeding on high fat diet for a total of sixteen weeks, no significant changes in fasting 
plasma glucose values were observed in the HFD group compared to the lean control rats. 
Medication with either S. frutescens or metformin did not influence plasma glucose levels 
(figure 4.11 a). The values for the fasting plasma glucose levels were 6.33 ± 0.34mmol/l 
(LFD), 6.22 ± 0.16mmol/l (HFD), 6.53 ± 0.2mmol/l (HFD+S.f.) and 6.17 ± 0.11mmol/l 
(HFD+Met). 
 
4.2.5. Fasting plasma insulin levels after treatment 
 
Fasting plasma insulin levels were significantly increased in the HFD group compared to the 
LFD group (1.26 ± 0.22ng/ml vs. 0.60 ± 0.08ng/ml p<0.05) (figure 4.11 b). 
Treating the high fat fed rats for 28 days with S. frutescens resulted in a significantly lower 
insulin level compared to the high fat diet only group (0.70 ± 0.05ng/ml vs. 1.26 ± 0.22ng/ml 
p< 0.05).  
Unexpectedly, the treatment with metformin did not result in significantly lower plasma 
insulin values compared to the HFD only group (1.15 ± 0.12ng/ml vs. 1.26 ± 0.22ng/ml).  
 
4.2.6. Changes in insulin resistance after treatment 
 
4.2.6.1. HOMA-IR 
 
Figure 4.11 c depicts the changes in insulin resistance after the 28 day treatment period. Rats 
in the HFD group displayed insulin resistance when compared to the LFD group (p<0.05).  
The IR observed in high fat fed rats was reversed by treatment with S. frutescens for 28 
days. This can be seen by the attenuated HOMA-IR values in the HFD+S.f. group compared to 
the HFD only rats (5.06 ± 0.33 vs. 10.12 ± 2.10 p<0.05).  
Treatment with metformin resulted in a decreased, although not significantly lower HOMA-
IR compared to the HFD group (6.79 ± 1.11 vs. 10.12 ± 2.10). 
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4.2.6.2. QUICK-index 
 
The Quick-index is another tool to assess insulin resistance; it displays a similar outcome to 
the HOMA-IR between the groups (figure 4.11 d). Rats on HFD only were significantly less 
insulin sensitive compared to the lean control rats (0.292 ± 0.007 vs. 0.319 ± 0.005 p<0.05).  
S. frutescens increased insulin sensitivity in high fat fed rats in comparison to the HFD 
group (0.304 ± 0.003 vs. 0.292 ± 0.007 p<0.05). The effects of S. frutescens as a treatment of 
IR were comparable to the effects seen in the prevention study. 
Metformin treatment also resulted in an elevated QUICK-index compared to the HFD group, 
but due to high variation within the group this was not significant (0.302 ± 0.013 vs. 0.292 ± 
0.007). 
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Figure 4.11: Fasting plasma glucose and insulin levels (a,b) and insulin resistance (c,d) in rats treated 
for 28 days with water (LFD, HFD group), S. frutescens (HFD+S.f.) or metformin (HFD+Met).  
Values are expressed as mean ± SEM (n=7 per group).  *p<0.05 compared to HFD group. 
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4.2.7. Glucose clearance after treatment 
 
Glucose was cleared at a significantly lower rate in the HFD group compared to the LFD 
group (0.016 ± 0.001mmol/min vs. 0.025 ± 0.002mmol/min p<0.01). Treating the rats with S. 
frutescens resulted in a slightly higher but not significant clearance rate compared to the HFD 
rats (0.018 ± 0.002mmol/min vs. 0.016 ± 0.001mmol/min). Metformin treatment for 28 days 
increased the clearance rate significantly compared to the HFD group (0.022 ± 
0.002mmol/min vs. 0.016 ± 0.001mmol/min p<0.05) (figure 4.12). 
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Figure 4.12: Glucose clearance rate in rats treated for 28 days.  
Values are expressed as mean ± SEM (n=6 per group).  *p<0.05, **p<0.01 compared to HFD group 
 
 
4.2.8. Glucose uptake after treatment 
 
After a total feeding period of sixteen weeks, rats in the HFD group displayed a significantly 
lower glucose uptake into liver (p<0.05), adipose tissue (p<0.05) and muscle (p<0.01) 
compared to the lean control group (figure 4.13). Although no difference in the glucose 
uptake into muscle tissue was seen after twelve weeks (see section 4.2.3), four weeks further 
into the experiment muscle tissue appeared to be less responsive to insulin and hence 
displayed a lower glucose uptake (p<0.01). 
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Treating the IR rats with S. frutescens resulted in a significantly higher glucose uptake into 
the muscle and adipose tissue. Glucose uptake was also improved by S. frutescens in the liver 
but was not significantly elevated.  
Twenty eight days of medication with metformin had a significantly improved effect on the 
liver and muscle glucose uptake (p<0.01).  Unexpectedly, metformin treatment significantly 
decreased the glucose uptake in the adipose tissue (p<0.05) compared to the HFD only group. 
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Figure 4.13: Glucose uptake (measured as 3H counts) in liver, muscle and adipose tissue 1h after an 
intravenous glucose load with 2-deoxy-D-[2,6-3H]-glucose in IR rats treated for 28 days with S. 
frutescens or metformin.  
Values are expressed as mean ± SEM (n=4 per group).  *p<0.05 **p<0.01 compared to HFD group; 
†p<0.05 ††p<0.01 compared to LFD group. 
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4.2.9. Plasma lipid parameters after treatment 
 
4.2.9.1. Free fatty acids 
 
As shown in figure 4.14 a, free fatty acid levels were significantly increased after sixteen 
weeks of HFD intake compared to the low fat diet group (85.27 ± 4.40mmol/l vs. 69.15 ± 
4.46mmol/l p<0.05).  
Rats which received S. frutescens treatment with their HFD displayed significantly lower 
levels of circulating FFA when compared to the HFD only group (48.32 ± 3.04mmol/l vs. 
85.27 ± 4.40mmol/l p<0.001) and also LFD group (48.32 ± 3.04mmol/l vs. 69.15 ± 
4.46mmol/l p<0.01). These effects of S. frutescens on plasma FFA levels are comparable to 
the results of the prevention study (see section 4.1.6.1) 
Metformin given to the rats had similar effects to S. frutescens, namely, it lowered FFA 
levels significantly compared to the HFD group (51.12 ± 6.51mmol/l vs. 85.27 ± 4.40mmol/l 
p<0.001) and LFD group (51.12 ± 6.51mmol/l vs. 69.15 ± 4.46mmol/l p<0.01). 
 
4.2.9.2. Triglycerides 
 
Plasma triglyceride levels were affected by high fat diet intake as shown in figure 4.14.b. Rats 
in the HFD group displayed a significantly higher plasma TG concentration than the LFD rats 
(0.86 ± 0.08mmol/l vs. 0.59 ± 0.03mmol/l p<0.05). 
Treatment of rats with S. frutescens resulted in significantly lower levels of plasma TG 
compared to HFD rats (0.59 ± 0.03mmol/l vs. 0.86 ± 0.08mmol/l p<0.01). This finding is in 
contrast to the effects of S. frutescens in the prevention study (see section 4.1.6.2). 
Treatment with metformin had no significant effect on plasma triglyceride levels compared 
to the HFD group (0.73 ± 0.13mmol/l vs. 0.86 ± 0.08mmol/l). 
 
4.2.9.3. Total cholesterol 
 
Prolonged intake of high fat diet led to increased plasma cholesterol levels in the HFD group 
compared to the LFD group (1.21 ± 0.10mmol/l vs. 1.50 ± 0.06mmol/l p<0.05) (figure 4.14 
c).  
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Treatment with S. frutescens for 28 days significantly decreased the total cholesterol level to 
1.306 ± 0.05mmol/l (p<0.05) compared to the HFD group, while metformin had no significant 
effect (1.32 ± 0.07mmol/l vs. 1.5 ± 0.06mmol/l). The lowering effect of S. frutescens on total 
cholesterol is in agreement with the findings from the prevention study (see section 4.1.6.3). 
 
4.2.9.4. HDL cholesterol 
 
As shown in figure 4.14 d, HDL-cholesterol levels in the HFD group were similar to the LFD 
group.  
Unexpectedly, rats in the HFD+S.f. group displayed significantly lower levels of HDL-
cholesterol compared to the remaining three groups (0.206 ± 0.03mmol/l vs. 0.303 ± 
0.02mmol/l LFD p<0.05, 0.298 ± 0.01mmol/l HFD p<0.05, 0.408 ± 0.04mmol/l HFD+Met 
p<0.01).These findings are comparable to the results in the prevention study after prolonged 
medication with S. frutescens.  
Rats in the HFD+Met group showed significantly higher levels of HDL-cholesterol 
compared to the lean control and HFD rats (0.408 ± 0.04mmol/l vs. 0.298 ±  0.01mmol/l 
p<0.05). 
  
4.2.9.5. LDL cholesterol  
 
No significant differences in LDL-cholesterol were noted between the four groups. There was 
an elevated but insignificant elevation in the HFD group, as shown in figure 4.14 e. The 
values observed were 0.82 ± 0.08mmol/l (LFD), 1.03 ± 0.06mmol/l (HFD), 0.98 ± 0.04mmol/l 
(HFD+S.f.) and 0.85 ± 0.07mmol/l (HFD+Met). 
 
4.2.9.6. LDL/HDL ratio 
 
Figure 4.14 f depicts the differences in the LDL/HDL-ratio between the groups. No 
significant difference was seen between the HFD and LFD groups.  
S. frutescens treatment resulted in a higher LDL/HDL-cholesterol ratio due to decreased 
levels of HDL-cholesterol (see 4.2.9.4). Despite the increase, the LDL/HDL-cholesterol ratio 
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in the HFD+S.f group was not significantly different to the HFD and LFD groups. However, 
the ratio was significantly higher than that of the HFD+Met group. 
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Figure 4.14: Plasma lipid parameters after treatment: free fatty acids (a), triglycerides (b), total 
cholesterol (c), high density lipoprotein (HDL)-cholesterol (d), low density lipoprotein (LDL)-
cholesterol (e), and LDL/HDL-cholesterol ratio (f).  
Values expressed as mean ± SEM (n=7 per group).  *p<0.05 **p<0.01 ***p<0.001 compared to HFD 
group; †p<0.05 ††p<0.01 compared to LFD group; ##p<0.01 compared to HFD+Met group. 
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4.2.10. Tissue lipid content 
 
 
4.2.10.1. Liver lipid content 
 
Figure 4.15 a, shows confirmation that prolonged intake of high fat diet significantly 
increased the lipid content in the liver compared to the LFD (45.48 ± 1.23mg/g vs. 71.69 ± 
4.20mg/g p<0.001). 
Treatment of high fat fed rats with S. frutescens did not lower the lipid content in the liver 
compared to HFD rats, and the rats in the HFD+S.f group still displayed significantly higher 
liver lipid concentrations than the LFD group (65.62 ± 2.02mg/g vs. 45.48 ± 1.23mg/g 
p<0.001). 
On the other hand, treating rats with metformin for 28 days resulted in a significantly 
lowered liver lipid content compared to the HFD (52.16 ± 1.79mg/g vs. 71.69 ± 4.20mg/g 
p<0.01) and HFD+S.f. groups (52.16 ± 1.79mg/g vs. 65.62 ± 2.02mg/g p<0.05). 
 
 
4.2.10.2. Muscle lipid content 
 
The prolonged intake of high fat diet for sixteen weeks caused a significant increase in lipid 
content in the skeletal muscle. As illustrated in figure 4.15 b, the total muscle lipid content in 
the HFD group was 15.82 ± 0.88mg/g compared to 11.16 ± 0.77mg/g in the LFD group 
(p<0.01). 
Excitingly, treating the HFD rats with S. frutescens or metformin for 28 days resulted in a 
significant decrease in the muscle lipid content compared to the untreated HFD rats (11.95 ± 
0.67mg/g and 11.67 ± 0.77mg/g, respectively vs. 15.82 ± 0.88mg/g p<0.01). 
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4.2.10.3. Adipose tissue lipid content 
 
The total amount of lipids in the adipose tissue remained unchanged between the LFD, HFD 
and HFD+S.f. group (805.15 ± 17.85mg/g, 801.36 ± 13.21mg/g and 772.52 ± 10.08mg/g, 
respectively) (figure 4.15 c). 
Surprisingly, the adipose tissue of rats treated with metformin contained significantly lower 
amounts of lipid compared to the LFD and HFD rats (634.26 ± 16.30mg/g vs. 805.15 ± 
17.85mg/g and 801.36 ± 13.21mg/g, respectively p<0.001).  
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Figure 4.15: Total tissue lipid content in liver (a), muscle (b) and adipose tissue (c).  
Values are expressed as mean ± SEM (n=7 per group).  **p<0.01 ***p<0.001 compared to HFD group; 
† p<0.05 †††p<0.001 compared to LFD group; ###p<0.001 compared to HFD+Met group. 
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4.2.11. Tissue lipid composition 
 
4.2.11.1. Liver lipid composition  
 
Figure 4.16 illustrates the amount of free fatty acids, triglycerides and cholesterol contained in 
the total liver lipid extract.  
 
4.2.11.1.1. Liver free fatty acids  
 
Rats fed with HFD displayed significantly higher amounts of free fatty acids in the liver 
compared to the lean control rats. This difference between the two groups was observed with 
FFA concentrations per mg lipid extract (1.54 ± 0.12mmol/mg lipids vs. 1.02 ± 0.07mmol/mg 
lipids p<0.01) (figure 4.16 a), as well as the FFA concentration per g liver tissue (110.29 ± 
11.45mmol/g tissue vs. 45.82 ± 2.11mmol/g tissue p<0.001) (figure 4.16 b). 
S. frutescens had a lowering effect on the liver free fatty acids. Rats in the HFD+S.f group 
contained 55.47 ± 3.90mmol/g liver compared to 110.29 ± 11.45mmol/g tissue in the HFD 
group (p<0.001). The same trend was clear in the FFA per mg lipid extract. 
Treatment with metformin did not show any lowering effects on FFA per mg lipid extract. 
However, looking at the amount of FFA in the liver tissue, a decrease in FFA was observed in 
the HFD+Met group compared to the HFD rats (70.39 ± 29.35mmol/g tissue vs. 110.29 ± 
11.45mmol/g tissue p<0.05). This difference was due to a lower total lipid concentration in the 
HFD+Met group (see section 4.2.11.1). 
 
4.2.11.1.2. Liver triglycerides  
 
Looking at the amount of triglycerides contained in the liver lipid extracts, a significant 
difference was only observed in the HFD+S.f group (figure 4.16 c). The TG concentration 
was lowered compared to the LFD and HFD group (p<0.01).  
However, TG concentrations per g liver tissue were more variable between the four groups 
(figure 4.16 d). In detail, rats fed with HFD had significantly more TG in the liver compared 
to the LFD rats (4767.91 ± 369.27mmol/g liver vs. 2892.01 ± 141.70mmol/g liver p<0.001). 
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Treatment with S. frutescens or metformin resulted in a decreased concentration of TG in the 
liver compared to the HFD rats (3443.42 ± 182.18mmol/g liver and 3004.02 ± 231.69mmol/g 
liver vs. 4767.91 ± 369.27mmol/g liver p<0.01). 
 
4.2.11.1.3. Liver cholesterol  
 
The total cholesterol concentration in the liver lipids was significantly higher in the LFD 
group and HFD+Met group compared to the HFD group and HFD+S.f. group (figure 4.16 e). 
In contrast cholesterol levels in the total liver mass (figure 4.16 f), were significantly higher 
in rats fed with HFD compared to the lean control rats (472.62 ± 27.76mmol/g liver vs. 345.49 
± 10.95mmol/g liver p<0.01). 
Although the amount of cholesterol in the liver lipids was significantly lower in the 
HFD+S.f. group than the LFD group (p<0.05), it was significantly increased when examining 
the cholesterol in the total liver mass (p<0.01). 
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Figure 4.16: Composition of liver lipids. Free fatty acids (a,b), triglycerides (c,d) and cholesterol (e,f). 
Values are expressed as mean ± SEM (n=7 per group).   
Values in left hand figures (a,c,e) are expressed per milligram lipids. Values in right hand figures (b,d,f) 
are expressed per gram tissue. *p<0.05 **p<0.01 ***p<0.001 compared to HFD group; †p<0.05 
††p<0.01 compared to LFD group; ##p<0.01 ###p<0.001 compared to HFD+Met group.  
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4.2.11.2. Muscle lipid composition 
 
The composition of the extracted total muscle lipids with regard to free fatty acids, 
triglycerides and cholesterol is displayed in figure 4.17. 
 
4.2.11.2.1. Muscle free fatty acids 
 
The FFA levels in the total muscle lipids were significantly elevated in the HFD+S.f. group 
(p<0.05 compared to LFD group) and in the HFD+Met group (p<0.05 compared to LFD group 
and HFD group) (figure 4.17 a). The values observed were 1.71 ± 0.13mmol/mg lipids 
(LFD), 1.97 ± 0.17mmol/mg lipids (HFD), 2.32 ± 0.16mmol/g lipids (HFD+S.f.) and 3.01 ± 
0.16mmol/mg lipids (HFD+Met). 
Adjustment of the concentrations to reflect the muscle mass resulted in significantly 
increased FFA concentrations in the HFD group compared to the LFD group (32.7 ± 
18.83mmol/g tissue vs. 18.83 ± 1.53mmol/g tissue p<0.01) (figure 4.17 b). At total tissue 
level HFD+S.f. and HFD+Met groups show similar levels of FFA which are significantly 
higher than in the LFD group (30.07 ± 3.84mmol/g tissue and 33.61 ± 3.19mmol/g tissue 
p<0.05 and p<0.01, respectively). 
 
4.2.11.2.2. Muscle triglycerides 
 
Muscle lipids from the HFD group contained significantly more TG than the lipids from LFD 
rats (11.33 ± 0.55mmol/g lipids vs. 9.32 ± 0.34mmol/mg lipids p<0.05) (figure 4.17 c).  
Treatment with S. frutescens resulted in significantly higher TG concentrations in the muscle 
lipids (14.50 ± 0.88mmol/mg lipids) compared to the HFD group (p<0.01) and also LFD 
group (p<0.001).  
Metformin treatment led to increased TG concentrations in the lipids (12.40 ± 0.77mmol/mg 
lipids) compared to the lean control rats (p<0.01) but not HFD rats.  
Adjusting the TG concentrations to the total muscle mass, gave significantly elevated levels 
in the HFD group compared to the LFD group (180.72 ± 16.32mmol/g tissue vs. 104.15 ± 
9.01mmol/g tissue p<0.01) (figure 4.17 d). The TG concentrations in rats treated with S. 
frutescens (186.25 ± 20.32mmol/g tissue) or metformin (143.07 ± 9.67mmol/g tissue) were 
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not significantly different to the HFD only group at total tissue level. However, TG levels in 
those two groups were significantly higher than in the LFD group (p<0.01 and p<0.05). 
 
4.2.11.2.3. Muscle cholesterol 
 
Muscle lipid cholesterol levels did not change with HFD intake compared to lean control 
(10.04 ± 0.34mmol/mg lipids vs. 9.41 ± 0.24mmol/mg lipids) (figure 4.17 e) but were 
significantly increased at total tissue level (159.05 ± 10.62mmol/g tissue vs. 105.37 ± 
8.27mmol/g tissue p<0.01) (figure 4.17 f). 
Treatment with S. frutescens for 28 days decreased the cholesterol fraction in the muscle 
lipids (8.11 ± 0.38mmol/mg lipids) compared to the LFD group (p<0.05) and HFD group 
(p<0.01). At total tissue level cholesterol concentration in the HFD+S.f. group (102.01 ± 
7.01mmol/mg lipids) was similar to the LFD group and significantly lower than the HFD 
group (p<0.001).  
Metformin significantly decreased cholesterol levels in the lipid fraction (8.51 ± 
0.36mmol/mg lipids p<0.01), as well as in the total muscle mass (98.03 ± 4.55mmol/g tissue 
p<0.001) compared to the HFD group.  
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Figure 4.17: Composition of muscle lipids. Free fatty acids (a,b), triglycerides (c,d) and cholesterol 
(e,f). Values are expressed as mean ± SEM (n=7 per group).   
Values in left hand figures (a,c,e) are expressed per milligram lipids. Values in right hand figures (b,d,f) 
are expressed per gram tissue. *p<0.05 **p<0.01 ***p<0.001 compared to HFD group; †p<0.05 
††p<0.01 †††p<0.001 compared to LFD group. 
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4.2.11.3. Adipose tissue lipid composition 
 
4.2.11.3.1. Adipose free fatty acids 
 
No significant changes in adipose free fatty acid concentrations were seen between the lean 
control rats and rats fed with HFD (figure 4.18 a & b). The values obtained from the lipid 
extracts were 0.102 ± 0.007mmol/mg lipids (LFD) and 0.106 ± 0.009mmol/mg lipids (HFD), 
and 82.66±6.93mmol/g tissue (LFD) and 84.45 ± 6.50mmol/g tissue (HFD).  
However, treating high fat fed rats with S. frutescens resulted in a significantly lower FFA 
amount in the adipose lipids (0.054 ± 0.005mmol/mg lipids p<0.001 compared to LFD and 
HFD; p<0.05 compared to HFD+Met) as well as in the total adipose mass (42.11 ± 
4.07mmol/mg tissue p<0.001 compared to LFD and HFD).  
Treatment with metformin led to significantly decreased levels of FFA in the adipose tissue 
(49.65 ± 4.65mmol/g tissue) compared to LFD (p<0.01) and HFD (p<0.05) groups.  
 
4.2.11.3.2. Adipose triglycerides 
 
Taking triglyceride concentrations in the adipose lipids into account, no significant differences 
between the four groups were observed (figure 4.18 c). The values observed were 14.66 ± 
1.05mmol/mg lipids (LFD), 15.02 ± 1.32mmol/mg lipids (HFD), 12.63 ± 0.97 (HFD+S.f.) and 
14.08 ± 1.02mmol/mg lipids (HFD+Met).  
However, TG levels in the total adipose mass were significantly reduced by treatment with 
metformin (8.98 ± 0.46mol/g tissue) compared to the HFD (11.99 ± 0.90mol/g tissue p<0.05) 
and LFD groups (11.76 ± 0.77mol/g tissue p<0.01, respectively) (figure 4.18 d). There was no 
significant difference in adipose tissue TG between the LFD, HFD and HFD+S.f. (9.74 ± 
0.67mol/g tissue) groups.  
 
4.2.11.3.3. Adipose cholesterol 
 
Surprisingly only very low quantities of cholesterol were detected in the entire adipose lipid 
extracts. The quantities detected were under the detection limit of 0.1mmol/mg and gave no 
reliable results.  
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Figure 4.18: Composition of adipose tissue lipids. Free fatty acids (a,b), and triglycerides (c,d).  
Values are expressed as mean ± SEM (n=7 per group).  Values in left hand figures (a,c,) are expressed 
per milligram lipids. Values in right hand figures (b,d,) are expressed per gram tissue. *p<0.05 
***p<0.001 compared to HFD group; †p<0.05 ††p<0.01 †††p<0.001 compared to LFD group; #p<0.05 
compared to HFD+Met group.  
 
 
 
4.2.12. Tissue fatty acid profile  
 
The extracted tissue lipids were separated into different fractions by thin-layer 
chromatography and the phospholipids (membrane lipids) and triglycerides (storage lipids) 
analyzed for their fatty acid profile.  
The amount of single fatty acids found in the LFD group was not compared to any of the other 
three groups, because changes in fatty acids were due to different fatty acid compositions in 
the diets. 
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4.2.12.1. Liver fatty acids 
 
Table 4.1 shows the fatty acid profile of the liver phospholipids and triglycerides. 
 
The major fatty acids (>10% of total fatty acids) found in liver phospholipids of Wistar rats 
were C16:0 (palmitic acid), C18:0 (stearic acid), C18:2n6 (linoleic acid, LA), C20:4n6 
(arachidonic acid, AA), and C22:6n3 (docosahexaenoic acid, DHA).  
Significant changes in the membrane fatty acid profile were observed in the HFD+Met 
group, where C20:3 n6 (dihomo-γ-linolenic acid, DGLA) (p<0.01) and total monounsaturated 
fatty acids (MUFA) (p<0.05) were significantly lowered compared to the HFD group. 
Rats treated with S. frutescens were similarly affected as the metformin treated rats and 
displayed significantly lower amounts of C20:3n6 and total MUFA (p<0.05) in the liver 
membrane compared to the HFD group. 
 
The major fatty acids found in the liver TG were C16:0 (palmitic acid), C18:1 n9 (oleic acid), 
and C18:2 n6 (LA).  
Significant changes in the fatty acid profile of liver TG were only observed in the HFD+Met 
group compared to the HFD group. In detail, C14:0 (myristic acid) (p<0.05), C18:2n6 (LA) 
(p<0.01) and total n6-fatty acids (p<0.01) were significantly decreased. 
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 Table 4.1: Fatty acid profile of liver phospholipids and triglycerides. Values are expressed as mean ± SEM (n=7 per group). *p<0.05 **p<0.01 compared to HFD group.
Liver phospholipids (% of total fatty acids)  Liver Triglycerides (% of total fatty acids)  
  LFD   HFD   HFD+S.f.   HFD+Met     LFD  HFD  HFD+S.f.  HFD+Met  
C14:0 0.14 ± 0.02   0.17 ± 0.03   0.16 ± 0.03   0.11 ± 0.01    C12:0     0.27 ± 0.06  0.21 ± 0.02  0.09 ± 0.01  
C15:0 0.18 ± 0.02  0.17 ± 0.04  0.08 ± 0.02  0.09 ± 0.01   C14:0 0.68 ± 0.05  0.78 ± 0.06  0.74 ± 0.06  0.58 ± 0.07 * 
C16:0 18.42 ± 0.64  20.33 ± 0.99  20.65 ± 0.53  20.31 ± 0.96   C15:0 0.50 ± 0.05  0.26 ± 0.03  0.26 ± 0.04  0.23 ± 0.03  
C16:1 0.75 ± 0.07  0.56 ± 0.04  0.49 ± 0.03  0.42 ± 0.03   C16:0 23.61 ± 0.83  28.54 ± 0.61  29.22 ± 0.73  27.33 ± 1.27  
C17:0 0.57 ± 0.03  0.31 ± 0.03  0.26 ± 0.02  0.25 ± 0.01   C16:1 2.18 ± 0.26  1.79 ± 0.13  1.62 ± 0.12  1.48 ± 0.10  
C17:1 0.33 ± 0.02  0.12 ± 0.01  0.09 ± 0.01  0.07 ± 0.01   C17:0 0.37 ± 0.04  0.20 ± 0.02  0.19 ± 0.02  0.17 ± 0.01  
C18:0 20.94 ± 0.67  20.72 ± 0.17  21.61 ± 0.40  21.27 ± 0.28   C17:1 0.24 ± 0.05  0.09 ± 0.02  0.12 ± 0.02  0.08 ± 0.01  
C18:1n12 3.10 ± 0.19  4.84 ± 0.13  4.43 ± 0.11  4.45 ± 0.10   C18:0 1.69 ± 0.08  1.58 ± 0.05  1.67 ± 0.05  1.61 ± 0.06  
C18:1n9 2.70 ± 0.19  1.50 ± 0.09  1.48 ± 0.02  1.52 ± 0.04   C18:1n9 20.49 ± 1.52  32.39 ± 0.39  31.97 ± 0.86  32.50 ± 0.68  
C18:2n6t 0.25 ± 0.01  0.26 ± 0.05  0.10 ± 0.02  0.14 ± 0.00   C18:2n6 32.57 ± 1.44  21.70 ± 0.32  21.53 ± 0.46  23.19 ± 0.29 ** 
C18:2n6 14.94 ± 0.29  12.10 ± 0.60  10.88 ± 0.37  10.84 ± 0.33   C18:3n6 0.48 ± 0.15  0.37 ± 0.01  0.37 ± 0.02  0.36 ± 0.03  
C18:3n6 0.18 ± 0.03  0.14 ± 0.03  0.08 ± 0.02  0.07 ± 0.00   C18:3n3 1.01 ± 0.07  0.40 ± 0.03  0.46 ± 0.02  0.44 ± 0.04  
C18:3n3 0.09 ± 0.01  0.06 ± 0.02  0.03 ± 0.01  0.02 ± 0.00   C20:1 0.49 ± 0.05  0.41 ± 0.04  0.42 ± 0.03  0.33 ± 0.03  
C20:0 0.06 ± 0.02  0.05 ± 0.01  0.04 ± 0.00  0.03 ± 0.01   C20:2 0.18 ± 0.05  0.36 ± 0.05  0.47 ± 0.04  0.30 ± 0.04  
C20:1n9 0.35 ± 0.02  0.12 ± 0.02  0.14 ± 0.01  0.12 ± 0.02   C20:3n6t 0.33 ± 0.08  0.37 ± 0.03  0.35 ± 0.02  0.35 ± 0.03  
C20:2 0.20 ± 0.02  0.35 ± 0.02  0.32 ± 0.02  0.26 ± 0.02   C20:4n6  2.39 ± 0.09  2.12 ± 0.09  2.31 ± 0.10  2.30 ± 0.13  
C20:3n9 0.13 ± 0.01  0.12 ± 0.02  0.12 ± 0.01  0.09 ± 0.01   C20:5n3 3.00 ± 0.32  0.86 ± 0.04  1.03 ± 0.12  0.99 ± 0.13  
C20:3n6 0.85 ± 0.05  1.11 ± 0.04  0.95 ± 0.04 * 0.89 ± 0.05 **  C22:4  0.28 ± 0.04  0.54 ± 0.06  0.47 ± 0.03  0.50 ± 0.05  
C20:4n6  25.07 ± 0.46  24.45 ± 0.75  24.61 ± 0.51  25.80 ± 0.58   C24:0 0.12 ± 0.04  0.15 ± 0.02  0.21 ± 0.01  0.17 ± 0.02  
C20:5n3 1.04 ± 0.06  0.41 ± 0.04  0.39 ± 0.04  0.29 ± 0.02   C22:5n3 1.59 ± 0.13  1.28 ± 0.05  1.26 ± 0.11  1.46 ± 0.18  
C24:0 0.09 ± 0.01  0.11 ± 0.02  0.13 ± 0.02  0.10 ± 0.02   C22:6n3  7.80 ± 0.56  5.56 ± 0.27  5.13 ± 0.38  5.54 ± 0.63  
C22:5n3  0.85 ± 0.04  0.81 ± 0.04  0.95 ± 0.07  0.83 ± 0.04                    
C22:6n3 8.76 ± 0.49  11.22 ± 0.77  12.00 ± 0.68  12.03 ± 0.52                    
                                    
n3 FA 10.75 ± 0.52  12.50 ± 0.79  13.37 ± 0.73  13.17 ± 0.54   n3 FA 13.40 ± 0.96  8.10 ± 0.29  7.88 ± 0.59  8.43 ± 0.92  
n6 FA 41.30 ± 0.42  38.05 ± 0.45  36.62 ± 0.37  37.74 ± 0.69   n6 FA 35.76 ± 1.55  24.56 ± 0.32  24.56 ± 0.56  26.20 ± 0.42 ** 
n6/n3 3.88 ± 0.17  3.11 ± 0.17  2.79 ± 0.17  2.89 ± 0.12   n6/n3 2.72 ± 0.17  3.05 ± 0.10  3.19 ± 0.15  3.31 ± 0.31  
trans FA 0.25 ± 0.01  0.26 ± 0.05  0.10 ± 0.02  0.14 ± 0.00   trans FA 0.33 ± 0.08  0.37 ± 0.03  0.35 ± 0.02  0.35 ± 0.03  
SFA 40.40 ± 0.98  41.84 ± 0.94  42.93 ± 0.76  42.16 ± 0.95   SFA 26.97 ± 0.85  31.51 ± 0.58  32.49 ± 0.78  30.18 ± 1.25  
MUFA 7.23 ± 0.42  7.14 ± 0.13  6.64 ± 0.10 * 6.58 ± 0.16 *  MUFA 23.41 ± 1.61  34.68 ± 0.41  34.13 ± 0.94  34.39 ± 0.66  
PUFA 52.37 ± 0.85   51.02 ± 1.02   50.43 ± 0.76   51.26 ± 1.00    PUFA 49.62 ± 2.21  33.56 ± 0.56  33.37 ± 1.14  35.43 ± 1.37  
SFA/PUFA 0.77 ± 0.03  0.82 ± 0.04  0.85 ± 0.03  0.83 ± 0.04   SFA/PUFA 0.55 ± 0.04  0.94 ± 0.03  0.98 ± 0.05  0.87 ± 0.07  
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4.2.12.2. Muscle fatty acids 
 
In accordance with the findings in the liver, the major fatty acids in the muscle phospholipids 
were C16:0 (palmitic acid), C18:0 (stearic acid), C18:2n6 (linoleic acid, LA), C20:4n6 (AA), 
and C22:6n3 (DHA) (table 4.2).  
Treatment with S. frutescens resulted in significant changes in the fatty acid profile of 
muscle phospholipids. Oleic acid (C18:1n9) and eicosapentaenoic acid (EPA) (C22:5n3) were 
significantly increased compared to the HFD group (p<0.05).  
Treatment with metformin significantly increased C18:1n12 (petroselinic acid) compared to 
the HFD group (p<0.01).  
The major fatty acids found in the muscle TG were C16:0, C18:1n9 and C18:2n6. 
S. frutescens significantly decreased C16:1 (p<0.001) and C22:6n3 (p<0.05) but increased 
C18:0 and the n6/n3 ratio (p<0.05) compared to the HFD group. The HFD+S.f rats also 
displayed lower amounts of C20:4n6 (AA) and C22:6n3 compared to the HFD+Met group 
(p<0.01 and p<0.05, respectively). 
Metformin treatment resulted in lower amounts of C16:1 (p<0.05) and elevated amounts of 
C18:0 (P>0.05) and 20:4n6 (p<0.01) compared to the HFD group. 
 
4.2.12.3. Adipose tissue fatty acids 
 
Table 4.3 shows that only five fatty acids were present in detectable amounts in the adipose 
tissue membranes. 
Treatment with S. frutescens led to decreased C18:1n9 (p<0.01) and increased C20:4n6 
(p<0.05) compared to the HFD rats, consequently resulting in lower MUFA and higher PUFA 
levels. Metformin also decreased C18:1n9 (p<0.05) and therefore total MUFA levels 
compared to the HFD group. 
After treatment with S. frutescens only C20:1 (gondoic acid) changed in the adipose 
triglycerides (p<0.01) compared to HFD group. Comparing triglyceride fatty acids from the 
HFD+S.f group with the HFD+Met group the following differences were observed:  C16:0, 
C18:0 and total saturated fatty acids (SFA) increased (p<0.01) while C16:1, C18:2n6, 
C18:3n3, total n6 FA and polyunsaturated fatty acids (PUFA) were decreased.  
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Table 4.2: Fatty acid profile of muscle phospholipids and triglycerides.  
Values are expressed as mean ± SEM (n=7 per group). *p<0.05 **p<0.01***p<0.001 compared to HFD group; #p<0.05 ##p<0.01 compared to HFD+Met group.  
 
Muscle Phospholipids (% of total fatty acids)    Muscle Triglycerides (% of total fatty acids) 
  LFD  HFD  HFD+S.f.  HFD+Met    LFD  HFD  HFD+S.f.  HFD+Met   
C14:0 0.13 ± 0.01   0.15 ± 0.02   0.16 ± 0.01   0.15 ± 0.01    C12:0 0.20 ± 0.02   1.98 ± 0.15   1.83 ± 0.08   1.62 ± 0.13   
C15:0 0.17 ± 0.01  0.06 ± 0.01  0.09 ± 0.01  0.06 ± 0.01    C14:0 1.96 ± 0.09  2.15 ± 0.13  1.97 ± 0.07  1.94 ± 0.08   
C16:0 22.91 ± 0.34  23.52 ± 0.48  23.29 ± 0.79  22.95 ± 0.62    C15:0 0.21 ± 0.04  0.11 ± 0.02  0.13 ± 0.07  0.10 ± 0.02   
C16:1 1.02 ± 0.03  0.60 ± 0.04  0.56 ± 0.02  0.61 ± 0.03    C15:1 0.31 ± 0.02  0.19 ± 0.01  0.21 ± 0.01  0.20 ± 0.01   
C17:0 0.44 ± 0.01  0.19 ± 0.01  0.19 ± 0.01  0.19 ± 0.00    C16:0 26.09 ± 0.61  29.75 ± 0.42  30.83 ± 0.29  30.93 ± 0.39   
C17:1 0.24 ± 0.01  0.11 ± 0.01  0.13 ± 0.01  0.09 ± 0.01    C16:1 7.80 ± 0.90  4.46 ± 0.22  3.06 ± 0.22 *** 3.65 ± 0.27 * 
C18:0 11.42 ± 0.18  12.53 ± 0.25  12.48 ± 0.33  12.44 ± 0.38    C17:0 0.36 ± 0.02  0.18 ± 0.01  0.22 ± 0.04  0.20 ± 0.01   
C18:1 n12 3.52 ± 0.15  4.38 ± 0.09  4.66 ± 0.12  4.93 ± 0.12 **  C17:1 0.51 ± 0.02  0.22 ± 0.02  0.19 ± 0.02  0.21 ± 0.02   
C18:1 n9 3.04 ± 0.06  2.38 ± 0.08  2.66 ± 0.06 * 2.55 ± 0.04    C18:0 3.94 ± 0.21  3.34 ± 0.14  3.84 ± 0.12 * 3.84 ± 0.13 * 
C18:2 n6t 0.12 ± 0.01  0.14 ± 0.01  0.14 ± 0.02  0.09 ± 0.02    C18:1n9 28.75 ± 0.54  39.66 ± 0.57  39.86 ± 0.36  38.99 ± 0.62   
C18:2 n6 18.92 ± 0.61  15.11 ± 0.52  14.08 ± 0.43  14.89 ± 0.56    C18:2n6 23.06 ± 0.86  15.13 ± 0.23  15.40 ± 0.24  15.38 ± 0.12   
C18:3 n6 0.11 ± 0.02  0.12 ± 0.02  0.03 ± 0.01  0.04 ± 0.01    C18:3n3 0.80 ± 0.04  0.35 ± 0.01  0.35 ± 0.01  0.38 ± 0.02   
C18:3 n3 0.08 ± 0.01  0.04 ± 0.01  0.05 ± 0.01  0.05 ± 0.01    C20:1 0.57 ± 0.05  0.35 ± 0.02  0.42 ± 0.01  0.42 ± 0.04   
C20:0 0.03 ± 0.00  0.04 ± 0.01  0.04 ± 0.00  0.05 ± 0.01    C20:2 0.13 ± 0.02  0.11 ± 0.01  0.11 ± 0.02  0.12 ± 0.01   
C20:1 n9 0.19 ± 0.01  0.16 ± 0.01  0.18 ± 0.01  0.17 ± 0.01    C20:3n6t 0.15 ± 0.01  0.07 ± 0.01  0.09 ± 0.01  0.10 ± 0.01   
C20:2 0.21 ± 0.00  0.23 ± 0.01  0.27 ± 0.01  0.23 ± 0.01    C20:4n6 1.08 ± 0.05  0.44 ± 0.02  0.43 ± 0.02 ## 0.56 ± 0.03 ** 
C20:3 n9 0.08 ± 0.00  0.07 ± 0.01  0.07 ± 0.01  0.07 ± 0.01    C20:5n3 0.35 ± 0.01  0.09 ± 0.01  0.11 ± 0.01  0.12 ± 0.02   
C20:3 n6 0.71 ± 0.02  0.73 ± 0.02  0.80 ± 0.04  0.73 ± 0.02    C22:2 0.33 ± 0.14  0.14 ± 0.06  0.08 ± 0.02  0.07 ± 0.01   
C20:4 n6 12.67 ± 0.51  14.27 ± 0.29  14.56 ± 0.36  14.56 ± 0.56    C22:4  0.14 ± 0.01  0.09 ± 0.01  0.08 ± 0.01  0.10 ± 0.01   
C20:5 n3 0.62 ± 0.05  0.33 ± 0.03  0.28 ± 0.03  0.27 ± 0.01    C24:0 0.05 ± 0.01  0.03 ± 0.00  0.05 ± 0.01  0.06 ± 0.01   
C22:4 0.17 ± 0.01  0.24 ± 0.01  0.25 ± 0.02  0.25 ± 0.01    C22:5n3 0.77 ± 0.06  0.26 ± 0.04  0.20 ± 0.01  0.27 ± 0.02   
C24:0 0.13 ± 0.01  0.20 ± 0.01  0.20 ± 0.02  0.18 ± 0.00    C22:6n3 2.44 ± 0.24  0.89 ± 0.14  0.56 ± 0.04 * # 0.77 ± 0.06   
C22:5 n3  1.88 ± 0.07  1.78 ± 0.09  2.02 ± 0.05 * 1.80 ± 0.09                       
C22:6 n3  20.89 ± 0.46  22.26 ± 0.53  22.51 ± 0.60  22.33 ± 0.42                       
C24:6 n3 0.30 ± 0.01  0.32 ± 0.02  0.30 ± 0.01  0.31 ± 0.03                       
                                       
n3 FA 23.77 ± 0.51  24.73 ± 0.59  25.16 ± 0.63  24.77 ± 0.47    n3 FA 4.36 ± 0.32  1.59 ± 0.18  1.22 ± 0.06  1.53 ± 0.09   
n6 FA 32.53 ± 0.21  30.37 ± 0.26  29.60 ± 0.50  30.31 ± 0.23    n6 FA 24.30 ± 0.89  15.64 ± 0.24  15.91 ± 0.26  16.04 ± 0.12   
n6/n3 1.37 ± 0.03  1.23 ± 0.03  1.18 ± 0.05  1.23 ± 0.02    n6/n3 5.73 ± 0.46  10.38 ± 1.01  13.14 ± 0.51 * # 10.68 ± 0.65   
trans FA 0.12 ± 0.01  0.14 ± 0.01  0.14 ± 0.02  0.09 ± 0.02    trans FA 0.15 ± 0.01  0.07 ± 0.01  0.09 ± 0.01  0.10 ± 0.01   
SFA 35.22 ± 0.43  36.70 ± 0.52  36.45 ± 0.57  36.02 ± 0.49    SFA 32.80 ± 0.74  37.55 ± 0.59  38.86 ± 0.36  38.67 ± 0.67   
MUFA 8.02 ± 0.15  7.64 ± 0.12  8.19 ± 0.11  8.35 ± 0.16    MUFA 37.93 ± 1.24  44.88 ± 0.47  43.73 ± 0.33  43.46 ± 0.75   
PUFA 56.76 ± 0.42   55.64 ± 0.58   55.36 ± 0.60   55.63 ± 0.54    PUFA 29.26 ± 0.91   17.57 ± 0.32   17.41 ± 0.32  17.87 ± 0.19   
SFA/PUFA 0.62 ± 0.01  0.66 ± 0.02  0.66 ± 0.02  0.65 ± 0.01   SFA/PUFA 1.13 ± 0.04  2.14 ± 0.07  2.24 ± 0.05  2.17 ± 0.04  
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Table 4.3: Fatty acid profile of adipose phospholipids and triglycerides.  
Values are expressed as mean ± SEM (n=7 per group). *p<0.05 **p<0.01 compared to HFD group; #p<0.05 ##p<0.01 compared to HFD+Met group.  
Adipose tissue Phospholipids (% of total fatty acids)  Adipose tissue Triglycerides (% of total fatty acids) 
 LFD  HFD  HFD+S.f.  HFD+Met    LFD  HFD  HFD+S.f.  HFD+Met   
C16:0 16.92 ± 1.18   23.65 ± 2.03   23.30 ± 1.82   23.55 ± 0.64    C10:0         0.06 ± 0.01   0.07 ± 0.00   0.07 ± 0.01   
C18:0 15.33 ± 0.77  15.18 ± 2.08  17.68 ± 1.48  15.65 ± 0.50    C12:0 0.10 ± 0.03  1.52 ± 0.12  1.61 ± 0.08  1.53 ± 0.10   
C18:1n9 29.74 ± 2.60  31.13 ± 1.75  22.33 ± 1.36 ** 24.24 ± 1.73 *  C14:0 1.35 ± 0.07  1.59 ± 0.08  1.67 ± 0.05  1.56 ± 0.07   
C18:2n6 26.08 ± 1.59  20.55 ± 0.99  19.94 ± 0.72  21.81 ± 1.19    C14:1 0.11 ± 0.01  0.05 ± 0.01  0.06 ± 0.01  0.05 ± 0.01   
C20:4n6  11.94 ± 0.86  9.48 ± 1.52  16.75 ± 1.77 * 14.76 ± 0.91 *   C15:0 0.33 ± 0.01  0.17 ± 0.01  0.20 ± 0.00  0.18 ± 0.01   
                    C15:1 0.12 ± 0.01  0.04 ± 0.00  0.05 ± 0.00  0.05 ± 0.00   
                    C16:0 22.57 ± 0.45  29.43 ± 0.53  29.49 ± 0.46 ## 27.76 ± 0.22   
                    C16:1 5.91 ± 0.35  4.06 ± 0.16  4.04 ± 0.12 # 4.69 ± 0.19 ** 
                    C17:0 0.34 ± 0.02  0.31 ± 0.07  0.27 ± 0.03  0.36 ± 0.01  
                    C17:1 0.40 ± 0.01  0.19 ± 0.02  0.21 ± 0.03  0.24 ± 0.01   
                    C18:0 2.65 ± 0.07  2.51 ± 0.09  2.60 ± 0.03 ## 2.28 ± 0.05   
                    C18:1n9 29.32 ± 0.29  40.91 ± 0.74  41.34 ± 0.33  41.20 ± 0.45 * 
                    C18:2n6 32.07 ± 0.80  17.84 ± 0.63  16.90 ± 0.26 ## 18.44 ± 0.24   
                    C18:3n3 1.26 ± 0.04  0.43 ± 0.03  0.46 ± 0.04 # 0.58 ± 0.02   
                    C20:1 0.68 ± 0.04  0.29 ± 0.02  0.37 ± 0.01 ** 0.34 ± 0.01 * 
                    C20:2 0.16 ± 0.01  0.05 ± 0.01  0.08 ± 0.01  0.08 ± 0.01  
                    C20:3 n6t 0.11 ± 0.00  0.04 ± 0.01  0.05 ± 0.00  0.06 ± 0.01   
                    C20:4n6 0.41 ± 0.03  0.11 ± 0.02  0.13 ± 0.01  0.14 ± 0.03   
                    C20:5n3 0.34 ± 0.03  0.07 ± 0.01  0.06 ± 0.00  0.06 ± 0.01   
                    C22:4 0.09 ± 0.00  0.05 ± 0.01  0.04 ± 0.00  0.04 ± 0.01   
                    C24:0 0.04 ± 0.00  0.02 ± 0.01  0.03 ± 0.00  0.02 ± 0.00   
                    C22:5n3 0.43 ± 0.03  0.08 ± 0.01  0.10 ± 0.00  0.10 ± 0.01   
                    C22:6n3 1.19 ± 0.09  0.17 ± 0.05  0.15 ± 0.01  0.19 ± 0.04   
                                       
                    n3 FA 3.22 ± 0.18  0.74 ± 0.10  0.78 ± 0.04  0.93 ± 0.09   
                    n6 FA 32.60 ± 0.80  17.99 ± 0.65  17.08 ± 0.25 # 18.64 ± 0.26   
                    n6/n3 10.28 ± 0.59  25.41 ± 1.75  22.11 ± 0.82  20.80 ± 1.31   
                    trans FA 0.11 ± 0.00  0.04 ± 0.01  0.05 ± 0.00  0.06 ± 0.01  
SFA 32.25 ± 1.67  38.83 ± 1.00  40.98 ± 1.33  39.20 ± 0.53    SFA 27.38 ± 0.46  35.61 ± 0.69  35.94 ± 0.51 ## 33.77 ± 0.25   
MUFA 29.74 ± 2.60  31.13 ± 1.75  22.33 ± 1.36 ** 24.24 ± 1.73 *  MUFA 36.55 ± 0.45  45.54 ± 0.68  46.08 ± 0.28  46.56 ± 0.28 * 
PUFA 38.02 ± 1.81   30.03 ± 2.01   36.70 ± 1.20 * 36.57 ± 1.64 *  PUFA 36.07 ± 0.80   18.83 ± 0.75   17.98 ± 0.27 ## 19.68 ± 0.35   
SFA/PUFA 0.86 ± 0.06  1.33 ± 0.10  1.12 ± 0.06  1.09 ± 0.05 *  SFA/PUFA 0.76 ± 0.03  1.91 ± 0.09  2.00 ± 0.06 ## 1.72 ± 0.04  
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Metformin treatment significantly elevated the amount of C16:1, C18:1n9, C20:1 and MUFA 
compared to the HFD group. The major fatty acids found in the adipose triglycerides were 
C16:0, C18:1n9 and C18:2n6. 
 
4.2.13. Plasma cytokine levels after treatment 
 
4.2.13.1. Tumor necrosis factor-α (TNF-α) 
 
As shown in figure 4.19 a & b, there was no significant difference in circulating TNF-α levels 
between the LFD and HFD group, although the levels appeared to be lower in the HFD group 
(36.7 ± 7.1pg/ml vs. 18.3 ± 5.8 pg/ml) 
Treating the high fat fed rats with S. frutescens for 28 days had a further lowering effect on 
the TNF-α levels (8.3 ± 2.3pg/ml), which dropped significantly compared to the LFD (p<0.01) 
and HFD+Met group (p<0.001), but not the HFD only group. 
Unexpectedly, rats that were medicated with metformin for 28 days displayed significantly 
higher levels of TNF-α (62.5 ± 13.7pg/ml) compared to the HFD group (p<0.01). 
 
Whilst the results for TNF-α in the prevention study were relatively inconclusive (see section 
4.1.7.1), the treatment study showed positive effects of S. frutescens in lowering circulating 
TNF-α. in insulin resistant rats.  
 
4.2.13.2. Interleukin-1α (IL-1α) 
 
Analyzing plasma IL-1α concentrations showed no significant differences between the four 
groups (figures 4.19 c & d). IL-1α levels appeared to be higher in rats fed with HFD (30.8 ± 
17.1 pg/ml) compared to rats fed with LFD (9.5 ± 4.3pg/ml). However, this was not significant 
due to a high variation within the HFD group.  
S. frutescens and metformin treatment had no effect on circulating IL-1α levels (35.0 ± 
11.3pg/ml and 44.5 ± 16.6pg/ml) compared to the LFD and HFD groups. 
 
These results are not in accordance with the findings in the prevention study where prolonged 
medication with S. frutescens resulted in a significantly lower IL-1α level (see section 4.1.7.2).  
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4.2.13.3. Interleukin-4 (IL-4) 
 
Figures 4.19 e and f illustrate the levels of plasma IL-4 in the four different groups. Rats fed 
with HFD for sixteen weeks showed elevated levels of IL-4 (2.1 ± 1.0pg/ml) compared to 
LFD, HFD+S.f. and HFD+Met groups (0.2 ± 0.1pg/ml, 1.0 ± 0.3pg/ml and 1.3 ± 0.4pg/ml, 
respectively). Due to a high variance in the HFD group, the differences were not significant, 
though. 
Compared to the HFD group, medication with S. frutescens or metformin appeared to 
diminish the IL-4 levels, but IL-4 concentrations in these two groups were still significantly 
higher than in the LFD group (p>0.01).  
 
The trend of lowered circulating IL-4 levels after medication with Sutherlandia confirms the 
findings of the prevention study (see section 4.1.7.3). 
 
4.2.13.4. Monocyte chemo-attractant protein-1 (MCP-1) 
 
Unexpectedly, plasma MCP-1 levels were not elevated by prolonged intake of HFD compared 
to the LFD group (213.2 ± 15.6pg/ml vs. 226.3 ± 31.8pg/ml), but significantly increased with 
medication of S. frutescens (317.6 ± 39.7pg/ml) or metformin (350.0 ± 36.6pg/ml) compared 
to the HFD only group (p<0.05 and p<0.01, respectively) (figures 4.19 g & h). 
 
The increase in MCP-1 in rats medicated with S. frutescens was not seen in the prevention 
study (see section 4.1.7.4). 
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Figure 4.19: Plasma cytokine levels after treatment: TNF-α (a,b), IL-1α (c,d), IL-4 (e,f), MCP-1 (g,h), 
and GM-CSF (i,j).  Values in left hand figures (a,c,e,g,i) are expressed as mean ± SEM (n=6 per group). 
Values in right hand figures (b,d,f,h,j) are expressed as median (n=7 per group). * p<0.05 **p<0.01 
compared to HFD group; †p<0.05 ††p<0.01 compared to LFD group; ###p<0.001 compared to HFD+Met 
group. 
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4.2.13.5. Granulocyte macrophage colony stimulating factor (GM-CSF) 
 
Looking at figures 4.19 i and j, it can be seen that circulating GM-CSF levels were increased 
in the HFD group compared to the LFD group, although not significantly (16.2 ± 7.5pg/ml vs. 
2.3 ± 1.1pg/ml).  
Treatment with S. frutescens (7.9 ± 2.4pg/ml) or metformin (10.7 ± 2.3pg/ml) appeared to 
lower the plasma GM-CSF concentrations in comparison to the HFD group. Unfortunately this 
was also not significant due to the high variance within the HFD group. 
 
Results from the prevention study showed that only prolonged medication with S. frutescens 
led to significant effects on lowering GM-CSF levels (see section 4.1.7.5). 
 
4.2.13.6. Interferon- γ (IFN-γ) 
 
No IFN-γ was detected in any of the plasma samples. 
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4.3. Lipid content and fatty acid profile of S. frutescens extracts 
 
The commercially available S. frutescens extract (Pinosundia®, Value Added Life Health 
Products (Pty) Ltd., South Africa) used for the prevention and treatment studies was analyzed 
for its total lipid content and compared to self prepared S. frutescens extracts (see section 
3.18). 
The total lipid content in the commercial plant extract was 133mg/g extract compared to 
21.1mg/g and 17.0mg/g for the 3 day and 14 day old S. frutescens leaf extract, respectively. 
Analysis of the lipid extracts by TLC showed that there were also differences in the lipid 
fractions. Figure 4.20 depicts the lipid fractions found in the commercial available plant 
extract and the self prepared S. frutescens leaf extracts. 
 
 
Figure 4.20: Thin layer chromatography of lipid extracts from S. frutescens aqueous extracts.  
The first six lanes correspond to standard lipids (phospholipids, cholesterol, monoglycerides,  
diglycerides, triglycerides, and free fatty acids).  
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The fatty acid analysis of the extracted total lipids showed considerable differences in the fatty 
acid profile between the three S. frutescens extracts (table 4.4). The fatty acids in the lipid 
extracts were identified by comparing them to standard fatty acid retention times (figure 
4.21). 
While the commercially available extract contained fourteen different fatty acids, only eight 
and ten were found in the 3-day and 14-day old leaf extracts, respectively. 
All S. frutescens extracts contained high amounts of omega-3 fatty acids (C18:3n3, C20:5n3 
and C22:5n3) and also high quantities of other long chain fatty acids. 
 
Table 4.4: Fatty acid profile of three aqueous S. frutescens extracts.  
Values are expressed as % of total fatty acids. 
 % of total fatty acids 
 
 
Commercial 
extract 
 
 
Self prepared 
extract (3 day old 
leafs) 
 
 
Self prepared 
extract (14 day old 
leafs) 
 
C15:0 4.0 18.4 9.5 
C16:0 13.8 23.5 22.4 
C18:0 3.5 8.0 11.2 
C18:1 n12c 1.6 - 6.1 
C18:1 n9c 3.0 9.3 14.7 
C18:2 n6c 6.1 8.0 9.5 
C18:3 n3 18.0 23.2 16.4 
C20:0 3.4 - - 
C20:1 2.9 - - 
C20:3 n6 - - 3.6 
C22:0 3.1 - - 
C20:5 n3 14.7 - - 
C22:2 4.1 4.1 5.2 
C22:4 1.6 5.5 - 
C22:5 n3 20.3 - 1.5 
    
n3 (total) 53.0 23.2 17.8 
n6 (total) 6.1 8.0 13.0 
n6/n3 ratio 0.1 0.3 0.7 
 
The drying time (3 days and 14 days) of the leaves appeared to alter the fatty acid profile 
(figures 4.22 and 4.23, table 4.4) as the two plant materials were harvested at the same time 
of the year and at the exact geographical location. 
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Figure 4.21: Retention times of standard fatty acids (Supelco 37 FAME).  
 
Figure 4.22: Retention times of fatty acids in 3-day old S. frutescens leave extracts. 
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Figure 4.23: Retention times of fatty acids in 14-day old S. frutescens leave extracts. 
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Chapter 5 
 
Discussion 
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The WHO estimates that by the year 2030 more than 360 million people will be diagnosed 
with diabetes type 2 (DMT2) world wide, with South Africa accounting for 1.3 million cases 
[11]. Diabetes is typically connected with various other pathological changes in the body 
(coronary artery disease, dyslipidaemia, renal failure, decreased wound healing, loss of eye 
sight, etc.) and therefore puts a huge burden on the health care system world wide. There are 
three major factors that increase the risk of developing DMT2 – genetic predisposition, age 
and high caloric food intake. In most countries in the world people have adapted to a 
“westernised” lifestyle which includes high caloric food intake and lack of exercise. This has 
lead to a pandemic in obesity and DMT2 which is especially worrying given the increase in 
childhood obesity. Currently, one in three adults in the US is obese [6] and it is estimated that 
there are 2.1 billion overweight and obese individuals worldwide [8]. Many scientific studies 
have proven the very tight connection between prolonged intake of high fat diet (HFD) and the 
development of obesity and insulin resistance (IR) [3,36,41,44,161], although many questions 
are still unanswered in the very complex interplay of obesity and IR.  
This study investigated the metabolic changes in male Wistar rats brought about by two 
different high fat diets. Developmental stages of insulin resistance, a pre-diabetic state, were 
examined in detail and compared to healthy individuals who were feeding on a low fat diet. 
South Africa, as a developing country, is also experiencing a steep increase in obese and 
diabetic patients. Problems are arising especially in rural areas were medical care is limited 
and people are still heavily reliant on traditional cures and remedies. Therefore Sutherlandia 
frutescens, a widely used medicinal plant in southern Africa with proven anti-IR properties 
[139], has been used in this study to further investigate its mode of action with special 
attention to alterations in the fat metabolism. This study was also aimed at examining the 
potential of S. frutescens to prevent the onset of HFD-induced IR and therefore DMT2. 
Metformin was used as a reference, to establish if S. frutescens has a similar mode of action to 
this well known anti-diabetic drug.  
 
 
Diets 
Due to budget constraints the imported diets from Harlan Teklad (USA) were only used in the 
prevention study. The high caloric diet TD.95217 was previously used in other studies to 
cause obesity in rats [155] and was chosen as the high fat diet for the prevention study to 
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achieve IR in male Wistar rats. The low fat diet TD.06683 was especially designed to have 
less than 10 kcal% of fat, without loosing the essential fatty acids necessary for normal 
development and health of the animals.   
Rats in the treatment study were fed a locally available product (Epol, South Africa) which 
served as the low fat control diet (LFD). To attain IR a set amount of fat was added to the LFD 
in form of two margarines and condensed milk.  
The criterion for the LFDs was a fat content lower than 10% of total energy to prevent the 
onset of obesity and IR. Fatty acid analysis of the LFDs showed no trans-FA were present, 
whereas C16:0 (palmitic acid), C18:1n9 (oleic acid) and C18:2n6 (linoleic acid) were the 
major FA in both diets. The ratios of SFA, MUFA and PUFA were similar in both LFDs 
(table 3.3)  
The HFDs were chosen to contain a much higher amount of fat (approx. 40% of the total 
energy) to induce IR in the rats within twelve weeks. However, there were considerable 
differences between the Harlan Teklad HFD and the self-prepared HFD. The foremost 
difference was the presence of trans-FA (20% of total FA) in the Harlan Teklad HFD, whereas 
there were no trans-FAs present in the self-prepared HFD. Furthermore, the self prepared HFD 
contained higher amounts of SFA than the Harlan Teklad HFD (55% vs. 33% of total fatty 
acids, respectively) (table 3.3).  
 
Body weight 
The most commonly used method to cause obesity, glucose intolerance and insulin resistance 
in rodents is ad libitum feeding of a diet containing 40 kcal% fat or more. A study found that 
peripheral IR in Sprague-Dawley rats was only influenced by the dietary fat content and not 
by the amount or source of dietary protein [23]. The rats in latter study were fed an Asian-style 
diet (low fat 10kcal%, plant protein), Western style (high fat 40kcal%, animal protein) or 
control diet (low fat 10kcal%, animal protein) and only rats fed western-style diet developed 
hyperinsulinaemia and IR after twelve weeks. Other studies conducted on rodents found that 
almost any kind of high fat diet, containing corn oil, olive oil, butter fat, lard, or safflower oil 
will result in the development of adiposity and increased fasting insulin levels [16,17]. Only 
fish oil, rich in n3-FA, was found to have positive effects on adiposity and insulin sensitivity 
[20,21]. Matsuzawa-Nagata et al. [26] found that C57BL/6J mice fed HFD (40weight% cocoa 
butter), developed impaired glucose tolerance and IR. Based on the findings in the literature, 
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the rats in the present studies were expected to develop obesity and subsequently insulin 
resistance.  
Obesity in humans can be determined via the body-mass-index (BMI in kg/m2), in which a 
BMI >30 kg/m2 indicates obesity [4]. To identify obesity in rats, the Lee obesity index was 
postulated more than 40 years ago, whereby the index is calculated by dividing the cube root 
of body weight by the naso-anal body length [162]. Since then several studies have questioned 
the reliability of the Lee obesity index [163,164] and recent studies rather refer to obesity as a 
significant increase in body weight (BW) connected with elevated adipose tissue weight 
[161,165]. The discussion of the current studies will not refer to obesity, but rather to 
significantly increased BW, because the combined weights for adipose tissues in the rats were 
not determined in the present studies.  
Furthermore, there is contradictory evidence in the literature as to whether or not rats 
become obese when fed HFD ad libitum. A study conducted on male Wistar rats fed for 19 
weeks on HFD showed insulin resistance and a decreased blood glucose clearance rate without 
a significant increase in BW [139]. Pedersen et al. [166] even observed a decrease in BW in 
rats fed HFD ad lib.  
Rats fed with HFD in the current prevention study showed a 10% higher BW after 84 days 
(12 weeks) compared to the LFD rats (figure 4.1), while LFD and HFD rats in the treatment 
study displayed similar BW at day 84 (week twelve), and only at day 95 was a significant 
weight increase noted in the HFD group (figure 4.6). As observed in the treatment study, rats 
fed LFD reached a plateau in BW while the HFD rats continued to increase BW, which 
resulted in a 16% higher BW after sixteen weeks compared to the lean control rats. It is very 
likely that the same trend would have been seen in the prevention study, if rats were left 
feeding longer on HFD. The difference in body weight at the beginning of the two studies was 
due to the longer acclimatization period in the treatment study. Prolonged feeding of HFD 
consisting of 40kcal% fat led to significantly increased BW at the end of both studies. 
Interestingly, Kretschmer et al. [167] noted that even 24kcal% fat in the diet can result in 
significantly increased BW in non-exercised male Wistar rats after eleven weeks.  
At present there is no unified standard calculation or value for a cut off point similar to the 
BMI in humans to distinguish between normal BW, adiposity or obesity in rats. 
Optimistically, a recent study on anthropometrical parameters in rats called for the use of the 
BMI (g/cm2) as a marker for obesity. The study found that an increased BMI in rats correlates 
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strongly with total body fat, serum triglyceride (TG) and oxidative stress, and therefore may 
be used to predict obesity and adverse consequences. Normal BMIs of male adult Wistar rats 
were determined in that study and ranged between 0.45 and 0.68g/cm2. [168] 
A previous animal study on the effects of S. frutescens in vivo did not observe any changes 
in body weight. Chadwick et al. [139] observed no significant differences in the BW of male 
Wistar rats after eight weeks of treatment, which is in agreement with the outcome of a three 
months clinical trial on healthy humans treated with S. frutescens that resulted in unaltered 
BW and BMI [169]. The present studies on S. frutescens treatment in HFD fed rats resulted in 
dissimilar effects regarding body weight between the two experiments. The prevention study 
showed that rats supplemented with S. frutescens displayed higher weight gain for the first 
four weeks of the experiment, which then declined and resulted in a 7% lower BW in the 
HFD+S.f group compared to the HFD rats at the end of the experiment. In comparison to the 
weight increase in the prevention study until week 4 (day 28), IR rats in the  treatment study 
showed a rapid decline in the growth rate compared to the untreated HFD rats which resulted 
in a 8% lower BW after 28 days of S. frutescens treatment. However, the average BW in the 
HFD+S.f. group in the treatment study was still significantly higher than the lean control 
group while the average BWs in the prevention study returned to normal. S. frutescens does 
not appear to negatively influence water intake (see chapter 4.1.2) and appetite seen as an 
increase in BW in the first four weeks of the prevention study (figure 4.1). This indicates that 
the metabolic effects seen with S. frutescens were not due weight loss per se, but rather 
through direct metabolic mechanisms. S. frutescens might have affected the BW in the two 
studies differently due to the different ages of the rats examined. In the prevention study rats 
were growing juveniles. Therefore, the increase in BW is not necessarily associated with the 
increase in adipose tissue, but due to increase in lean body mass. The treatment of these young 
rats with S. frutescens might have stimulated the physiological growth, resulting in the 
significantly increased BW in these rats. S. frutescens is currently under clinical investigation 
for its appetite stimulating and anti-cachexic effects (reviewed in [129]). Rats in the treatment 
study were fully grown and had reached maturity at the start of the treatment regime (day 84). 
The continuous weight increase seen in the HFD group was very likely due to increase in body 
fat rather than lean body mass. The reduced weight gain caused by S. frutescens treatment in 
these mature rats was therefore more likely due to the attenuation of adipose tissue expansion.  
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Studies on obese patients have shown a decrease in BW after medication with metformin 
due to a decreased food intake and lower intestinal glucose uptake [170]. The loss in BW was 
mainly due to an decrease in adipose tissue, as shown in diabetic and non-diabetic obese 
humans [170,171]. On the other hand, meta-analyses do not support a consistent weight-
reducing effect of metformin relative to placebo in diabetic or non-diabetic patients [172]. 
Rats in the present treatment study receiving daily 13.3mg metformin/kg BW (equivalent to 1g 
metformin/75kg human adult/d) for 28 days as a treatment for HFD-induced IR did not display 
a significant weight loss, although the growth curve appeared to decline after 16 days of 
treatment (figure 4.7). This finding agrees with a short term study in non-obese humans, 
where healthy men were given a dose of 850mg twice daily and showed no changes in body 
weight and body fat content [173]. It has been shown in clinical trails that metformin is most 
effective in producing weight loss in younger patients and in patients with BMI >35kg/m2. 
The rats treated with metformin in the current study were not obese, which might explain the 
lack of significant weight loss in those animals.  
In future studies, treatment periods of IR rats with metformin or S. frutescens should be 
prolonged to determine if the body weight can be reduced back to normal. Body lengths as 
well as body weights should be measured to determine the onset of obesity via BMI as 
proposed by Novelli et al. [168].   
 
Fasting plasma glucose  
Normoglycaemia and hyperinsulinaemia are characteristic changes in IR individuals. In the IR 
state, the body is still able to maintain blood glucose levels within the normal physiological 
range but target tissues need much higher concentrations of insulin to utilize the glucose 
present. [36,174]   
 
Rats in the treatment study displayed similar plasma glucose values in all four groups, ranging 
from 6.2 to 6.5mmol/l (112.1 – 117.7mg/dl) after 28 days of treatment (figure 4.11a). In 
agreement with this finding, plasma glucose levels were similar in the LFD, HFD and 
HFD+S.f. groups at all of the time points in the prevention study. After twelve weeks, plasma 
glucose levels in the prevention study ranged from 6.63 to 8.18mmol/l (119.5 – 147.4mg/dl) 
(figure 4.2a). These findings confirm that rats with prolonged HFD intake (16 weeks and 12 
weeks, respectively) had not yet developed diabetes, but displayed normoglycaemia. The 
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plasma glucose values and the maintenance of normoglycaemia in HFD fed rats were 
comparable to observations in other rat studies [17,23,139]]. Mithieux et al. [175] found that 
the arterial plasma glucose levels of male Sprague-Dawley rats did not differ after 6 weeks of 
HFD feeding compared to control rats (10.3mmol/l vs. 9.3mmol/l). In contrast to findings in 
both the current studies, Akiyama et al. [176] observed significantly higher serum glucose 
levels in adult male Wistar rats after 28 days of HFD feeding (196mg/dl HFD group vs. 
136mg/dl control group). The rapid elevation of the blood glucose levels can be explained by 
the administration of HFD via continuous intragastric infusion rather than voluntary ad libitum 
intake by the rats. The infusion method overrides the voluntary food consummation control in 
the rats. It has been previously reported that the intake of HFD stimulates endogenous 
cholecystokinin (CCK) release which in turn attenuates the voluntary food intake [177-179].  
As mentioned above, rats medicated with metformin or S. frutescens did not have altered 
blood glucose levels compared to the lean control rats or HFD rats. This is consistent with 
previous publications [139,175].  
Slight variations in plasma glucose levels between the different time points were observed in 
the prevention study. Rats in this study started off as very young adolescents and underwent 
maturation during the 12 weeks of the experiment. Variations in glucose levels over time have 
been observed in other publications [23].  
 
Fasting plasma insulin   
While plasma glucose levels remained unchanged, the fasting plasma insulin levels became 
significantly elevated after prolonged high caloric food intake. Data obtained in the prevention 
study showed normal insulin levels in the HFD group until week four, which then became 
42% and 49% higher than the LFD insulin values at weeks eight and twelve, respectively 
(figure 4.2 b). Surprisingly, plasma insulin levels in the LFD group at week four showed 
significant elevation compared to the insulin levels in the HFD group. This observation was 
unexpected and can not be explained scientifically. The plasma samples taken for insulin 
determination were analyzed three times and confirmed the above finding. It is possible that 
the plasma samples from the LFD and HFD group for insulin determination were aliquoted 
into the wrong cryo-vials on the day of sacrifice. Therefore, insulin results from week four of 
the prevention study will are not reliable and are not discussed in detail below.  
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The slight increase in glucose and insulin values within each group from the start of the 
prevention study to the end of the experiment appear to coincide with findings in humans. 
Goran and Gower [180] observed a transient development of IR during puberty in healthy 
humans, caused by a rise in fasting glucose levels and incremental rise in fasting insulin 
levels. The same trends over time can be observed in all three groups of the prevention study. 
Glucose levels in the lean control group rise from 5.74mmol/l (week 1) to 6.63mmol/l (week 
12) (1.2 fold increase), whereas insulin levels rise from 0.57ng/ml to 1.48ng/ml (2.6 fold 
increase). To be able to observe changes specifically caused by HFD and S. frutescens in the 
prevention study, the findings at one time point were not compared to other time points, but 
differences between the groups were compared within the same time point.  
Intake of HFD for sixteen weeks in the treatment study also had detrimental effects on 
fasting plasma insulin concentrations. Insulin levels were more than 2 fold increased in the 
HFD group compared to the LFD group at the end of the experiment (figure 4.11 b). The 
insulin values observed in the treatment study were 0.60ng/ml (14.4µU/ml) for the LFD group 
compared to 1.26ng/ml (30.24µU/ml) for the HFD group. These values coincide with insulin 
values found by Matsuzawa-Nagata et al. [26], in which male C56BL/6J mice displayed 
fasting insulin levels of 14.64µU/ml (LFD) and 18.14µU/ml (HFD) at week 6, rising to 
15.74µU/ml (LFD) and 43.34µU/ml (HFD) at week 24 of the feeding regime. Akiyama et al. 
[176] in comparison found much higher fasting insulin levels in male Wistar rats, of 1.1ng/ml 
for the LFD group and 9.1ng/ml for the HFD group. This more than 8 fold increase in plasma 
insulin was observed after only 28 days of HFD feeding and is, like the increased glucose 
levels discussed earlier, likely to be a consequence of the continuous infusion of the diet into 
the stomach of the rats, which might have caused a more rapid development of 
hyperinsulinaemia. It can be speculated that HFD rats in the current study were still in an early 
stage of developing hyperinsulinaemia, which would likely have become progressively worse 
with continued HFD feeding reaching levels similar to the latter mentioned study.   
 
Supplementation of the HFD with S. frutescens prevented the onset of hyperinsulinaemia, seen 
as 43% lower insulin levels in the HFD+S.f. group compared to the HFD group in the 
prevention study at week two. The insulin concentrations remained lower in the HFD+S.f. 
group at all the time points (except week 4, as discussed above) (figure 4.2 b). The insulin 
values observed in the HFD+S.f. group were even lower than the insulin levels in the lean 
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control group from week two until the end of the experiment, although these differences were 
not significant. At the end of the prevention study (week twelve) the insulin levels in the 
HFD+S.f group were 51% (significant) and 26% (non-significant) lower than in the HFD and 
LFD group, respectively. Rats in the treatment study fed for twelve weeks with HFD and 
treated for 28 days with S. frutescens also displayed significantly lower insulin levels than the 
HFD only group (44%) and insulin levels were reversed almost back to normal (0.70ng/ml 
HFD+S.f. vs. 0.60ng/ml LFD). These findings show that S. frutescens is able to attenuate 
HFD-induced hyperinsulinaemia, confirming previous findings that S. frutescens treatment in 
IR Wistar rats brings fasting insulin levels back to normal [139]. The exact mechanism by 
which S. frutescens is able to do so is not understood yet. From the effects seen in the current 
studies it seems unlikely that S. frutescens directly influences insulin secretion from the 
pancreas, but rather exerts its effects by preventing or reversing IR within the target tissues 
(figures 4.3 a,b and 4.11 c,d) . If target tissues are more insulin sensitive, less insulin will 
need to be secreted from the pancreas. The major contributing factor for the normalization of 
insulin sensitivity during S. frutescens treatment is clearly the prevention or attenuation of 
increased plasma FFA (figures 4.4 a and 4.14 a). This will be discussed in detail below.  
 
Unexpectedly, treating rats for 28 days with metformin only slightly lowered the diet induced 
hyperinsulinaemia, and rats in the HFD+Met group displayed similar fasting insulin levels to 
the HFD only group (1.15ng/ml vs. 1.26ng/ml) (figure 4.11 b). This finding is consistent with 
another study where a high dose metformin treatment (50mg/kg BW) for one week did not 
lower fasting insulin levels [175]. A study in humans diagnosed with hyperinsulinaemia 
observed a decrease in blood insulin after twelve week treatment with 3x 500mg metformin 
daily [181]. This suggests that the lack of a significantly insulin lowering effect of metformin 
in our study may be due to the short treatment period (28 days) and the lower dose (equivalent 
to 1g metformin/ human adult/d) given to the IR rats in the treatment study. It has been 
observed that metformin has no direct effect on insulin secretion [182] which might also 
explain the only slightly lowered insulin levels in the HFD+Met group. 
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Insulin resistance  
The most commonly used and validated indices to estimate insulin sensitivity in vivo are 
HOMA-IR and QUICK-index [157,158]. Both indices use fasting plasma glucose and insulin 
values. HOMA-IR measures the extent of the resistance of the body to insulin and values are 
increased during IR; whilst the QUICK-index measures the insulin sensitivity and therefore 
results in lower values during IR. There are no set QUICKI and HOMA-IR values for rodent 
models giving a clear cut off point below or above which IR is confirmed. Publications on IR 
in rodents typically use the significant difference between a control group and a test group to 
indicate the onset of IR.  
 
The calculation of HOMA-IR and QUICKI using fasting glucose and insulin values 
determined in the present studies, gives a clear indication of the development of IR in both 
studies. Rats in the prevention study displayed HFD-induced IR at week eight of the feeding 
regime, which persisted until the end of the experiment. This can be seen as a significantly 
higher HOMA-IR (24.34 vs. 10.72 p<0.001, week 8) and significantly lower QUICK-index 
(0.25 vs. 0.27 p<0.05, week 8) in the HFD group compared to the lean control rats (figures 4.3 
a,b).  
Confirming IR in rats in the treatment study was essential before starting the treatment 
regime with S. frutescens and metformin. After twelve weeks of HFD, rats displayed 
significantly lower insulin sensitivity (QUICKI) and therefore had a higher HOMA-IR than 
rats in the lean control group (figures 4.8 c,d). Glucose uptake and glucose clearance results 
for the treatment study also confirmed the development of insulin resistance after twelve 
weeks of HFD. These results are discussed in detail below. Four weeks further into the 
experiment, rats in the HFD group still had significantly increased HOMA-IR (2.2 fold) and 
lower QUICKI values (9% decrease) compared to the LFD group, again confirming HFD-
induced IR. The findings correlate well with a human study on non-obese and obese 
individuals, where the HOMA-IR was 2.7 fold increased and the QUICK-index was 14% 
lower in the obese patients [183].  A study on male Wistar rats fed for 6 weeks with control 
diet or HFD determined HOMA-IR values of 13.3 and 21.4 and a QUICKI of 0.44 and 0.30 in 
control rats and HFD rats, respectively. There are no set reference values in the literature for 
HOMA-IR and QUCKI in rodents. Therefore a significant increase/decrease compared to 
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control rats indicates IR. Although there are several other indices that can also be used to 
indicate IR, HOMA-IR and QUICKI are the most commonly used indices for fasting animals.      
Supplementing the HFD with S. frutescens, as discussed above, resulted in significantly 
lowered blood insulin levels (treatment study) which were already apparent from 2 weeks of 
treatment onwards (prevention study). The decrease in insulin levels in the presence of 
homeostatic blood glucose levels led to reversion to or preservation of normal HOMA-IR and 
QUICKI values in HFD+S.f. groups in the treatment and prevention study, respectively 
(figures 4.3 a,b and 4.11 c,d). There is no published data in the literature in which HOMA-IR 
or QUICK-index was used to assess the effects of S. frutescens on HFD-induced IR. 
Metformin treatment had no significant effect on HOMA-IR and QUICKI. Rats in the 
HFD+Met group still displayed insulin resistance after 28 days of medication. This is due to 
only slightly diminished fasting insulin levels in this group compared to the HFD group. This 
finding agrees with previous studies where metformin only displayed weak or no effects on 
peripheral IR [184,185]. Acute treatment of patients with type 2 diabetes with 1g metformin 
resulted in a significantly reduced endogenous glucose production, but had no effect on 
insulin-stimulated glucose disposal after 12 hours [186]. Also, a study on diabetic patients 
failed to see an improvement in IR, measured as HOMA-IR, after six months of metformin 
treatment (750g/d) [187].  
 
Effect of dietary fat composition on the development of insulin resistance 
The HFDs used in the present two studies both consisted of approximately 40kcal% fat but 
had very different fatty acid profiles (table 3.3). While the FA profile of the HFD (Harlan 
Teklat) in the prevention study contained 20% (of total FA) trans-FA (C18:1n9 trans, elaidic 
acid) and 19% palmitic acid (C16:0), the self made HFD in the treatment study had no trans-
FA, but contained 40% palmitic acid. The prevention study HFD was also higher in total 
polyunsaturated fatty acids (PUFA) compared to the treatment study HFD (22.8% vs. 14.9% 
of total FA). Nevertheless, both HFD resulted in the development of IR in male Wistar rats. 
After twelve weeks of HFD intake rats in the prevention study displayed a 12% decrease in 
insulin sensitivity (QUICK-index, figure 4.2 b) and similarly, insulin sensitivity decreased by 
11% in the HFD rats in the treatment study (figure 4.8 d). Christiansen et al. [19] reported that 
both saturated FA (SFA) and trans-FA induce insulin resistance in obese patients. In a similar 
study to the present animal setup and diets, Ibrahim and co-workers [18] examined WNIN 
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male weanling rats fed for eleven weeks with control diet, SFA-diet (high in C16:0) or trans-
FA-diet (high in C18:1 trans). The outcome of the study was that rats in the SFA and TFA 
groups showed hyperinsulinaemia and lowered adipocyte glucose transport compared to the 
control rats. Diets rich in SFA have consistently been proven to induce IR [16,188] but there is 
contradicting evidence about the effects of trans-FA on IR. For example, a short term study on 
humans noted that a moderate intake of C18:1 trans-FA does not alter insulin sensitivity [189], 
while other human studies have linked trans-FA intake with IR indices in obese patients [19] 
and increased risk of diabetes mellitus type 2 [190]. The current data suggest that a HFD rich 
in SFA, as well as a HFD rich in trans-FA, lead to the development of IR in rats after 
prolonged intake. The resemblance in structure between SFA and trans-FA (figure 5.1) could 
be responsible for their similar metabolic effects [189]. 
 
 
 
Figure 5.1: Chemical structure of palmitic acid (C16 saturated), palmitoleic acid (C16-cis 
monounsaturated) and 3E-hexadecenoic acid (C16 trans-monounsaturated). [191] 
 
Glucose uptake 
Deoxy-glucose is taken up into tissues in the same way and at the same rate as normal glucose, 
however it can not be metabolized due to its unique structure and therefore accumulates in the 
tissue [192]. Labelling the deoxy-glucose with Tritium (3H) enables the quantification of 
radioactivity in the tissue as a measurement of glucose uptake.   
C16:0 
C16:1 cis 
C16:1 trans 
 - 121 - 
The glucose uptake into muscle, liver and adipose tissue was determined in the treatment 
study as a further indicator of IR before and after treatment with S. frutescens and metformin. 
Rats displayed a 3-fold lower glucose uptake in liver and 39% lower glucose uptake in adipose 
tissue after twelve weeks of HFD compared to the LFD group. This confirms the development 
of HFD-induced IR in liver and adipose tissue, although the glucose uptake into skeletal 
muscle tissue did not seem to be significantly affected at this point (figure 4.9). This finding 
correlates with other studies where it was proposed that IR occurred in adipose tissue before 
the onset of IR in the skeletal muscle [193]. However, at the end of the experiment (16 weeks) 
all three tissues displayed IR seen as a significantly lower glucose uptake in the HFD tissues 
compared to the LFD tissues (figure 4.13). Surprisingly, another study on male Wistar rats 
found a significantly decreased glucose uptake in skeletal muscle and kidneys but not liver or 
adipose tissue after 19 weeks of HFD intake [139]. 
Treatment of IR-rats with S. frutescens resulted in a significantly increased glucose uptake 
into muscle by 15% and a notable but not significant increase in liver (19%) and adipose tissue 
(17%) compared to the HFD rats (figure 4.13). The liver glucose uptake in the HFD+S.f. 
group returned to similar levels as the lean control group, but was still significantly lower for 
muscle and adipose tissue. The values obtained for the glucose uptake should be a reflection of 
the IR-state in the body. S. frutescens treatment significantly improved total body IR 
(measured as HOMA-IR and QUICKI) (figures 4.11 c,d) and therefore resulted in a higher 
glucose uptake into tissues. Chadwick et al. [139] also observed a significant elevation in 
glucose uptake in muscle, but no changes in liver glucose uptake after eight weeks of 
treatment with S. frutescens. The findings in the present treatment study agree with those 
results. In contrast to current findings, Chadwick et al. [139] observed a significant increase in 
glucose uptake into adipose tissue compared to HFD rats after eight weeks of S. frutescens 
treatment. The stronger effect of S. frutescens on the adipose tissue glucose uptake can be 
explained by the longer medication period in Chadwick’s study.  There are no further studies 
on the effect of S. frutescens on glucose uptake in vivo to the author’s knowledge. A possible 
mechanism through which S. frutescens exerts its effects on glucose uptake will be discussed 
at a later stage.  
Metformin treatment resulted in a significantly higher glucose uptake into muscle tissue and 
liver. Surprisingly, metformin caused significantly lower amounts of glucose to be taken up 
into adipose tissue compared to the HFD and LFD groups (figure 4.13). Previous studies have 
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shown that metformin treatment in IR- rats leads to an increase in glucose uptake in muscle, 
but not liver and  adipose tissue, where similar glucose uptake was observed to the HFD group 
[139]. Stumvoll et al. [194] summarizing the findings of previous studies noted that the 
metformin-induced increase in insulin-stimulated whole body glucose uptake is 15-40%, 
whereby muscle is a major side of glucose uptake. Metformin is an activator of AMPK [63] 
which in turn increases GLUT-4 expression via MEF2 and GEF [120], two transcription 
regulators, and therefore increases glucose uptake. The activation of AMPK by metformin is 
indirectly achieved via an increase in the AMP/ATP ratio and activation of the LKB1, a tumor 
suppressor gene, which is upstream of the AMPK kinase cascade [195] (figure 5.2). In 
contradiction to the above, a meta-analysis observed that metformin does not significantly 
improve insulin-mediated glucose uptake in peripheral tissues [196]. However, the current 
observation of a decreased glucose uptake in adipose tissue after metformin treatment is not in 
agreement with other published data. Metformin should exert the same effect on AMPK 
activation and increased glucose transporter expression in the adipose tissue as in liver and 
muscle. However, there is evidence that metformin fails to up-regulate the expression of 
GLUT-1 and GLUT-4 in adipocytes [197] which could partly explain the findings in the 
present study.  
The glucose uptake experiment was performed in the treatment study only, as shortage of 
cage space prohibited the set up of more animals in the prevention study.  
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Figure 5.2: AMPK signalling pathways in the cell. (www.cellsignal.com) 
 
 
Glucose clearance rate 
In the IR state glucose stays longer in circulation due to the diminished effect of insulin on 
target tissues. In the present treatment study starved rats were injected with 0.4g/kg glucose 
and 2µCi/kg 2-deoxy-D-[2,6-3H]-glucose, and the decrease in blood  glucose concentration 
was measured at 5, 10, 15 and 20 min. As expected, rats in the HFD group displayed a lower 
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glucose clearance rate compared to the LFD rats after twelve and sixteen weeks on the 
respective diets (figures 4.10 and 4.12). These findings correlate well with the deceased 
glucose uptake in insulin target tissues (muscle, liver and adipose tissue) (figures 4.9 and 
4.13) and the onset of insulin resistance (figures 4.8 and 4.11) after HFD feeding.  
Treatment with S. frutescens did not significantly increase the glucose clearance rate 
compared to HFD only group. This was somewhat unexpected because of the increased insulin 
sensitivity and muscle glucose uptake seen in these rats (figures 4.11 and 4.13). The lack of a 
significant elevated glucose uptake in the liver and adipose tissue of HFD+S.f. rats compared 
to the HFD rats could be responsible for the unaltered glucose clearance rate.    
The present finding of a significantly faster glucose clearance rate in metformin treated rats, 
compared to HFD rats, correlates with the increased glucose uptake in muscle and liver tissue 
seen in the HFD+Met group. However, this finding is not in agreement with other published 
observations. Many studies found that metformin does not affect the glucose clearance rate but 
exerts its effect on glucose metabolism through decreased endogenous glucose production 
(reviewed in [194]). However, those studies were conducted on diabetic subjects and it is 
possible that the different outcome in the current study is due to the pre-diabetic state of the 
rats. Metformin, as an activator of AMPK and resulting GLUT-4 expression (figure 5.2), 
should be able to induce a faster glucose clearance from the blood than that of rats displaying 
IR (HFD group). The tissues mainly responsible for the higher glucose disposal in the 
HFD+Met rats were liver and skeletal muscle as they showed increased glucose uptake (figure 
4.13), although metformin treated rats displayed only a slight improvement of IR (figure 
4.11). 
 
Plasma free fatty acids 
It is very clear from both studies that plasma free fatty acids (FFA) were elevated in rats fed 
with HFD. Already from week one in the prevention study plasma FFA were elevated by 44% 
in the HFD group with FFA levels becoming significantly raised from week two compared to 
the LFD group  and stayed significantly elevated till week twelve, with an exception for week 
four (figure 4.4 a). HFD-induced elevation of plasma FFA by 23% was also observed in the 
treatment study after 16 weeks of HFD feeding (figure 4.14 a).  
The connection of elevated plasma FFA and insulin resistance is well established in the 
literature [reviewed in [32,36,44]. High caloric food intake and lack of exercise are the two 
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key factors for the development of obesity, which is associated with the expansion of adipose 
tissue mass in the body [198,199]. While FFA from the visceral adipose tissue are directly 
released into the portal vein and affect liver metabolism, subcutaneous adipose tissue releases 
FFA into the peripheral circulation [53]. Circulating FFA have a variety of complex effects on 
tissues in the body.  In the liver, FFA provide substrates for TG and VLDL-synthesis, as well 
as gluconeogenesis [3]. FFA can cause a decrease in insulin clearance in the liver, which 
contributes to rising insulin levels [31].   Excess amounts of circulating FFA also lead to 
increased β-oxidation in muscle, which diminishes glucose uptake and oxidation [200]. 
Moreover, FFA have been shown to act as signalling molecules that activate protein kinases 
[36,37], which in turn inhibit the insulin signalling cascade. FFA are also known to act as 
mediators for inflammatory responses in vivo [36,42]. Overall, FFA are a key factor, if not 
even the key factor, for the complex development of insulin resistance in several tissues. 
Taking together the present findings in the prevention study on pathological changes in body 
weight, insulin sensitivity and plasma FFA, it can be observed that the increase in FFA 
(significant at week two) is apparent before the development of IR (week eight) and the 
increase in body weight (week twelve), comparing HFD rats to LFD rats. For future studies, 
the expansion of adipose tissue mass should be measured to determine if the amount of 
adipose tissue had already increased at two weeks of HFD intake. It is not clear from the 
current data if elevated plasma FFA had indeed been released by an expanding adipose tissue 
mass, or if other HFD-induced alterations in the body were responsible for the high circulating 
FFA. Alternatively, increased lipolysis of chylomicron-TG and VLDL-TG, both circulating in 
vast concentrations during high fat feeding, by lipoprotein lipase could be responsible [30,44]. 
It is currently not clear to what extent intracellular adipose tissue lipolysis and circulating TG 
lipolysis contribute to the FFA spillover into the blood [44].  The increased expression of 
sterol regulatory element binding protein 1c (SREBP-1c) in the liver [26] could also lead to an 
FFA-overspill into the blood stream. The exact source for the FFA spillover needs to be 
established in future studies.  
Supplementing the HFD with S. frutescens in the prevention study had a substantial effect on 
plasma FFA levels (figure 4.4 a). Already after one week of medication rats had a significant 
decrease of 35% in circulating FFA compared to the HFD group. This effect was maintained 
until the end of the experiment. S. frutescens treated rats had 40% less plasma FFA compared 
to HFD rats, and even had even significantly lower levels of FFA than the lean control rats at 
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week eight and twelve (48% and 27%, respectively). These findings suggest that S. frutescens 
may eliminate the main factor for the development of IR, elevated plasma FFA levels. 
Findings in the treatment study confirm that short term treatment of IR-rats with S. frutescens 
significantly decreases circulating FFA levels by 43% compared to the HFD group, and by 
30% compared to the LFD group. This study is the first to examine the effect of S. frutescens 
on blood lipid parameters, and therefore current findings can not be compared with other 
published data. The effects of S. frutescens on plasma FFA levels could be due to reduced 
adipose or LPL-mediated lipolysis, enhanced fatty acid oxidation and/or stimulated FFA 
uptake into tissues.  This theory is partly supported by the findings of [52], who observed an 
increase in the enzymes 2,4-dienoyl CoA reductase and 3-hydroxyacyl-CoA dehydrogenase 
that are involved in FA β-oxidation in the liver in S. frutescens treated rats.  
A likely explanation could be the action of S. frutescens compounds as PPAR agonists or as 
a co-activator in the heterodimer formation with RXR. Previous studies have found that the 
ligation of PPAR-γ leads to adipocyte differentiation [81,83] and therefore the increased 
uptake of FFA from circulation [82]. However, if S. frutescens was purely a PPAR-γ activator, 
an increase in adipose tissue mass and body weight [86] should have been observed in the S. 
frutescens treated rats, which was only the case in the beginning of the prevention study and 
was likely due to increase in lean body mass (figure 4.1). However, the opposite effect on BW 
can be seen after twelve week preventative treatment with S. frutescens and also in the 
treatment study. Taking the decreased plasma FFA and variable changes in BW into account, 
it can be proposed that S. frutescens may not just act as a PPAR-γ agonist but as a general 
PPAR agonist (pan agonist) or co-activator, including PPAR-α and PPAR-δ/β. Previous 
studies have shown that PPAR-α activation is tightly connected with the lipid metabolism. 
This is seen as an increase in β- and ω-oxidation of FA, ω-hydroxylation of FA and decreased 
TG-synthesis [87,88,201] resulting from the alteration of transcription rates for FA-transport 
protein and FA-translocase [202] as well as acyl-CoA oxidase [89], carnitine palmitoyl 
transferase [91] and cytochrome P450-4A [201].  All these PPAR-α regulated changes could 
be responsible for the decreased FFA levels seen in the current studies. S. frutescens may also 
act as a PPAR-δ/β agonist which would lead to deceased obesity and elevated FA-oxidation 
via activation of heat-producing uncoupling enzymes in brown adipose tissue (UCP1 and 3) 
and muscle (UCP2) [90,203,204]. Decreased BW and fasting insulin levels in the present 
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studies are also in agreement with the effects of PPAR-β/δ agonists in obese rhesus monkeys 
[92]. Figure 5.3 gives an overview of the biological effects of PPARs in vivo.   
 
 
Figure 5.3: PPARs and their biologic effects in different organs.  [100] 
(A) PPAR-γ exhibits its anti-diabetic and anti-atherosclerotic effects in adipocytes and skeletal muscles. (B) 
PPAR-α exerts its multiple effects in the liver, heart and vessel wall by regulating expression of corresponding 
genes. (C) PPAR-β/δ is expressed ubiquitously in the body and displays expression of genes involved in glucose 
and lipid metabolism. 
 
Treatment of IR-rats with metformin also resulted in a significant decrease in plasma FFA 
levels by 40% compared to the HFD only rats and 26% compared to the LFD rats (figure 4.14 
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a). It has been shown in clinical trials that metformin lowers plasma FFA levels in patients 
with DMT2 [60,205,206]. The lowering effect of metformin on plasma FFA can be explained 
by its potent stimulation of AMPK [63], as well as the enhanced expression of the peroxisome 
proliferator-activated receptor-γ coactivator-1α (PGC-1α) [64] (figure 5.2). Both, AMPK and 
PGC-1α are responsible for an increase in fatty acid oxidation in the liver and muscle [64,194] 
and could therefore lower plasma FFA levels. Other studies also noted a decrease in FFA 
release from adipose tissue after metformin treatment [207]. A study published in 1997 
suggests that metformin acts primarily on lipid metabolism by decreasing FFA, which in turn 
leads to the well known effects on the glucose metabolism [206]. The findings in the present 
study agree with this finding, metformin treatment resulted in plasma FFA decrease, but the 
effect on lowering IR was not yet achieved. 
 
Plasma triglycerides 
It has been shown that patients with type 2 diabetes exhibit an abnormal blood lipid profile 
characterized by elevated TG levels and low levels of HDL-cholesterol, while LDL-
cholesterol levels usually remain unchanged [73,208,209]. Dyslipidaemia can be already 
observed in the IR-state [210,211] and is part of the metabolic syndrome [54].  
Data obtained in IR-rats in the treatment study agree with this finding of 
hypertriglyceridaemia, as a significant increase in plasma TG levels was observed in the HFD 
group after 16 weeks, compared to the LFD rats (figure 4.14 b). The increase in plasma TG 
can be explained by a variety of changes associated with high fat intake and the IR state of the 
body (reviewed in section 1.4.1). Key factors that led to the elevated plasma TG levels, such 
as increased circulating FFA levels (figure 4.14 a), hyperinsulinaemia (figure 4.11 b) and 
liver-IR (figure 4.13), were present in the treatment study after 16 weeks of HFD, which 
explains the occurring hypertriglyceridaemia.   
High fat fed rats in the prevention study displayed significantly elevated levels of plasma TG 
at week one but surprisingly not at any later time point in the study (figure 4.4 b). 
Triglyceride levels were very similar to the lean control rats even after IR was fully developed 
at week twelve. It is possible, that the plasma TG in these young rats were used for growth in 
lean body mass, and therefore did not increase in the circulation. It is furthermore possible 
that, although whole-body IR was observed in those rats (seen as increased HOMA-IR), IR at 
the liver level may have not yet developed. The tissue glucose uptake was not determined in 
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the prevention study. Although the liver glucose uptake in the treatment study was decreased 
after twelve weeks of HFD rich in SFA, there might have been a different effect caused by the 
trans-FA rich HFD in the prevention study. The liver therefore might have been still able to 
cope with the clearance of increased TG-rich remnants and also had the normal inhibitory 
response to insulin regarding de novo lipogenesis in the prevention study. The elevated plasma 
TG levels in the HFD group at week one could have developed due to the increased levels of 
TG-rich chylomicrons from the small intestine. Adaptation to the increase in plasma TG, e.g. 
increased LPL synthesis and secretion, or increased LDL-receptor expression might have only 
developed after week one and the plasma TG concentration decreased to normal levels. A 
study by Matsuzawa-Nagata et al. [26] also showed no significant differences in plasma TG 
levels between the control and HFD mice, even after 24 weeks of feeding. The authors of the 
study reported that gene expression of SREBP1c and PPAR-α in the liver were up-regulated in 
HFD mice, but SREBP1c was down-regulated in the adipose tissue. These compensatory 
alterations in expression of genes that regulate fatty acid metabolism appeared to be the 
mechanism maintaining plasma TG levels. This might have also been the case in the current 
prevention study. Boivin et al. [212] studied the effects of a high carbohydrate (HCHO) diet 
on the development of IR and hypertriglyceridaemia in comparison to a high fat (HFAT) diet. 
It was found in the study that IR and hypertriglyceridaemia are not necessarily going hand in 
hand. However, it does not explain why two HFDs, which are very similar in carbohydrate and 
fat content, result in different outcomes regarding plasma TG levels in the present studies. 
Nevertheless, the dissimilarities seen could be due to the different fatty acid profile between 
the two HFDs. The HFD used in the treatment study contained no trans-FA but was high in 
SFA, while the HFD used in the prevention study contained less SFA but higher levels of 
trans-FA as well as PUFA. The similar chemical structures of SFA and trans-FA may cause 
comparable detrimental effects in lipoprotein metabolism and endothelial function in vivo 
[213,214]. Therefore, revisiting the nutritional values in table 3.3, trans-FA may be better 
placed with the total SFA, rather than total MUFA. This would then result in similar amounts 
of total SFA (54.7% treatment HFD vs. 53.1% prevention HFD) and total MUFA (30.3% 
treatment HFD vs. 24.0% prevention HFD) in both HFDs, while the total PUFA content 
remains higher in the prevention study HFD (14.9% vs. 22.8%).  Studies have shown that 
increased amounts of n3-PUFA and also linoleic acid (C18:2n6) in the diet have positive 
effects on the plasma lipid profile, as well as being able to counteract undesirable effects of 
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trans-FA [188,215]. The HFD used in the prevention study had higher amounts of n3-FAs, as 
well as linoleic acid, which could have prevented the negative effects caused by trans-FA and 
therefore no increase in plasma TG was seen.  
Treating IR-rats with S. frutescens for 28 days resulted in a reversal of the 
hypertriglyceridaemia to normal levels with a 32% decrease in plasma TG levels compared to 
the HFD (figure 4.14 b). In contrast Johnson et al. [169] found no difference in plasma TG 
levels in healthy adults after three months of treatment with 800mg/d S. frutescens leaf 
powder. This indicates that S. frutescens does not cause a drop in plasma TG levels below 
normal, therefore acting in the IR-state by normalizing lipid metabolism and not directly 
affecting circulating TG levels. There are no other published data on the effect of S. frutescens 
on blood lipid parameters whatsoever. The results obtained in the prevention study were 
contradictory to those in the treatment study and correlate better with the findings of Johnson 
et al. [169]. Plasma TG levels in S. frutescens treated rats in the prevention study were not 
lowered compared to the HFD group and were even significantly elevated at week one, eight 
and twelve compared to the lean control rats (figure 4.4 b). It is difficult to draw conclusions 
about the mode of action of S. frutescens as a regulator of plasma TG from the current results. 
The withdrawal of circulating FFA and improvement in liver insulin sensitivity is likely to 
play a role in the deceased plasma TG levels. Further investigation of LPL activity, SREBP1c 
and PPAR-α expression in the liver is needed to gain a more detailed insight into pathological 
changes during IR in these rats. As a likely PPAR-α and -δ agonist or co-activator, S. 
frutescens treatment should lead to increased LPL activity [216] and decreased plasma TG 
levels [201,217], as previously shown for other PPAR agonist (figure 5.3).  
Metformin treatment did not alter plasma TG levels significantly, although a drop in TG 
levels of 15% was observed compared to the HFD group (figure 4.14 b). Ginsberg et al. [218] 
observed a similar lowering effect in plasma TG of 10-15%, while Strack [62] reviewed a 
positive effect of metformin on lowering cardiovascular risk markers, including a decrease of 
20-30% in TG levels. These data were compiled from studies of individuals with DMT2, 
which might explain the difference to present findings. Other authors noted inconsistent and 
inconclusive effects of metformin on plasma TG, LDL- and HDL-cholesterol levels [219,220], 
although diminished VLDL production in the liver appears to be a possible action of 
metformin [62] which should therefore decrease plasma TG levels. An increase in LPL 
activity was noted after 3 months of metformin treatment which led to a decrease in TG-rich 
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VLDL and normalization of LDL particle size [221]. The mechanism by which metformin 
increases LPL was proposed to be through AMPK activation, which in turn leads to the 
translocation of LPL to the endothelial surface of muscle and adipose tissue [221,222]. The 
treatment period of 28 days in the current study might have been too short to achieve 
significant lowering effects on hypertriglyceridaemia.  
 
Total plasma cholesterol  
Total plasma cholesterol levels were altered by the HFD in both studies. A significant increase 
in total cholesterol by 19% was observed in the treatment study after 16 weeks of HFD (figure 
4.14 c). Cholesterol levels were also elevated in the prevention study HFD group at all time 
points, although significantly higher levels were only observed at weeks four and eight 
compared to the lean control rats (figure 4.4 c). Chadwick [52] noted a significant up-
regulation in the expression of 3-hydroxy-3-methylglutaryl-CoA synthase 2 in HFD-induced 
IR-rats. This liver enzyme catalyses the condensation of acetyl-CoA and acetoacetyl-CoA 
during the second step of cholesterol synthesis [106]. This up-regulation might indicate 
increased cholesterol production, which agrees with the current study. Matsuzawa-Nagata et 
al. [26] noted that 10 out of 15 genes encoding enzymes involved in cholesterol biosynthesis 
were up-regulated in the liver of mice fed a high caloric diet for 6 weeks. This finding 
correlates with higher plasma cholesterol levels in these mice (85mg/dl control vs. 117.7mg/dl 
HFD) at week 6 which became significantly elevated by week 24 (84.6mg/dl control vs. 
132.6mg/dl HFD). Akiyama et al. [176] in contrast observed significantly elevated total 
plasma cholesterol levels after 28 days of hyper-caloric diet in rats, which correlates closely to 
the findings of the prevention study where a 24.7% significant increase in total plasma 
cholesterol was observed, compared to the control group after four weeks of HFD. Total 
plasma cholesterol is the sum of VLDL-cholesterol (plasma TG divided by 5), LDL-
cholesterol and HDL-cholesterol [159] and is therefore influenced by the complex regulation 
of synthesis and secretion of these other lipoproteins. The increase in VLDL (plasma TG) in 
insulin resistance has been discussed already. HFD-induced changes in LDL- and HDL-
cholesterol will be discussed later.  
A previous study has shown that treating healthy adults with S. frutescens leaf powder for 3 
months did not result in significant changes in total plasma cholesterol concentrations [169]. 
The HFD rats in the current treatment study were insulin resistant, and displayed 
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hypercholesteraemia. Treatment with S. frutescens for 28 days resulted in the normalization of 
total plasma cholesterol levels in these rats (figure 4.14 c). Similar findings were noted in the 
prevention study where S. frutescens treatment resulted initially in slightly increased 
cholesterol levels (week one and two), which dropped significantly compared to the HFD 
group as the experiment progressed (week four and twelve) (figure 4.4 c). The cholesterol 
lowering effect of S. frutescens was also observed by [52], who found an increase in two 
enzymes involved in bile synthesis, namely aldo-keto reductase family 1 and bile-acid co-
enzyme A, amino acid N-acyltransferase. It appears that S. frutescens can reduce cholesterol 
levels in vivo by increasing the excretion of cholesterol via bile. Suggesting that S. frutescens 
also has antagonistic properties to PPAR-β/δ could also be responsible for the attenuated 
plasma cholesterol levels. Activation of PPAR-β/δ has been previously shown to decrease the 
cholesterol efflux [90,203]. 
Metformin treatment had a non-significant lowering effect on total plasma cholesterol levels 
in IR-rats (figure 4.14 c). Metformin as an AMPK activator is known to inhibit the enzyme 
activity of HMG-CoA reductase which is the rate limiting enzyme in cholesterol biosynthesis 
in the liver and should therefore result in decreased plasma cholesterol levels (figure 5.2). 
Chadwick [52] also observed no significant change in 3-hydroxy-3-methylglutaryl-CoA 
(HMG-CoA) synthase 2, an enzyme involved in cholesterol biosynthesis, between rats treated 
with metformin for 8 weeks and rats on HFD only. A possible reason for the cholesterol 
lowering, but not significant, effect of metformin in the present model could be the shorter 
treatment period. Stumvoll et al. [194] reviewed findings of between 5 and 10% decrease in 
total plasma cholesterol after metformin treatment, which was attributed mainly to reductions 
in LDL-cholesterol, since HDL-cholesterol was either increased or unaltered by metformin.  
 
Plasma HDL- and LDL-cholesterol 
As already mentioned above, dyslipidaemia in diabetic patients typically comprises of 
hypertriglyceridaemia and low levels of HDL-cholesterol, while LDL-cholesterol is usually 
unaltered [73,209,223]. The findings of the present studies on HFD fed rats did not agree with 
the published data per se. As discussed previously, rats in the treatment study showed 
hypertriglyceridaemia, while TG levels in the prevention study were mostly unaffected.  HDL-
cholesterol levels in both studies were unaltered by high caloric food intake and were not 
decreased in association with the development of IR (figures 4.4 d and 4.14 d). 
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Plasma LDL-cholesterol concentrations did not significantly change with exposure to HFD, 
although a slight elevation in LDL levels was observed in both studies (figures 4.4 e and 4.14 
e). VLDL is the precursor of LDL and therefore the complex mechanisms that regulate 
VLDL-cholesterol concentrations will also influence LDL-cholesterol concentrations in the 
blood [29]. Furthermore, patients with diabetes mellitus and hypertriglyceridaemia often 
display a shift in LDL particles towards small, dense LDL. The lipid fraction of LDL consists 
normally of 5-15% TG and 40-50% cholesterol, but this can be changed by the action of 
cholesteryl ester transfer protein (CETP). CETP is a protein associated with HDL and 
mediates the exchange of cholesterylesters from cholesterylester-rich LDL particles to apoB 
containing lipoproteins (e.g. VLDL, LDL) [224]. The product is a LDL that is cholesteryl ester 
depleted and rich in TG, which can then be hydrolysed by LPL or hepatic lipase resulting in a 
small, dense LDL. Small, dense LDL particles are susceptible to oxidation and have a lowered 
affinity to LDL receptors, therefore remain in circulation for a longer period and increase the 
risk of cardiovascular diseases through their highly atherogenic potential [225]. The 
occurrence of small, dense LDL appears to be closely connected to insulin resistance [226]. 
The method for LDL determination used in the present studies could not differentiate between 
normal and small, dense LDL.  
As discussed above, HDL-levels were not lowered, as seen in the typical dyslipidemic 
picture of diabetic patients, by the HFD and IR in both current studies. Previous studies have 
shown that apoA1 levels are characteristically reduced in the IR-state due to increased apoA1 
catabolism. Furthermore, apoA1 is likely to dissociate from TG-rich HDL in association with 
hypertriglyceridaemia and is cleared by the kidney [227]. Insulin resistance was present in the 
rats in the current studies but had only just developed, which might be the reason for a still 
normally functioning apoA1 metabolism and therefore normal HDL-cholesterol levels.  
Supplementing S. frutescens to the HFD from the start of the feeding regime resulted in 
initially decreased HDL-cholesterol levels at week one (compared to the HFD group) which 
later into the prevention study became significantly increased compared to the LFD group 
(week eight and twelve) and HFD group (week eight) (figure 4.4 d). The LDL-cholesterol 
levels in the HFD+S.f. group in this study showed an almost reversed trend to the HDL-
cholesterol. At week one LDL-cholesterol levels were elevated in the HFD+S.f group 
compared to the LFD group, but then became significantly lower at week twelve (compared to 
LFD and HFD group) (figure 4.4 e). The proposed action of S. frutescens compounds as a 
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PPAR-α agonist could explain the increased HDL and decreased LDL levels, as previous 
studies observed an elevated expression of apoA1, which would lead to a higher production of 
HDL-precursors [92,124] (figure 5.3). Diminished circulating LDL levels have been observed 
after PPAR-α and -δ activation in the literature [92,201]. The treatment study resulted in 
unaltered LDL-cholesterol levels and significantly lowered HDL-cholesterol levels compared 
to the other three groups after 28 days of S. frutescens medication (figures 4.14 d and 4.14 e). 
Looking at the results obtained in the prevention study, S. frutescens appears to have an initial 
(week one and two) negative effect on blood cholesterol levels, but positively alters them from 
week four onwards. Johnson et al. [169] observed no effects of S. frutescens on HDL- and 
LDL-cholesterol concentrations in the blood of healthy individuals after 3 months treatment. It 
is difficult to draw firm conclusions about the mechanism by which S. frutescens alters blood 
lipids. Very complex mechanisms are in place to regulate synthesis, secretion, transport, 
storage and excretion of tissue and blood lipids. More detailed analyses of enzyme activity 
(e.g. fatty acid synthase, phosphatidate phosphohydrolase, CPT-1, HMG-CoA reductase, acyl 
CoA: cholesterol acyltransferase), gene expressions (e.g. PPAR-γ, PPAR-α, SREBPs) and 
expression of apo proteins (e.g. apo A, apo B, apo C and apo E) are needed to give further 
information about the action of S. frutescens in vivo. These will be undertaken in future 
studies.  
 Rats in the HFD+Met group displayed significantly elevated HDL-levels compared to the 
other three groups, while LDL levels were somewhat decreased (figure 4.14 d and 4.14 e). 
These findings agree with results found in other studies. Fleming et al. [228] reported a 
significant increase in HDL level after metformin treatment, and a study of obese, non-
diabetic women observed decreased plasma cholesterol, triglyceride, and increased HDL-
cholesterol concentrations [229]. A review by Staels [219] only noted moderate improvements 
in LDL-cholesterol and HDL-cholesterol, while Strack [62] reviewed findings of 10-20% 
reduced LDL-cholesterol levels after metformin treatment. It is known that metformin 
activates AMPK in the liver and therefore inhibits FA synthesis and enhances FA oxidation, as 
well as suppressing the expression of SREBPs [230] (figure 5.2). Although these hepatic 
changes give an explanation how metformin exerts its effects on the lipid metabolism, 
contradicting results in the literature leave many questions.  The LDL particle size has been 
found to be increased after three months metformin treatment which adds to the positive 
effects of this anti-diabetic drug [221]. Normal size LDL particles are cleared faster from 
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circulation due to their higher affinity to LDL receptors and are also less atherogenic than 
small, dense LDL particles [225,226].  
 
A summary of alterations observed in the plasma lipid parameters in association with tissue 
lipid content and tissue lipid profile is given in table 5.1. 
 
Total tissue lipid content 
It is well established in the literature that IR and ectopic fat accumulation are closely 
associated [108]. In the present studies total lipid content and the profile of these lipids were 
analysed in the three tissues most affected by IR – liver, muscle and adipose tissue.  
 
The intake of HFD for 16 weeks caused a substantial increase in liver (58%) and muscle fat 
(42%) deposits. However, the lipid content of the adipose tissue was unaffected by the HFD 
(figure 4.15, table 5.1).  
The increase in liver fat content is a well documented phenomenon in IR and diabetic 
individuals, named non-alcoholic fatty liver disease (NAFLD) which can lead to non-alcoholic 
steatohepatitis (NASH) [108]. NAFLD is common in patients with type 2 diabetes and in 
obesity, with 50-75% of subjects displaying fat accumulation in the liver [108]. It has also 
been found that fat accumulation in the liver associated with IR is independent of body mass 
index and obesity [109]. A study by Samuel et al. [231] observed hepatic fat accumulations in 
rats already after three days of HFD feeding. Although no alterations in peripheral insulin 
sensitivity were seen after those three days, insulin-stimulated phosphorylation of IRS-2 was 
blunted in the liver. Circulating FFA derived from increased lipolysis in adipose tissue, are the 
main contributor to intrahepatic lipid accumulation [232]. A study has found that TG 
accumulating in the liver of NAFLD patients given a HFD containing 30 kcal% fat, derives 
59% from circulating FFA, 26% from de novo lipogenesis and 15% from the diet [233]. As 
proposed by Krssak et al. [234], an increased influx of FFA results in elevated production of 
long-chain fatty acyl-CoA in the hepatocytes, which would favour the deposits of lipids in the 
liver. Obesity not only leads to an increased FFA flux from adipose tissues, but is also 
connected with low levels of adiponectin [85]. Adiponectin normally activates AMPK in the 
liver, thus stimulating FA oxidation. With low levels of adiponectin less FA are oxidized and 
FFA accumulate in the liver. Insulin resistance impacts on the development of NAFLD by 
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increasing lipolysis of TG in adipose tissue and therefore increasing flux of FFA, as well as 
increased lipogenesis in the liver which is usually suppressed by insulin [108].  
 
 
Figure 5.4: Potential sources of and mechanisms for the accumulation of fat in the liver. [108] 
 
It was established in the present study that rats displayed liver IR, which was indicated by the 
decrease in glucose uptake in this tissue, and elevated levels of circulating FFA in the HFD 
group. Both parameters could be responsible for the increased accumulation of liver fat.  
Intramyocellular (IM) lipid stores are associated with IR and appear to be more strongly 
correlated with IR than FFA levels in the plasma [110,235]. A 42% increase in total muscle 
lipids was observed in the HFD rats in the current treatment study compared to the lean 
control group. A study on humans with high intramyocellular lipid concentrations observed 
that insulin-receptor autophosphorylation and IRS-1-associated PI3-kinase activity were 
reduced [111], which gives evidence that muscle fat is associated with muscle IR. Wu et al. 
[236] proposed a mechanism for IR leading to intramyocellular fat accumulation, which has 
since been confirmed in other studies. A decrease in the expression of nuclear-encoded genes 
that regulate mitochondrial biogenesis, such as PPARγ co-activator 1α (PGC-1α), in IR 
subjects results in a lower number of muscle mitochondria and therefore less FA oxidation. It 
has also been shown that the activation of PGC-1α is associated with improved mitochondrial 
function, as well as increased insulin sensitivity in humans and animals [65,237]. AMPK is a 
key regulator of fatty acid β-oxidation and Liu et al. [120] found that five months of high fat 
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feeding caused 58.7% decrease of AMPKa protein contents as well as lower activation of 
AMPK in rat skeletal muscle. The conclusion of this latter study was that HFD causes a 
decrease in AMPK action and was therefore directly responsible for the lipotoxic effects in 
muscle by inhibiting β-oxidation (figure 5.2). The adipose tissue as a major endocrine tissue 
also plays an important role in regulating the energy metabolism in the skeletal muscle [84]. In 
a normal metabolic state adipose tissue releases adiponectin into circulation, which then 
activates AMPK in the myocytes (as well as hepatocytes), resulting in increased FA oxidation 
in the muscle. In the obese state the circulating adiponectin is diminished and the myocytes 
therefore can not cope with increased FFA levels [84]. This mechanism could explain why 
muscle IR had not yet developed in the current treatment study after 12 weeks of HFD (figure 
4.9). Rats in the HFD group displayed normal body weight at this point and adiponectin levels 
still might have been in the normal range. However, four weeks further into the HFD feeding 
rats had significantly increased body weights due to HFD intake (figure 4.6) and circulating 
adiponectin levels were likely to be diminished, resulting in decreased β-oxidation and storage 
of excess FFA in the muscle. However, the liver, having the same response to adiponectin, 
was already IR. The direct connection between adiponectin and IR needs to be confirmed by 
determining adiponectin levels in the blood at week 12 and 16.  
The total lipid content in the adipose tissue was not altered by the HFD. In obese patients 
adipocytes are characteristically hypertrophic [238] and can reach diameters up to 150µm 
[239]. In the present studies the total adipose tissue mass was not determined. Nevertheless, 
definite increases in adipose mass in the HFD groups compared to the LFD groups were 
observed with the naked eye upon dissection of the rats. With hypertrophy the adipocytes 
should accumulate more TG while other tissue components (e.g. vasculature, cell organelles, 
and other residing cells) should become relatively less, resulting in increased total lipids per 
gram tissue.  Two possible explanations can be proposed for the present finding of unaltered 
adipose total lipid content in the HFD rats. Firstly, the increase in adipose tissue mass could 
result not only from hypertrophy of the adipocytes, but also from hyperplasia. Previously it 
has been found that obesity can either develop through adipose hypertrophy or hyperplasia 
[240]. A study on male Sprague-Dawley rats observed that the epididymal fat pad mass had 
increased 3-fold after two weeks of HFD intake. It was furthermore seen, that the fat cell size 
had reached a plateau and the TG-to-DNA ratio levelled off already after one week of HFD 
(figure 5.5), suggesting that adipocyte hyperplasia was an important mechanism in the 
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development of obesity after the initial hypertrophy [165]. These findings could partly explain 
the unchanged adipose lipid content in the current study. Although the total adipose tissue 
mass was increased, the total lipid content per gram tissue was unchanged. Secondly, a very 
common feature in obese adipose tissue is the infiltration of macrophages [33]. A large 
number of macrophages in adipose tissue could relatively lower the total amount of fat and 
give inaccurate results. It has been previously observed that macrophages can account for up 
to 50% of the adipose tissue mass in obese individuals [33]. For further studies in this regard 
various fat pads should be removed, prepared for light microscopy and then stained for 
macrophage infiltration, lipid accumulation and adipocyte size.   
 
 
Figure 5.5: Assessment of the chronology of hypertrophy and hyperplasia of adipocytes in rats fed a high-fat 
(60%) diet (HFD). [165]  
A: change in the wet weight (mean±SE) of rat epididymal fat pad at 1, 2, and 3 wk after a 4 or 60% fat diet 
(n=3 experiments). B: comparison of fat cell diameter at the 1-, 2-, and 3-wk time points (mean±SE; n=40). C: 
fat pad histology after 1, 2, and 3 wk of the 60% fat diet. D: ratio of triglyceride (TG) to DNA, reflecting the 
fat per cell in the epididymal fat pad from rats on a 4 or 60% fat diet. 
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S. frutescens showed lipid lowering effects at tissue level, especially in the skeletal muscle 
where the total lipid content dropped by 24.5% compared to the HFD and was returned to the 
normal level (figure 4.15 b, table 5.1). The total lipid content in the liver was also lowered by 
S. frutescens treatment (8.5%) but was not significantly different compared to the HFD group 
(figure 4.15 a, table 5.1). S. frutescens had no effect on the lipid content of adipose tissue 
(figure 4.15 c, table 5.1). There are no previous studies on the effects of S. frutescens on 
tissue lipid contents. It can be speculated that S. frutescens exerts its lipid lowering effects on 
muscle and liver indirectly by reducing plasma FFA. With less FFA arriving at the muscle and 
liver, less substrate is available for TG synthesis in these tissues. Also rats treated with S. 
frutescens were more insulin sensitive, which results in a more normal fat metabolism (e.g. 
suppressed lipogenesis in the liver). The suggested action of S. frutescens as a PPAR-β/δ 
agonist may also explain the decrease in liver fat agreeing with a previous study on PPAR-β/δ 
ligands in obese mice where this effect was also observed [241]. It needs to be established if S. 
frutescens acts directly on the lipid metabolism through PPAR agonist or co-activator activity. 
 
Metformin treatment resulted in strongly lowered lipid contents in all three tissues in the 
current study and brought the lipid content of muscle and liver back to normal (figures 4.15 
a,b; table 5.1). Lin et al. [66] observed the reversal of NAFLD in Ob/Ob mice after 
metformin treatment. Metformin, as an activator of AMPK, causes decreased lipid synthesis 
by inhibiting fatty acid synthase and increased FA oxidation in the liver [63] (figure 5.2), 
which explains the decrease in liver fat to almost normal levels in the present study. This is 
also in agreement with a study by Liu et al. [120] where metformin treatment of HFD rats 
resulted in increased activation of AMPK in rat skeletal muscle. Another study found 
histological improvement and reduced steatosis in children with NAFLD and treated with 
metformin [242]. In addition to the possible activation of AMPK, metformin treatment 
achieved a reduction of circulating FFA in the present study. Lower amounts of FFA arriving 
at non-adipose tissue mean less substrate is available for the lipogenesis in these tissues. In 
contrast to the present findings, other studies have failed to note an improvement of liver 
histology and fat content, even after 6 months or 16 weeks of medication, respectively 
[243,244]. The significantly decreased total fat content in the adipose tissue of metformin 
treated rats is somewhat unexpected as the rats did not show a significant decrease in weight 
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gain (figure 4.7) and insulin sensitivity (figure 4.8) compared to the HFD rats. The low fat 
content in the adipose tissue could be directly connected with the decreased glucose uptake 
seen after 28 days of metformin treatment (figure 4.13). Glucose can be converted by the 
adipose tissue to FFA, which are building blocks for TG. With less glucose taken up, less 
substrate for FFA production is available and therefore cannot be stored as TG in adipose 
tissue. The low concentration of FFA in the adipose tissue also supports this hypothesis 
(figure 4.19 a,b).    
 
The tissue lipid extracts obtained were subjected to further analysis to determine cholesterol, 
FFA and TG concentrations were determined within the lipid extract (see discussion below). 
These three fractions make up a majority of tissue lipids and were analysed to correlate plasma 
lipid changes with tissue lipid changes. Other lipids, e.g. diacylglycerol, fatty acyl CoA, 
ceramides, phospholipids and glycolipids, are also contained in the tissue lipid extracts, but 
these were not quantified. Some of these fatty acid metabolites, namely diacylglycerol, fatty 
acyl CoA and ceramides are also important in the development of FFA-induced IR [38]. They 
exert their effects via activation of a serine/threonine kinase which phosphorylates the 
serine/threonine residues on IRS-1, which in turn reduces PI-3 kinase activation. As a 
consequence the downstream events of the insulin signalling cascade are decreased and less 
glucose is taken up into the cell via GLUT4 (figure 5.6). However, not all tissue lipid 
fractions could be quantified due to budget constraints.  
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Figure 5.6: Mechanism of FFA- and FA metabolites-induced IR in skeletal muscle. [38] 
 
 
In recent years many diabetes and IR-studies have focused on the effects of ectopic fat 
accumulations in non-adipose tissue. However, most of the published work lacks a more 
detailed investigation into the lipid profile of these fat accumulations. Special attention should 
be given to the FFA levels as a major factor for the development of IR, not only in the 
circulation but also in tissues affected by IR.  
 
Liver lipid composition 
As discussed above, the total fat content in the liver was significantly increased in the HFD 
group compared to the lean control rats (figure 4.15 a). An increase in all three analysed lipid 
fractions (total cholesterol, FFA and TG) was seen in liver tissue (figure 4.16 b, table 5.1).  
Focusing on fractionation of the liver lipids only, it can be observed that the lipid profile in 
the HFD group is shifted towards substantially elevated FFA levels which were 51% higher 
than the FFA in the LFD liver lipid extracts (figure 4.16 a). Interestingly, the TG fraction was 
not elevated within the lipid extracts (figure 4.16 c). A reason for this could be the ability of 
the liver to rid itself of TG by producing and secreting more VLDL. The increased plasma TG, 
which is normally bound to VLDL, in the HFD group, is in agreement with this theory (figure 
4.14 b). Matsuzawa-Nagata and co-workers [26] also found significantly elevated hepatic FFA 
levels in mice fed a HFD for 24 weeks, while hepatic TG concentrations were unchanged. 
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Substantially elevated FFA levels were only observed in the liver lipids (figure 4.17 a), but 
not in muscle or adipose lipids of HFD fed rats (figures 4.17 a, 4.18 a). It is likely that the 
liver is more susceptible to FFA accumulation than other tissues, as it is the main metabolic 
organ for lipid metabolism and homeostasis. This accumulation of FFA also could be due to 
its close proximity to visceral fat depots releasing FFA directly into the portal vein and to the 
liver. The increased circulating FFA in the HFD group might be therefore directly associated 
with the increase in liver FFA. In addition, the liver also produces FFA by means of lipolytic 
enzymes and de novo lipogenesis. Indeed, an increase of de novo lipogenesis has been 
observed in NAFLD patients with IR [245]. In normal subjects the contribution of hepatic de 
novo lipogenesis to the pool of hepatic fatty acids is less than 5%, this was found to be 
increased to as much as 25% in NAFLD patients [245]. Although the amount of cholesterol 
was significantly increased in the total liver mass of HFD rats (figure 4.16 f), the lipid profile 
showed a significant decrease in the cholesterol fraction (figure 4.16 e). A possible 
explanation for this could be the decrease in LDL-receptor expression in the liver (as 
discussed above), which would result in a diminished uptake of LDL-cholesterol and VLDL-
cholesterol in the liver. The data obtained for the plasma lipids agrees with this hypothesis. 
Plasma TG, which is transported via VLDL, was significantly increased and plasma LDL-
cholesterol levels were slightly increased in the HFD group. This could be an effect of the 
diminished uptake via the LDL-receptors. 
Although S. frutescens only slightly reversed total lipid content in the liver (figure 4.15 a), 
treatment with S. frutescens resulted in significantly decreased FFA and TG levels at tissue 
level compared to the HFD group (figures 4.16 b,d; table 5.1). The same trend was seen in 
the lipid fractions (figures 4.16 a,c). Tissue cholesterol concentrations were not significantly 
altered by the plant extract compared to the HFD (figures 4.16 e,f). Cholesterol concentrations 
in the liver are influenced by many factors, e.g. bile synthesis, endogenous cholesterol 
synthesis and also circulating lipoproteins. The low FFA levels in the liver of HFD+S.f rats 
can be explained by less circulating FFA arriving at the liver due to decreased plasma  FFA 
concentrations (figure 4.14 a). With the reversal of IR, as seen in the S. frutescens treated rats, 
the liver metabolism is normalized and TG do not accumulate in the liver. Also, the lack of 
substrate for lipogenesis is very likely connected to the decrease in plasma TG seen in the 
HFD+S.f. rats. FFA are increasingly oxidized and lipogenesis (from FFA or de novo) is 
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suppressed as a normal response to insulin, lower availability of FFA and possible activation 
of PPAR-α and –β/δ (figure 5.3).  
Metformin treatment had a substantial lowering effect on the accumulation of lipids in the 
liver (figure 4.15 a, table 5.1). The lower lipid amount is responsible for the significant 
decrease of FFA and TG at tissue level (figures 4.16 b,d). However, these findings were not 
reflected in the lipid composition where FFA and TG fractions were similar to the HFD group 
(figures 4.15 a,c). An explanation for this unexpected finding could be that although plasma 
FFA were decreased with metformin treatment, plasma TG were as high as in the HFD group 
(figures 4.14 a,b). The high levels of plasma TG could either have been taken up directly by 
the liver, or hydrolyzed into FFA, which would explain unchanged TG and FFA levels in the 
liver lipids. Liver cholesterol was significantly increased in the liver lipids (figure 4.16 e) and 
was not affected by metformin in the total liver mass when compared to the HFD group 
(figure 4.16 f). The increase in total liver cholesterol was unexpected because the AMPK 
activation by metformin is known to lead to a decrease in activity of HMG-CoA reductase, the 
rate limiting enzyme in cholesterol synthesis [246,247]. The increased amount of cholesterol 
in the liver lipids could be explained by the increased HDL-cholesterol concentrations in the 
plasma. Cholesterol from extra-hepatic tissues can be taken up by HDL particles and 
transported back to the liver [106]. The increase in plasma HDL and decrease in muscle 
cholesterol seen in HFD+Met rats compared to HFD rats supports this hypothesis (figures 
4.14 a; 4.17 e,f). The decrease in the total liver lipid content of metformin treated rats could 
not have resulted from a combined decrease in the three analyzed fractions, but was more 
likely to be due to reductions in other lipids. As mentioned above, concentrations of 
diacylglycerol, fatty acyl CoA, and ceramides could also have been reduced by the metformin 
treatment. This hypothesis puts a very important question mark on other published data in the 
literature. The majority of studies on ectopic fat accumulations connected with IR and diabetes 
do not probe further than the total fat content in tissues like muscle and liver. As a 
consequence, important pathophysiological mechanisms of different lipids could be missed or 
wrongly interpreted. 
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Muscle lipid composition 
As already stated above, the total fat content of skeletal muscle was elevated in rats of the 
HFD group compared to the lean control rats (figure 4.15 b).  
Analysis of the lipid extracts showed a significant increase in TG only, while the FFA and 
cholesterol fractions were only slightly elevated in the HFD group compared to the LFD group 
(figures 4.17 a,c,e; table 5.1). Due to the high total fat content in the muscles of HFD rats, all 
three lipid fractions (FFA, TG and cholesterol) were significantly elevated in the total muscle 
mass compared to the LFD rats (figures 4.17 b,d,f). It has been shown in animal and human 
studies that circulating TG can be directly taken up into muscle tissue without prior lipolysis 
by LPL [248,249]. The amount of TG taken up into non-adipose tissue depends on the plasma 
TG concentration and the LPL activity in the microcirculation of the tissue [44]. This might 
explain why only the TG fraction is elevated in the muscle lipid extract in the present study. 
Plasma TG levels were significantly elevated in the HFD rats (figure 4.14 b) and might have 
directly contributed to the TG concentrations inside the muscle. It is also likely that the 
increased influx of FFA from the blood (figure 4.14 a) was used for the synthesis of 
metabolites, e.g. TG and therefore no elevation of the FFA fraction was observed within the 
muscle lipids. Other FFA metabolites, such as diacylglycerol, fatty acyl CoA and ceramides 
(as discussed above) could have also been synthesized from the arriving FFA. These 
metabolites were not quantified in the lipid extracts in the current study. The increase in the 
TG content in the total muscle mass of HFD rats can also be directly associated with muscle 
IR (figure 4.13). This is in agreement with a study by Storlien et al. [16], where a 
deterioration of skeletal muscle insulin action was associated with an increase in muscle TG 
and long-chain acyl CoA. The cholesterol concentration at muscle lipid level was not 
influenced by the increased plasma cholesterol levels. This can be explained by the ability of 
skeletal muscle to regulate cholesterol efflux via nuclear receptors and contribute to the total 
body cholesterol homeostasis [250].    
Unexpectedly, S. frutescens treatment for 28 days resulted in significantly elevated muscle 
TG concentrations in the muscle lipid extract in comparison to the LFD and HFD groups 
(figure 4.17 c, table 5.1). The higher TG level was also reflected in the total tissue mass 
(figure 4.17 d) as TG levels in the HFD+S.f rats were significantly higher than in the LFD 
group, but not HFD group. TG concentrations in the HFD+S.f. group were similar to those in 
the HFD group at total tissue level, although the total fat content in the HFD+S.f. was 
 - 145 - 
substantially lower than in the HFD group (figure 4.15 b). An increase in myocellular TG can 
be associated with a repartitioning of FFA and FA metabolites towards TG-synthesis. This 
effect was observed by Schenk and Horowitz [251], who found an attenuation of IR in human 
skeletal muscle after one session of endurance exercise. They observed that muscle TG levels 
increased, while FFA and FA metabolites were suppressed, which resulted in the prevention of 
FA-induced IR. Rats medicated with S. frutescens displayed similar muscle FFA levels to rats 
on HFD, however, other FA metabolites could have been repartitioned for the synthesis of TG. 
More research is needed to confirm this hypothesis. As mentioned, in the HFD+S.f. rats FFA 
concentrations in muscle lipid extract and total muscle tissue were not significantly different 
to the HFD rats, but were still significantly higher than in the LFD group (figures 4.17 a,b). 
The lower amount of total fat in the muscle of HFD+S.f. rats appears to derive in parts from 
the significantly lower quantity of cholesterol, which can be seen in the total lipids as well as 
total muscle mass (figures 4.17 e,f). The lower cholesterol amounts in the HFD+S.f. rats can 
not be explained by an increase in plasma HDL-cholesterol. The HDL-cholesterol 
concentrations were significantly decreased in this group and therefore could not have taken 
up the excess cholesterol in the muscle in increased amounts. A possible explanation for the 
decreased muscle cholesterol levels could be either a decreased uptake from the blood, which 
would correlate to the attenuated total plasma cholesterol levels, or by lower synthesis of 
cholesterol within the muscle. Interestingly, in a very recent study on β-sitosterol, a similar 
plant sterol to that found in S. frutescens [144], β-sitosterol has been shown to have beneficial 
effects on lipid metabolism in the myocytes [153]. These effects are mediated through the 
activation of AMPK, resulting in decreased cholesterol levels, increased FA oxidation and 
GLUT4 translocation in myocytes [153]. Although the cholesterol levels in the muscle tissue 
were decreased with S. frutescens treatment, they might not account alone for the lower 
intramyocellular fat content observed. Other FFA metabolites (diacylglycerol, fatty acyl CoA 
and ceramides) could have been attenuated, which could explain the increased insulin 
sensitivity in the muscle, seen as an increase in glucose uptake. Further analyses are necessary 
to confirm this hypothesis.    
Surprisingly, metformin treatment resulted in significantly higher FFA levels in the total 
muscle lipids compared to LFD and HFD rats (figure 4.17 a, table 5.1). This increase was 
also reflected in higher FFA levels in the total muscle mass, although it was only significant to 
the LFD group (figure 4.17 b). Metformin, as an AMPK activator, should result in increased 
 - 146 - 
mitochondrial β-oxidation [64,194] (figure 5.2) and therefore lower FFA levels in the muscle, 
which was not the case in the present study. On the other hand metformin has also been found 
to increase the endothelial LPL activity [221,222], which could lead to an increased influx of 
FFA from TG-rich VLDL and chylomicrons into the muscle tissue. Interestingly, metformin 
appears to exert its effect of LPL activation more in muscle tissue than adipose tissue [221]. 
Therefore the FFA influx might outweigh the FA oxidation and FFA will accumulate within 
the muscle tissue. The TG concentrations in the lipid extract and total muscle mass were 
unaltered compared to the HFD group, and still significantly higher than in the LFD group 
(figures 4.17 c,d). The effects of metformin on muscle cholesterol levels were similar to those 
of S. frutescens. Cholesterol concentrations were significantly lower in the HFD+Met group 
compared to the HFD group in both total muscle lipids and total muscle mass (figures 4.17 
e,f). The substantial decrease in muscle cholesterol can be explained by the significantly 
elevated plasma HDL levels in the HFD+Met group (figure 4.14 d). Cholesterylester-free 
HDL precursors are produced by the liver and small intestine and are able to take up free 
cholesterol from other circulating lipoproteins and extra-hepatic tissues and transport them 
back to the liver [106]. Again the question arises to what extent other lipid fractions might 
have played a role in decreasing total muscle fat, as the lowering of the cholesterol fraction 
alone could not have been responsible  for the effect.  
 
Adipose tissue lipid composition 
There was no difference in total fat content and lipid profile in the adipose tissue of the HFD 
and LFD groups (figures 4.15 c and 4.18 a,c). As already discussed above, higher TG levels 
were expected in the adipose tissue of HFD rats but might not have been detected due to high 
amounts of infiltrating macrophages, a typical occurrence in diet-induced IR [41,252]. The 
potential higher numbers of non-adipose cells could have masked the accumulation of lipids in 
the adipose cells. Weisberg et al. [33] reported that the cell content in subcutaneous adipose 
tissue of obese patients can consist of 50% macrophages compared to 10% in lean individuals. 
No changes in adipose FFA concentrations were seen in the HFD group compared to the LFD 
group (figures 4.18 a,b; table 5.1), although in the IR state, adipose tissue is the major 
contributor to circulating FFA [44]. Significantly elevated FFA levels were observed in the 
plasma of HFD rats in the treatment study (figure 4.14 a) and were very likely the result of 
FFA spill-over from the adipose tissue. This means that FFA did not accumulate in the adipose 
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tissue, but were rapidly released into circulation, hence resulting in normal FFA levels within 
the tissue.  
 
 
Table 5.1: Summery of changes in plasma and tissue lipid parameters in the treatment study.  
↑ significantly increased; ↓ significantly decreased; = no significant change a compared to the LFD group; b 
compared to the HFD group 
 
  HFDa HFD+S.f.b HFD+Metb 
Plasma  lipids     
FFA  ↑ ↓ ↓ 
TG  ↑ ↓ = 
Total cholesterol  ↑ ↓ = 
HDL cholesterol  = ↓ ↑ 
LDL cholesterol  = = = 
Total tissue lipid content     
Liver  ↑ = ↓ 
Skeletal muscle  ↑ ↓ ↓ 
Adipose tissue  = = ↓ 
Liver lipids     
FFA per mg lipid extract ↑ ↓ = 
 per g tissue ↑ ↓ ↓ 
TG per mg lipid extract = ↓ = 
 per g tissue ↑ ↓ ↓ 
Cholesterol per mg lipid extract ↓ = ↑ 
 per g tissue ↑ = = 
Muscle lipids     
FFA per mg lipid extract = = ↑ 
 per g tissue ↑ = = 
TG per mg lipid extract ↑ ↑ = 
 per g tissue ↑ = = 
Cholesterol per mg lipid extract = ↓ ↓ 
 per g tissue ↑ ↓ ↓ 
Adipose tissue lipids     
FFA per mg lipid extract = ↓ ↓ 
 per g tissue = ↓ ↓ 
TG per mg lipid extract = = = 
 per g tissue = = ↓ 
 
Although there was no significant change in the total fat amount in adipose tissue of the 
HFD+S.f. rats compared to the HFD and LFD groups (figure 4.15 c), the treatment with S. 
frutescens resulted in substantially lower FFA concentrations in the lipid extract and total 
adipose tissue mass (figure 4.18 a,b). Plasma FFA concentrations in S. frutescens treated rats 
were significantly lower compared to the lean control and HFD rats (figure 4.14 a) and were 
very likely the result of diminished FFA production (via lipolysis and de novo) in the adipose 
tissue, which is also seen as a lower FFA concentration in the adipose tissue lipids. Adipose 
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tissue TG concentrations were not altered in the HFD+S.f. rats compared to HFD rats (figure 
4.18 c,d). It is not clear from the present analysis if S. frutescens had no effect on adipose TG 
levels, or if there was less macrophage infiltration into the tissue. The decrease in non-adipose 
cell numbers could have concealed the decrease in TG storage in the adipose cells. Further 
research needs to be conducted to test this hypothesis. 
Metformin significantly decreased FFA levels in the adipose lipids and total tissue mass 
(figure 4.18 a,b), while TG levels were unaltered in the lipid extract and significantly 
decreased in the total adipose mass compared to the LFD and HFD groups (figure 4.18 c,d; 
table 5.1). Although metformin has been found to increase endothelial LPL activity and 
therefore lead to a higher FFA influx into tissue, the effect was mainly seen in muscle tissue 
and not adipose tissue [221]. The activation of AMPK and its down-stream effect of increased 
FA oxidation (figure 5.2) is most likely to be responsible for decreased adipose tissue and 
circulating FFA levels.  
 
 
Tissue fatty acid profiles 
The fatty acid profile of cell membranes and lipid stores is mainly influenced by the intake of 
dietary fatty acids. For example, looking at the FA profile of muscle, liver and adipose TG 
(tables 4.1, 4.2, 4.3) in LFD and HFD rats, it can be seen that there are only minute amounts 
of lauric acid (C12:0) in the LFD tissues, but noticeable amounts in the HFD tissues. The 
reason for this difference is that the HFD in the treatment study contained lauric acid (5.1% of 
total FA, table 3.3) and no lauric acid was detectable in the LFD. A similar influence of the 
dietary FA on membrane and storage FA was observed for palmitic acid (C16:0), linoleic acid 
(C18:2n6), α-linolenic acid (C18:3n3), eicosapentaenoic acid (EPA, C20:5n3) and 
docosahexaenoic acid (DHA, C22:6n3). These changes in the FA profile are not necessarily 
associated with the development of IR and are rather reflecting the availability of FA. For this 
reason, the FA profile of the LFD lipids is included in tables 4.1, 4.2, and 4.3, but not 
compared statistically to any of the other three groups. The FA profile of metformin and S. 
frutescens treated rats was compared to the HFD only group to observe changes associated 
with the improvement of IR in these two groups.  
Animal models have been previously used to show alterations in plasma membrane lipids in 
various tissues in diabetic individuals [253,254]. While the dietary FA profile has a direct 
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influence, desaturase enzymes also have an important function in changing membrane fluidity 
in all cells [255]. The desaturase enzyme transcription is insulin dependent [256] and might 
therefore be altered in the IR-state and diabetes. Indeed, studies have found a decrease in Δ5, 
Δ6, and Δ9-desaturase activities in association with diabetes and IR [254,257-259]. Saturated 
fatty acids (SFA) as well as trans-FA incorporated in cell membranes are known to decrease 
fluidity and lead to membrane rigidity [260]. Berlin et al. [261] reported a direct correlation 
between membrane fluidity and insulin binding in humans. The ratio of SFA/PUFA (S/P-ratio) 
can be used to determine membrane fluidity [261,262], and increased S/P-ratios were seen in 
the HFD phospholipids (PL) compared to LFD-PL in all three tissues (tables 4.1, 4.2, 4.3). 
These elevated S/P-ratios are most likely the result of increased SFA, especially C16:0, in the 
HFD and not due to defects in desaturase enzyme activity caused by IR. Allen et al.  [255] 
analyzed the membrane fluidity in red blood cells of diabetic and non-diabetic humans and 
observed higher S/P-ratios in the diabetic group. The storage lipids in the current HFD tissues 
also showed an increased S/P-ratio.  
Delta-5 (Δ5) and Δ6-desaturase are rate limiting enzymes in the metabolism of essential fatty 
acids, which leads to the formation of other metabolically active long-chain FA (GLA, DGLA, 
AA, and EPA), as well as eicosanoids (prostaglandins, thromboxanes, and leukotrienes [257] 
(figure 5.7). It has been found, that incorporation of essential FA and long-chain FA into cell 
membrane phospholipids increases cell membrane fluidity and therefore increases the 
expression, affinity, and number of insulin and other receptors [263,264]. As mentioned 
before, IR can lead to a decrease in desaturase activity and less incorporation of long-chain FA 
in cell membranes. This process also works in the reverse direction – diets high in SFA/trans-
FA and low in essential FA lead to rigid cell membranes with impaired insulin action, 
therefore leading directly to IR [257,263-265].  The content of long-chain FA in tissue 
membranes of the present HFD group is unquestionably lower than in the LFD group. 
However, it can not be established from the current results if this was the cause of IR in the 
HFD rats (by leading to rigid membranes), or if the changes in the FA profile were a result of 
the existing IR and inhibition of desaturase enzymes.  
Interestingly, treatment with S. frutescens led to the reversal of IR but not to a major 
improvement of the membrane FA-profile. The only significant membrane FA alterations that 
could be connected with increased insulin sensitivity were the increased total PUFA and 
arachidonic acid (AA, C20:4n6) content in the adipose tissue membranes (table 4.3) and the 
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increase in docosapentaenoic acid (DPA C22:5n3) in the muscle membranes. The higher 
amounts of DPA observed in the S. frutescens treated rats might not be due to metabolic 
changes, but could have derived directly from the S. frutescens extract itself (table 4.4). Also, 
increases in C20:1 (in adipose TG), C18:0 (in muscle TG) and C18:1n9 (in muscle PL) could 
be related to the FA in the S. frutescens extract. Holman and co-workers [254] observed a 
decrease of PUFA in tissue PL of diabetic type I rats, in which AA especially was decreased, 
pointing towards a defect in Δ5-desaturase. Another explanation for decreased membrane AA 
in the diabetic state could also be the increased activity of phospholipase A2 leading to 
elevated production of pro-inflammatory prostaglandins of the 2 series [266] (figure 5.8).  
 
 
Figure 5.7: Metabolism of essential fatty acids. [257]  
Prostaglandins of 2 series, formed from AA, have more pro-inflammatory actions compared to those of the 3 
series formed from EPA. PGI2 and PGI3 inhibit platelet aggregation and cause vasodilatation; PGI2>PGI3. 
Resolvins are formed from both EPA and DHA and are believed to have anti-inflammatory action and participate 
in the resolution of inflammation. Resolvins also inhibit production of pro-inflammatory cytokines and inhibit 
leukocyte migration. EPA is converted to form DHA and DHA can be retroconverted to EPA. 
 
The increase in adipose membrane AA in the current S. frutescens treated rats therefore could 
be caused by increased, Δ5desaturase activity, or by a decreased production of prostaglandins. 
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Further analyses are necessary to confirm these changes in enzyme activities. The adipose 
tissue membrane lipids from the HFD+S.f rats displayed a lower S/P-ratio compared to the 
HFD rats, which may account for increased insulin sensitivity due to higher membrane 
fluidity. Unfortunately, this improvement was not seen in muscle and liver membranes.   
Metformin treatment had a stronger effect on changes in membrane and storage FA than 
treatment with S. frutescens. However, similar to the HFD+S.f. rats, metformin treated rats 
displayed an improvement in adipose, but not muscle and liver membrane fluidity (table 4.3) 
and also had higher amounts of AA in the adipose membranes. The increase in AA could be 
caused by either increased Δ5desaturase activity or by a decreased production of 
prostaglandins of the 2 series. Metformin itself does not contain any fatty acids; therefore, 
changes seen in the tissue FA profile of metformin treated rats are purely metabolic. Muller et 
al. [267] tested the effect of metformin on erythrocyte membranes and found an increase in 
membrane fluidity. The FA profile of skeletal muscle membranes was mainly unaffected by 
metformin treatment, with the exception of increased C18:1n12 levels compared to the HFD 
group. The FA profile of liver phospholipids showed a decrease in dihomo-γ-linolenic acid 
(DGLA, C20:3n6) after S. frutescens and metformin treatment. This could imply that either 
less DGLA was metabolized from LA (C18:2n6) and GLA (C18:3n6), or more DGLA was 
used as a substrate for prostaglandins of the 1 series (figure 5.7). Prostaglandin E1 (PGE1) has 
been previously reported to have anti-inflammatory and immunosuppressive effects [268], and 
metformin and S. frutescens may promote the synthesis of prostaglandins of the 1 series.   
Changes in the FA profile of storage lipids were seen in the IR-rats and also rats treated with 
S. frutescens or metformin. To what extent this FA profile directly correlates with the 
development or treatment of IR, and subsequently diabetes, is uncertain. To the author’s 
knowledge, there are no previous publications on this topic.  
Comparing the FA profile of HFD+Met adipose TG to that of the HFD group an increase in 
total MUFA was observed. This increase was due to the elevation of C16:1, C18:1 and C20:1 
(table 4.3). No similar pattern was seen in the liver TG and muscle TG, the latter even 
displayed lower amounts of C16:1 (tables 4.1 and 4.2). Palmitoleic acid (C16:1n9) and oleic 
acid (C18:1n9) are the most common MUFA in animal tissues and can be synthesised from 
their precursors palmitic acid (C16:0) and stearic acid (C18:0) through introduction of a 
double bond catalysed by Δ9desaturase [106]. Desaturase activity is decreased in the diabetic 
state [254,257-259] and elevated C16:1 and C18:1 concentrations after metformin treatment 
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could point towards increased Δ9desaturase activity. A decrease of the precursors, C16:0 and 
C18:0 in adipose TG agrees with this hypothesis.  
Muscle TG displayed higher amounts of C18:0 and lower amounts of C16:1 after S. 
frutescens and metformin treatment, which opposes the findings in the adipose tissue storage 
TG. The decreased docosahexaenoic acid (DHA, C22:6n3) levels could be connected with 
lipolytic activities in the skeletal muscle of S. frutescens treated rats. As discussed above, rats 
treated with S. frutescens had a decreased total fat content (figure 4.16 b) and previous studies 
showed that long chain PUFA are more easily liberated under lipolytic stimuli [269-271].  
The lower amounts of myristic acid (C14:0) observed in the HFD+Met liver TG were very 
close to the GC detection limit of 0.5%  and may therefore not be reliable. Unexpectedly, the 
concentration of linoleic acid (LA, C18:2n6) was also increased in the HFD+Met liver TG. 
Linoleic acid is an essential FA for mammals, as it can not be synthesized from oleic acid due 
to the lack of Δ12 and Δ15desaturases. The higher levels of LA also can not be explained by 
decreased down-stream products (figure 5.7), as GLA, DGLA and AA were not found in 
significantly altered amounts.  
 
To gain more insight in specific metabolic pathways that lead to the above outcomes, enzyme 
activities (e.g. desaturases, elongases) and levels of eicosanoids should be determined in future 
studies.  
 
S. frutescens - lipid content and fatty acid profile  
The current analyses of different S. frutescens hot water extracts showed a very high total lipid 
content in the commercial extract (133mg/g) compared to the self prepared extracts (21.1mg/g 
and 17.0mg/g). The reason for this is unclear The high lipid content in the commercial extract 
could be explained by the use of different extraction methods for the commercial and self-
prepared extract. It was not possible to obtain more detailed information about the commercial 
extraction procedure due to patent rights; however, it is definitely a hot water extract without 
any additives.  
 
Tai et al. [144] identified only one fatty acid in a methylene chloride extract of S. frutescens 
leaf powder: hexadecanoic acid (palmitic acid, C16:0).  However, the GC-MS method used in 
that study was not specific for FA analysis. Since then no other research has been published 
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identifying FA contained in S. frutescens or S. frutescens extracts. The lipid extraction and 
methylation method used for the present FA analysis, as well as GC column (BPX-70) and 
program was specifically aimed at short, medium and long-chain FA determination. The 
chromatograms confirmed that the aqueous  S. frutescens extract contained some FA, most of 
wich have not been previously published in connection with S. frutescens (table 4.4). In 
agreement with previous findings [144], palmitic acid was one of the main FA in the lipids 
extracted with 13.8 to 23.5% of total FA. The other major FA found were C15:0, C18:0, 
C18:1n9, C18:2n6, C18:3n3, C20:5n3, C22:5n3, as well as several minor FA. Particularly 
remarkable is the high n3-FA content in the hot water extracts of S. frutescens.  
The variations in the fatty acid profile between the commercial and the self-prepared extracts 
could be explained by the differences in extraction procedures, parts of the plant used, time of 
harvest, stress (drought, heat, etc.), and storage conditions. Comparing the two self-prepared 
extracts (figures 4.22 and 4.23, table 4.4), it was observed that the length of drying of the 
leaves altered the lipid content and fatty acid profile. These two plant materials were harvested 
at the exact geographical location and the same time of the year.   
 
Inflammatory processes  
In recent years it has become increasingly evident that inflammatory processes are a major 
component of IR, whereby chronic activation of pro-inflammatory signalling pathways results 
in decreased insulin sensitivity [42]. For example elevated levels of circulating TNF-α, IL-1, 
IL-6, IL-8, MCP-1, and C-reactive protein (CRP) have all been reported in various diabetic 
and IR-states in humans and animals [32,42,252,272-275]. The adipose tissue appears to play 
a key role in the secretion of inflammatory mediators [55,252].  Insulin signalling is negatively 
affected by cytokines as shown in figure 5.8.  
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Figure 5.8: Direct interaction of insulin signalling and inflammatory pathways. [42] 
Activation of the insulin receptor leads to tyrosine phosphorylation of IRS1 thereby initiating signal transduction. 
Stimulation of the NFκB and AP-1 Fos/Jun inflammatory pathways results in the activation of the serine kinases, 
Ikkb and Jnk1, which reduce the signaling ability of IRS1. Additional inflammation-related negative regulators of 
IRS proteins include the Socs proteins and NO, which are induced in inflammation, and promote IRS 
degradation. NO also reduces PI3K/Akt activity by s-nitrosylation of Akt. 
 
However, not all cytokines induce inflammation and IR. For example IL-10, produced by 
anti-inflammatory M2-macrophages (figure 5.9) in adipose tissue, has been found to increase 
insulin sensitivity [3,47]. This was also confirmed in an in vitro study where IL-10 treated 3T3 
adipocytes were protected from TNF-induced IR [276]. Interestingly, it has also been shown 
that cytokines like TNF-α and IL-1 can directly alter lipid metabolism [277].  
S. frutescens has been reported to have anti-inflammatory properties [129] and studies 
suggest that the inhibition of DNA-binding of NFκB and AP-1/Fos is the mechanism 
responsible [278,279].  
Previous studies have shown that metformin treatment only has a modest or no effect on 
sub-clinical inflammation [280,281]. Also, TNF-α levels have been found to be either not 
affected or even increased after metformin treatment [282-284].  
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Figure 5.9: Classical and alternative activation of macrophages. [41] 
Microbial stimuli, which are recognized by pattern recognition receptors and the type 1 T-helper cytokine 
interferon γ promote classical activation of resident and recruited macrophages. These activated cells produce 
pro-inflammatory cytokines, such as tumor necrosis factor and interleukin 6, and reactive oxygen species and 
nitric oxide. Induction of major histocompatibility complex class II and co-stimulatory molecules increases 
antigen presentation by these cells. Classically activated macrophages play an essential part in antibacterial 
responses. By contrast, interleukins 4 and 13 promote alternative macrophage activation, which has a critical 
role in allergic and antiparasitic responses. Although these cells also induce major histocompatibility complex 
class II, their repertoire of co-stimulatory molecules and pattern recognition receptors is different. The co-
stimulatory molecule program death ligand 2 and pattern recognition receptors, mannose receptor and dectin-1, 
are highly induced in alternatively activated macrophages. Induction of arginase 1 diverts arginine catabolism 
away from nitric oxide synthesis to that of ornithine and urea. In addition, in a paracrine and autocrine manner, 
alternatively activated macrophages suppress inflammation.  
Abbreviations: IFN-γ, interferon γ; IL, interleukin; LPS, lipopolysaccharide; MHC, major histocompatibility complex; 
MR, mannose receptor; NO, nitric oxide; PD-L, program death ligand; PPAR, peroxisome proliferator-activated 
receptor; ROS, reactive oxygen species; TH, T helper; TNF, tumor necrosis factor.  
 
 
 
The cytokines analysed in the current studies can not all be directly linked to IR. Originally it 
was only intended to determine TNF-α levels in the rat plasma, however, a 6-plex flow 
cytometry kit allowed the simultaneous measurement of other cytokines. 
 
TNF-α 
Tumor necrosis factor alpha has been shown to be one of the most prominent cytokines 
associated with IR and obesity [3,32,42,274]. It is predominantly secreted by monocytes and 
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macrophages and stimulates Ikkb and NFκB signalling via the activation of a membrane TNF-
receptor (figure 5.8) [42]. In addition to the inhibition of the insulin signalling cascade, TNF-α 
also induces gene expression for other inflammatory mediators such as IL-1 and IL-6 [285].  
Surprisingly, there were no significant differences in plasma TNF-α concentrations between 
the LFD and HFD groups in both studies (figures 4.5 a,b and 4.19 a,b). However, HFD rats in 
the prevention study had elevated TNF-α levels at week eight and twelve compared to the 
LFD and HFD+S.f. groups, but this was not significant due to high variation within the 
groups. It should be noted that most of the published data in regard to the association of IR 
and TNF-α was conducted in obese or diabetic individuals, which may explain the 
discrepancies to the present results. However, the current findings are in close agreement with 
data published by Jiao et al. [286]. Male Sprague-Dawley rats fed with HFD showed no 
increase in plasma TNF-α levels for the length of the experiment (28 days), although HOMA-
IR and plasma FFA were significantly increased from day 21. This indicates that circulating 
plasma TNF-α plays a minor role in the development of HFD-induced IR [286], which agrees 
with the unaltered TNF-α levels in liver and adipose tissue of HFD fed mice [26]. Usually 
circulating TNF-α concentrations are regarded as good biomarkers for chronic low grade 
inflammation in obese patients [287] and it is possible that TNF-α becomes a more important 
factor in obesity and late stages of IR. Also, pathologically elevated TNF-α concentrations 
might be more prevalent at adipose tissue level than in the circulation. 
In the prevention study HFD+S.f. rats showed a trend towards improved plasma TNF-α 
concentrations, which were similar to the levels seen in the LFD group at all time points. An 
even stronger effect of S. frutescens on plasma TNF-α levels was seen in the treatment study 
where TNF-α was significantly lower compared to the lean control rats, although there was no 
significant decrease compared to the HFD group. However, it needs to be kept in mind, that 
the TNF-α concentrations at the adipose tissue level might be more relevant than in the 
circulation. The TNF-α levels in the adipose tissue should be determined in future studies. It 
can be speculated that S. frutescens could be involved in a switch in macrophage phenotype 
from M1 (classically activated) to M2 (alternatively activated) via PPAR-γ and –β/δ action, 
whereby M2 macrophages produce no TNF-α (figure 5.9) [41,42]. Also, pinitol, one of the 
several bioactive compounds found in S. frutescens, has been shown to decrease TNF-α and 
IL-1β [144].  
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Somewhat unexpectedly, rats treated with metformin displayed elevated TNF-α levels 
compared to the HFD rats. It has been noted in previous studies that metformin has differential 
effects on plasma TNF-α levels. Metformin increased TNF-α in lean subjects and had no 
effect in obese individuals [282]. It is possible that the lack of true obesity in the HFD rats is 
connected to the current findings. Other studies also failed to note an improvement in 
circulating TNF-α after ten weeks of metformin treatment [283], which could be directly 
linked to unchanged numbers of macrophages in adipose tissue after metformin treatment 
[284]. The high TNF-α concentration seen in the current study may be connected with the low 
glucose uptake in adipose tissue in the HFD+Met rats (figure 4.13). A previous study on 3T3 
adipocytes treated with TNF-α found a decrease in insulin stimulated glucose uptake in 
adipocytes [288], which could explain the decreased adipose glucose uptake in the HFD+Met 
rats.  
 
IL-1α 
Interleukin-1 is a pro-inflammatory cytokine [285] and has been previously connected to β-
cell damage and the development of diabetes [289-291]. Published data does not always 
differentiate between IL-1α and IL-1β. However, it is usually IL-1β that is connected with 
obesity and IR. As mentioned above (figure 5.8) certain cytokines, e.g. TNF-α and circulating 
FFA activate the Ikkb/NFκB and JNK/AP-1 signalling, culminating in the expression and 
secretion of other pro-inflammatory mediators like IL-1β [42]. The 6-plex cytokine assay used 
in the current studies determined IL-1α. Although IL-1α and IL-1β have a low homology 
[292], their biological functions are similar [293,294]. IL-1α is known to be an early acting 
inducer of other inflammatory cytokines including IL-1, IL-6, IL-8 and interferons [295,296]. 
Rats in the HFD group displayed a trend towards elevated IL-1α levels (only significant at 
week four) compared to the lean control rats in both studies (figures 4.5 c,d and 4.19 c,d). 
This finding may indicate the start of a systemic low grade inflammation induced by HFD. Di 
Renzo et al. [297] observed increased plasma IL-1α and IL-1β concentrations in obese women 
compared to non-obese women. The results for IL-1α concentrations in LFD and HFD rats in 
the current treatment study are very similar to those found in the above mentioned study 
(9.5pg/ml LFD vs. 30.8pg/ml HFD and 13.7pg/ml non-obese vs. 32.0pg/ml obese). 
S. frutescens treated rats in the prevention study showed a trend towards attenuated IL-1α 
concentrations in the plasma. PPAR-γ activators suppress the production of IL-1 and have 
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been shown to prevent diabetes in animals [298,299] and it is possible that S. frutescens 
affects IL-1 levels in that manner and therefore may prevent the onset of inflammatory 
processes. Pinitol contained in S. frutescens leaves has also been found to attenuate IL-1β 
levels [144]. However, S. frutescens and metformin had no lowering effects in the treatment 
study. It has been previously published that metformin diminished IL-1β-induced production 
of other pro-inflammatory cytokines [300], but no studies have been published on the effects 
of metformin on plasma Il-1α levels.  
 
 
IL-4 
Interleukin-4 is a type 2 T-helper cell cytokine and has been shown to promote the alternative 
activation of macrophages. Alternatively activated macrophages (M2) have anti-inflammatory 
effects which are exerted via the induction of arginase 1, resulting in lower levels of nitric 
oxide and TNF-α [41] (figure 5.9). Unexpectedly, HFD rats in the prevention and treatment 
study showed higher levels of circulating IL-4 compared to the LFD rats (figures 4.5 e,f and 
4.19 e,f). An explanation for this finding could be a suspected lower activity of PPAR-γ and -
β/δ in the HFD rats. While IL-4 provides the initial signal for M2 activation, PPARs are 
needed to sustain its expression. Further analyses are necessary to obtain evidence for this 
hypothesis. 
Rats in the HFD+S.f. group had somewhat lower plasma IL-4 concentrations compared to 
the HFD rats. This may be explained by a possible activation of PPARs by S. frutescens and 
hence lower amounts of IL-4 would be needed to produce adequate alternative macrophage 
activation.  
Metformin treatment did not appear to influence plasma IL-4 concentrations. This is 
consistent with another study where metformin treatment had no affects on plasma IL-4 in 
pregnant mice [301]. There is no literature available associating IR, metformin and IL-4.  
 
MCP-1 
The chemokine MCP-1 is produced by monocytes and endothelial cells and has been 
previously associated with the obese state. As adipocytes enlarge with elevated TG 
accumulation they secrete large amounts of MCP-1 [275]. MCP-1 acts as a chemo-attractant 
that increases macrophage infiltration into adipose tissue [42,302,303]. Adipocytes and 
 - 159 - 
macrophages then secrete MCP-1, TNF-α, IL-1β and other cytokines as well as chemo-
attractants [32,304]. MCP-1 appears to be directly implicated in IR as it was shown to impair 
insulin stimulated glucose uptake and insulin receptor tyrosine phosphorylation in adipocytes 
in vitro [275]. The increased expression of MCP-1 in epicardial adipose tissue is also directly 
involved in increasing the risk for cardiovascular diseases by increasing inflammatory 
processes in the heart and arteries [305]. There was no apparent difference in the plasma 
MCP-1 levels between rats in the LFD and HFD groups in both studies (figures 4.5 g,h and 
4.19 g,h). It is possible that adipocytes in the HFD rats had not yet reached a critically 
enlarged size and therefore did not increase the secretion of MCP-1.  
Treating rats with S. frutescens had no effect on MCP-1 levels in the prevention study but 
surprisingly increased plasma MCP-1 concentrations in the treatment study. 
Metformin treatment also resulted in elevated MCP-1 levels. This is in contrast to other 
published data where metformin treatment decreased postprandial MCP-1 concentrations in 
patients [306]. However, rats in the current study were in a fasting state, which might explain 
the difference in MCP-1 levels.  
 
GM-CSF 
The physiological function of GM-CSF is to stimulate the differentiation of bone marrow 
myeloid precursor cells into granulocytes, monocytes, macrophages and dendritic cells as well 
as to activate monocytes and macrophages in inflammatory responses (reviewed in [307]). In 
the early stages of inflammation mature myeloid cells produce GM-CSF in response to toll-
like receptor (TLR)-induced activation, IL-6, and IL-1β cytokine signalling [308]. GM-CSF 
then supports the activation of prostaglandin synthase 2/cyclooxygenase 2 (PGS2/COX2) thus 
resulting in pro-inflammatory prostanoid production [309,310]. In the later stages of 
inflammation GM-CSF induces IL-10 production, attenuating inflammatory processes and 
returning the system to homeostasis [311]. In the current studies there was no significant 
difference in GM-CSF plasma concentrations between the LFD and HFD rats (figures 4.5 i,j 
and 4.19 i,j), although a trend towards elevated levels was seen in the treatment study HFD 
group. Plasma GM-CSF concentrations show variable trends in S. frutescens treated rats. 
However data from week twelve in the prevention study and results from the treatment study 
display a tendency towards lowered GM-CSF concentrations. Metformin treated rats had 
slightly decreased GM-CSF levels compared to the HFD rats. Metformin treatment has been 
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previously published to have no effects on liver GM-CSF levels in rats with liver injury [312].  
No connection has been published between the circulating GM-CSF levels during metformin 
treatment of IR or diabetes.  
These results are inconclusive and difficult to compare to published data. To the author’s 
knowledge no previous connection has been established between circulating GM-CSF levels 
and IR.  
 
A persistent state of systemic low grade inflammation was apparently not reached in the 
present studies after twelve or sixteen weeks of HFD, although an increase in IL-1α levels 
points towards pre-inflammatory processes taking place.  
 
 
Mode of action and potential active compounds of S. frutescens 
The hot water extract of S. frutescens contains a number of biologically active compounds and 
the broad effects observed in the current studies are very likely the result of more than one 
pharmacological active compound. Nevertheless, taking all the present findings into account 
one factor appears to stand out as being the apparent mode of action for most of the metabolic 
effects in vivo – the activation of PPAR.  
The increased glucose uptake in HFD rats treated with S. frutescens could be the result of 
elevated GLUT4 expression in skeletal muscle and adipose tissue via PPAR-γ activation 
[313,314], resulting in higher glucose uptake into these tissues.  The activation of PPAR-γ 
could also play a role in differentiation of adipocytes and an increased uptake and storage of 
FFA, lowering the circulating FFA levels [81-83] and improving IR by similar action to TZDs. 
In disagreement with the latter hypothesis is the overall decrease in weight gain in HFD+S.f. 
rats. However, a potential agonistic effect to PPAR-α and –β/δ, rather than PPAR-γ, could 
explain both findings: a decrease in weight and circulating FFA. PPAR-α activators have been 
shown to increase FA-oxidation and hydroxylation [87,88], while PPAR-β/δ ligands lead to 
the disposal of FA via the activation of uncoupling proteins in brown adipose tissue and 
muscle [90,203,204]. A decrease in body weight and fasting insulin levels has been previously 
reported for PPAR-β/δ agonists [92], and similar effects were seen in the present studies. The 
attenuation of fasting plasma TG concentrations in S. frutescens treated rats could derive from 
the agonistic properties to PPAR-α and –β/δ, which led to increased LPL activity and 
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decreased plasma TG in previously conducted studies [201,216,217]. Longer term treatment 
with S. frutescens for eight and twelve weeks resulted in elevated HDL-cholesterol levels, 
which can be explained by a possible increase in apoA1 expression via PPAR-α [92,124]. 
Lower levels of LDL-cholesterol observed in the treatment study agree with other published 
data showing the same effect for PPAR-α and –β/δ agonists [92,201]. Agonists of PPAR-β/δ 
not only show an effect on plasma lipids, but have also been found to ameliorate fat 
accumulation in the liver [241] and to improve total plasma cholesterol levels [90,203], effects 
also observed in the present studies.  S. frutescens has been previously published to have anti-
inflammatory properties by inhibiting the DNA-binding of NFκB and AP-1/Fos [278,279]. 
Current results also showed potential anti-inflammatory effects of S. frutescens in rats by 
attenuating TNF-α and IL-1α levels.  These findings tie in with the current hypothesis of S. 
frutescens as a PPAR agonist or PPAR activator. PPAR-γ activation led to the suppression of 
IL-1 production and has been shown to prevent diabetes in animals [298,299] and several 
PPAR-γ and -α agonists have been noted for their anti-inflammatory properties [82,100] 
(figure 5.3). A variety of mechanisms have been found to be altered via PPAR activation. For 
example, TNF-α and IL-6 secretion was repressed by PPAR-γ agonists in cultured 
macrophages [315] and inhibition of inducible NOS was achieved by repressing AP-1 and 
NFκB activity [316]. PPAR-α agonists also inhibited NFκB, as well as COX2 activity, and 
were found to reduce plasma IL-6 concentrations [317].  
PPARs have a limited number of ligands with long-chain PUFA (AA, LA, EPA) being the 
key activators for PPAR actions [100]. However, in recent years other drugs (e.g. TZDs, L-
tyrosine based insulin sensitizers) and several natural compounds have been identified as 
PPAR-γ agonists [318,319]. Diterpens, flavanoids and phenolic compounds from different 
plants are now known PPAR-γ activators [320-322]. Flavanoids and triterpenoid saponins 
were observed in S. frutescens [129] and may be responsible for the proposed mechanism of S. 
frutescens as a PPAR agonist. Pinitol, an inositol phosphoglycan also contained in S. 
frutescens, has recently been found to have anti-diabetic properties in its pure form, with 
similar action to TZDs. However, one of the key effects of pinitol in vivo was to lower fasting 
blood glucose levels [135], which was not seen in the present studies.  
Furthermore, S. frutescens contains a non-protein amino acid, L-canavanine as a major 
constituent [129]. L-canavanine competes with L-arginine for binding sides on cellular 
enzymes [145] and could therefore limit the substrate for the production of nitric oxide by M1 
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macrophages [41], thus attenuating the development of IR [42] (figures 5.8 and 5.9). 
However, it is unlikely that L-canavanine is the major active compound responsible for the 
alleviation of IR seen in the current studies. Firstly, L-arginine contained in S. frutescens is a 
structural analogue of L-canavanine [129] and with prolonged intake of L-canavanine, 
disruptions of normal enzyme activities [145,146] and toxic effects can be expected, which 
were not seen in the current studies. Tai et al. [144] noted the presence of γ-sitosterol in S. 
frutescens, which could act similar to β-sitosterol. Latter has been shown to phosphorylate and 
thereby activate AMPK in myocytes, which led to decreased cholesterol and TG 
concentrations, as well as increased FA oxidation and GLUT4 translocation [153]. However, 
γ-sitosterol is only present in very small quantities in S. frutescens [144]. 
The triterpenoids found in S. frutescens [129,147] should be given special attention as they 
are likely to act as PPAR agonists. The major triterpenoid isolated from S. frutescens is a 
cycloartane-type triterpene glycoside called SU1 ((24R)-25-β-D-glucopyranosyloxy-3α,7α,24-
trihydroxycycloartane), although at least 56 different triterpenoid glycosides are suspected 
(reviewed in [129]). A very recent study was also able to isolate four new cycloartane 
glycosides [147]. The chemical structure of SU1 is similar to several PPAR agonists (figure 
5.10) and therefore may be the most suitable candidate to act as a general PPAR ligand or co-
activator for the action of PPAR. PPARs form large transcription complexes with RXR and 
co-activators, or co-repressors [94]. This complex then binds to the PPRE at the taget gene to 
control the transcriptional response (figure 1.10). It is unclear in which way the suspected 
active compounds of S. frutescens can influence the heterodimer formation or binding to the 
target gene.   
PPAR agonists are clinically used to treat type 2 diabetes (PPAR-γ) and dyslipidaemia 
(PPAR-α). Recent research also identified PPAR-β/δ as an important regulator of cholesterol 
and lipid metabolism, and in the last five years PPAR-β/δ agonists have been shown to 
increase insulin sensitivity and HDL-cholesterol, as well as decreasing weight gain and 
improving other lipid parameters [92]. This wide range of metabolic effects has led to the 
search for simultaneous PPAR activators, which are also termed pan PPAR agonists. Cantin 
and co-workers were also able to synthesize a pan agonist, named compound 33 (figure 5.10 
e).  Compound 33 was tested in different animal models where anti-diabetic properties and 
positive effects on plasma HDL-cholesterol and TG levels were observed [93].  
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Figure 5.10: Chemical structures of known and suspected PPAR agonists. 
a. SU1, a cycloartane-type triterpene glycoside isolated from S. frutescens (reviewed in [129]); b. Fenofibrate, a 
known PPAR-α agonist [323]; c. Rosiglitazone, a known PPAR-γ agonist [323]; d. Ragaglitazar, a known PPAR-
α and -γ agonist [323]; e. Compound 33 [93], f. Bezafibrate [95] and g. Indeglitazar [96] all three are known pan 
PPAR agonist; h. abietic acid, a diterpene isolated from Conifer species [149]; i. 3-O-β-D-glucopyranosyl-4-
methylerdost-7-en-3-ol, a novel active compound isolated from Liliaceae  [324] 
 
Other pan PPAR agonists include a well known lipid lowering fibric acid derivate 
(bezafibrate, figure 5.10 f), and the newly discovered drugs PLX 204, GW 67795 and DRL 
11605 [reviewed in [94]). Bezafibrate has been successfully shown to improve IR, and inhibit 
atherosclerosis without weight gain [95]. Another novel drug very recently recognized as a 
pan PPAR agonist is indeglitazar (figure 5.10 g), which had positive effects on insulin 
sensitivity, body weight and lipid metabolism in animal trials [96]. Another very interesting 
discovery is the isolation of 3-O-β-D-glucopyranosyl-4-methylerdost-7-en-3-ol from organic 
extracts, hot water extracts and squeezed liquid from plants of the Liliaceae family (Aloe vera 
and others) (figure 5.10 i) [221]. This active compound is currently patented for its effects in 
Compound 33 
Rosiglitazone 
Fenofibrate 
Ragaglitazar 
 SU1  
((24R)-25-β-D-glucopyranosyloxy-3α,7α,24-trihydroxycycloartane)  
3-O-β-D-glucopyranosyl-4-methylerdost-7-en-3-ol 
a. 
c. 
e. 
b. 
d
 
f. g. 
Abietic acid 
h. i. 
Bezafibrate Indeglitazar 
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lowering adipocyte derived FFA, and the subsequent amelioration of IR. However, the direct 
mode of action is not described in the patent application. Interestingly, the structure of the 
patented compound is very similar to the triterpene glycoside SU1 isolated from S. frutescens. 
Terpenoids, contained in many herbs, have been found to activate PPAR-α and -γ resulting in 
anti-inflammatory effects and improvements in lipid metabolism [150]. The diterpene abietic 
acid isolated from Conifer species (figure 5.10 h) has also been found to act as a PPAR-γ 
ligand resulting in anti-inflammatory effects [149]. 
Last, but not least, an emphasis should be put on the substantial amounts of long-chain FA 
observed in three different S. frutescens hot water extracts in the current study. 
Polyunsaturated fatty acids (AA, EPA, LA), MUFA (oleic acid) and SFA (stearic acid, 
palmitic acid) are known endogenous ligands for all three PPAR isoforms [100], thus the FA 
contained in S. frutescens could also act as agonists for PPAR action in vivo.  
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The aim of the study was to investigate the developmental stages of HFD-induced IR, to 
illuminate the pathogenesis of IR with a focal point on modifications in the lipid metabolism. 
Furthermore, the effects of S. frutescens as a treatment or preventative drug for IR and 
associated metabolic changes were examined. 
 
The present study on male Wistar rats observed the development of insulin resistance induced 
by the prolonged intake of HFDs (40kcal% fat) rich in SFA or trans-FA. The first metabolic 
change determined in the pathogenesis of IR was the increase in plasma FFA, already 
noticeable after seven days, leading ultimately to the development of HFD-induced IR after 
eight weeks. The elevated FFA were most likely derived from an increased adipose tissue 
mass and also increased lipolysis of TG-rich chylomicrons and VLDL by endothelial LPL. At 
week eight fasting plasma insulin levels were increased while glucose levels stayed in the 
normal range, resulting in increased HOMA-IR and decreased QUICKI values. Interestingly, 
the BW of HFD rats was unaltered at the onset of IR and only became significantly increased 
at later stages. Insulin resistance was also confirmed by a decreased glucose uptake in liver, 
skeletal muscle and adipose tissue, as well as lowered glucose clearance rate from the blood. 
Associated with the development of IR in the HFD rats were pathological changes in the 
plasma and tissue lipid profiles. Rats in the treatment study displayed hypertriglyceridaemia 
and hypercholesterolemia after sixteen weeks, while rats in the prevention study only had 
significantly increased total plasma cholesterol levels. Pathological changes in the plasma lipid 
profile can be explained by the increased FFA flux to the liver, hyperinsulinemia and 
abnormal metabolic regulations in the liver due to IR. The occurrence of ectopic fat 
accumulation was observed in liver and skeletal muscle tissue, caused by the increased FFA 
flux to the tissues, increased circulating TG-rich VLDL and chylomicrons, as well as 
decreased FA oxidation in the tissues. Looking more closely, it was observed that not only the 
amount of TG, but also cholesterol and FFA were increased in the HFD rats at the liver and 
muscle tissue level. The FA profile of membrane and storage lipids was influenced by the 
dietary FA intake and a decrease in membrane fluidity was determined for muscle, liver and 
adipose tissue membranes. Systemic inflammation was not observed in HFD rats during the 
experimental period of twelve and sixteen weeks, respectively. However, the trend towards 
elevated IL-1α levels in the HFD rats could indicate pre-inflammatory processes taking place 
in the early stages of IR.  
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The widely used medicinal plant S. frutescens was used successfully in the current studies to 
prevent the onset of HFD-induced IR and to reverse pathological changes already established 
in IR-rats. While S. frutescens did not affect glucose levels, fasting plasma insulin 
concentrations were brought back to normal levels, even though rats still received HFD during 
the treatment period. Further investigation pinpointed the attenuation of plasma FFA as the 
key factor to prevent or reverse HFD-induced IR. However, S. frutescens treatment also 
resulted in other important metabolic improvements. The increase in insulin sensitivity was 
not only seen in the improvement of HOMA-IR and QUICK-index but also in the significant 
increase in muscle glucose uptake and the improvement of liver and adipose tissue glucose 
disposal. Blood and tissue lipids negatively affected by HFD and IR were also positively 
altered by the S. frutescens treatment. In detail, total plasma cholesterol levels were attenuated 
in both studies and ectopic lipid accumulation in skeletal muscle tissue was reversed to normal 
levels. The total liver fat content was also decreased, although not significantly. Taking a 
closer look at the tissue lipid fractions, S. frutescens treatment decreased the total FFA and TG 
liver content and total muscle cholesterol content. A higher fluidity was observed in the 
adipose tissue membranes, which was achieved through higher concentrations of AA, DPA 
and total PUFA. Circulating TNF-α levels, although not significantly increased in association 
with the development of IR, were attenuated by S. frutescens treatment. Improvements in the 
pre-inflammatory cytokine IL-1α were also observed in connection with S. frutescens 
treatment.    
 The author proposes that the hot water extract of S. frutescens used contains one or several 
PPAR agonists or co-activators responsible for the multiple metabolic effects observed in the 
current studies. The activation of PPAR-γ through suspected antagonistic compounds or co-
activators in S. frutescens could lead to increased expression of GLUT4, resulting in the 
observed glucose uptake in muscle and adipose tissue. Agonists of PPAR-γ and -α are able to 
lower the synthesis of cytokines and may be responsible for the decreased circulating TNF-α 
and Il-1α levels. PPAR-α and –β/δ activation could be responsible for the improvement of 
plasma and tissue FFA and TG, ultimately leading to the prevention or reversion of IR.  
S. frutescens did not improve all the pathological changes observed in the IR state and 
contradicting results were obtained for some of the parameters in the prevention study and 
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treatment study. For example, plasma HDL-cholesterol, plasma TG and circulating MCP-1 
levels were differently affected by the S. frutescens treatment in the two studies. 
It needs to be kept in mind, that rats receiving S. frutescens in the prevention study were 
younger and did not display pathological alterations induced by the HFD. In contrast, rats in 
the treatment study were twelve weeks older and had fully developed IR with associated 
metabolic changes. Also, the treatment period was only four weeks for the treatment study and 
stronger effects can be expected with prolonged treatment. 
 
Metformin was used as a positive control for the treatment of HFD-induced IR in rats. Even 
though the treatment period was relatively short, significant improvements in the pathological 
changes were expected. However, body weight and fasting plasma insulin levels were not 
significantly decreased by metformin. This was also reflected in only slightly improved 
HOMA-IR and QUICK-index, although glucose uptake in liver and muscle was significantly 
increased. Plasma FFA were significantly attenuated and plasma TG levels slightly decreased. 
Metformin also resulted in a positive shift in plasma cholesterol by increasing HDL-
cholesterol and slightly decreasing LDL-cholesterol. Metformin treatment resulted in 
decreased total lipid contents in all three tissues analysed, with lowered TG and FFA fractions 
in liver and adipose tissue, as well as decreased cholesterol in the skeletal muscle. Like S. 
frutescens, metformin treatment improved the membrane fluidity of adipocytes, with higher 
amounts of AA in the adipose phospholipid fraction. Short term metformin treatment had no 
positive effects on plasma cytokine concentrations and even caused increased TNF-α levels.  
Metformin exerts its effects by increasing AMPK activity, which results in a range of 
different metabolic effects. The current results are in agreement with this mode of action. 
Glucose uptake is stimulated by increased expression of GLUT4 and beta-oxidation of FA is 
increased resulting in lower circulating FFA. The treatment period may have been too short to 
observe the full effects of metformin in vivo. For example, endothelial LPL should be 
activated and SREBP activity should be inhibited by AMPK, resulting in lower plasma TG 
and total cholesterol levels. However, these two parameters were only slightly influenced by 
metformin. 
 
In summary, an animal model for HFD-induced insulin resistance was established using a 
locally available, cost efficient and easily accessible diet. Analysing developmental stages of 
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IR confirmed the detrimental effects of elevated plasma FFA on the glucose metabolism, as 
well as fat metabolism. Obesity and low-grade systemic inflammation did not appear to be the 
causative agents of IR. The current study also took a novel approach, connecting not only 
dyslipidaemia but also changes in tissue lipid profiles to IR. The current studies on the anti-
diabetic properties of S. frutescens not only confirmed its positive outcomes on glucose 
metabolism, but also showed exciting results for the improvement in plasma and tissue lipid 
parameters. A completely new and interesting finding was the prevention of HFD-induced IR 
by S. frutescens supplementation. Metformin as an established anti-diabetic drug was not as 
effective as S. frutescens in ameliorating IR, although several of the lipid parameters were 
similarly affected by both short term treatments. The findings suggest that metformin works 
through different metabolic mechanisms than S. frutescens, with the latter showing promising 
potential as a general PPAR agonist or co-activator. This could make S. frutescens not only a 
suitable herbal remedy for insulin resistance and diabetes, but also for improving pathological 
altered lipid parameters, which are usually associated with the metabolic syndrome.     
 
The current study has confirmed the close interaction of lipid and glucose metabolism in the 
development of IR and has found some novel effects of S. frutescens treatment in vivo. 
However, several questions are still unanswered and should be addressed in future studies. In 
order to examine the state of obesity in rats using BMI, the body length of the animals needs 
to be determined. Furthermore, adipose tissue mass expansion should be examined for 
adipocyte size, fat accumulation, macrophage infiltration and macrophage activation, as well 
as the secretion of pro-inflammatory markers (TNF-α, MCP-1). To gain detailed insight into 
metabolic changes observed for plasma and lipid parameters the gene expression or activation 
of PPARs, AMPK, PGC-1α, SREBP, LPL, CPT-1, HMG-CoA reductase, FA-synthase, FA-
elongases and FA-desaturases should be determined. Information on gene expressions can be 
obtained by RT-PCR analysis, while protein expression and enzymatic functions can be 
analyzed by Western Blot and enzyme assays, respectively. Fatty acid metabolites, such as 
DAG, ceramides and fatty acyl CoA should be determined in addition to the FFA, TG and 
cholesterol fractions already measured. The assessment of a pro-inflammatory state in the 
current study by measuring circulating cytokines was somewhat inconclusive. Future studies 
need to be conducted at tissue level, where local changes in cytokines could be measured. Not 
only pro-inflammatory cytokines, but also several kinases involved in inflammatory signalling 
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pathways need to be examined. This could provide information on the sorce of inflammatory 
changes and confirm the pathological action of FFA on these signalling pathways locally 
within specific tissues. The analysis should investigate activities of Ikkb, JNK, NFkB, iNOS 
and COX-2.  
To gain further evidence for the mode of action of S. frutescens as a ligand or co-activator of 
PPARs, the state of activation of the receptor, heterodimer formation with RXR, as well as 
binding to PPRE should be assessed. Triterpenoids contained in S. frutescens may be the 
active compounds responsible for the effects seen in the present study. To test this hypothesis, 
isolated single triterpenoids or a cocktail of triterpenoids should be assessed for their effects in 
vitro or in vivo. In this way more information could be obtained on the exact mode of action of 
S. frutescens, which may provide insight into new methods of treating IR and the metabolic 
syndrome.  
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Figure 6.1: Summary of metabolic changes between the HFD rats and LFD rats.  
Changes in the grey boxes are observed changes, while the white boxes give a possible mechanisms for the 
alterations observed.  
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Figure 6.2: Summary of metabolic changes between the HFD+S.f. rats and HFD rats.  
Changes in the grey boxes are observed changes, while the white boxes give a possible mechanisms for 
the alterations observed.  
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INTRODUCTION
Diabetes mellitus type 2 (DTM2) is increasingly preva-
lent in children and adults worldwide, and is commonly
caused by high caloric food intake leading to obesity
and insulin resistance (Abbasi et al., 2002; Ebbeling
et al., 2002). Insulin resistance (IR) is a pre-diabetic
state in which target tissues have decreased glucose
uptake and therefore higher amounts of insulin are
needed to maintain normoglycemia (Wang et al., 2004).
In the past decade extensive research has been con-
ducted to investigate the connection between high fat
diet intake, obesity and IR (Mlinar et al., 2007). An
increase in plasma free fatty acid (FFA) levels is a major
factor in the development of IR (Mook et al., 2004),
although other pathophysiological aspects also play a role.
High fat diet-induced obesity causes elevated plasma
FFA levels, which in turn induce several other meta-
bolic changes. In 1963 Randle and co-workers (1963)
proposed the ‘glucose–fatty acid cycle’, whereby in-
creased availability of FFAs leads to more β-oxidation
of FFAs and elevated amounts of acetyl-CoA. Subse-
quently acetyl-CoA inhibits pyruvate dehydrogenase
which results in a decrease in glucose oxidation in the
cell, as well as inhibiting glucose utilization. Elevated
plasma FFAs have since been found to have substan-
tial effects on other metabolic processes. Non-esteriﬁed
fatty acids can stimulate Toll-like receptor 4 (Tlr4),
which in turn activates I kappa b kinase beta (IkKβ).
IkKβ phosphorylates the insulin receptor substrate-1
(IRS1) and therefore inhibits downstream insulin
signaling in target cells (de Luca and Olefsky, 2008).
FFA can also serve as signaling molecules for other
protein kinases, such as protein-kinase C (PKC) and Jun
kinase (JNK) which leads to impaired insulin signaling
in muscle and liver cells (Qatanani and Lazar, 2007).
The liver is further affected by FFA as it receives FFA-
rich blood from the visceral adipose tissue via the portal
vein. In the hepatocyte FFAs are used as a substrate for
increased triglyceride (TG), VLDL-synthesis and glucon-
eogenesis (Ginsberg et al., 2005; Mlinar et al., 2007).
In IR-patients low levels of HDL-cholesterol are
characteristically found (Ginsberg et al., 2005). Insulin
secretion from pancreatic β-cells is directly inﬂuenced
by high levels of plasma FFAs. The binding of FFAs
to the GPR40 receptor, expressed in β-cells and in the
gastrointestinal tract, leads to increased glucose stimu-
lated insulin secretion (Milligan et al., 2006). Other studies
have also found extensive evidence that FFAs directly
inﬂuence basal and glucose mediated insulin secretion
(Carpentier, 2008).
In recent years there has been an increased interest
in the use of medicinal plants, partly due to patients
expecting fewer side effects and lower costs. Further-
more, in remote areas of developing countries the
population has easier access to medicinal plants than
to pharmaceutical preparations.
Sutherlandia frutescens (L.) R.Br. (Fabaceae) is a tradi-
tional South African medicinal plant. The aqueous
extract of the leaves and stems is frequently used to treat
cancer, stomach problems, inﬂuenza, diabetes, inﬂammation
and rheumatism (van Wyk and Albrecht, 2008). Although
S. frutescens has various applications, little scientiﬁc
evidence is available about its effects on the human body.
Previous studies on cell cultures and in animals demon-
strated antioxidative and antiinﬂammatory properties
(Fernandes et al., 2004; Ojewole 2004; Tai et al., 2004).
Studies in vitro have shown that S. frutescens contains
inhibitory compounds that are active against HIV enzymes
and can induce apoptosis in cancer cells (Chinkwo, 2005;
Harnett et al., 2005; Stander et al., 2007). Johnson et al.
(2007) conducted a clinical trial to assess the safety of
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S. frutescens and found no indication of toxicological
effects after 3 months treatment. In recent years only
two studies have conﬁrmed the antidiabetic properties
of S. frutescens. Ojewole (2004) showed a signiﬁcant
increase in glucose uptake in STZ-induced diabetic rats
treated with S. frutescens. A detailed study on high-fat
diet induced insulin resistant rats conﬁrmed this ﬁnding
and showed that S. frutescens extract restored blood
glucose clearance rate and blood insulin levels to normal
(Chadwick et al., 2007). Although these two studies pro-
vide evidence that S. frutescens can be used as a potential
treatment for diabetes, the exact mode of action was
not identiﬁed. It is also not clear from these studies if S.
frutescens can be used as a herbal remedy to prevent the
onset of diabetes. The predominant active compounds
identiﬁed in S. frutescens that are thought to be responsi-
ble for its various biological activities are L-canavinine,
L-arginine, pinitol, γ-aminobutyric acid, asparagines, saponin,
parabens and γ-sitosterol (Sia, 2004; Tai et al., 2004).
The objective of this study was to determine the poten-
tial of an aqueous extract of S. frutescens to prevent the
onset of insulin resistance, and consequently DMT2.
Furthermore the study was used to determine changes
in blood lipid parameters during the development of
high fat diet induced IR and treatment with S. frutescens.
MATERIALS AND METHODS
Animals and experimental design. After weaning, 63
male Wistar rats were evenly divided into three groups.
Group one received a normal diet (ND group) (Harlan
Teklad, TD.06683, Wisconsin, USA) ad libitum. The
normal diet consisted of 20.7% protein, 69.8% carbo-
hydrates and 9.5% fat (expressed as % energy per 100 g).
Rats in group two received a high fat diet (HFD group)
(Harlan Teklad, TD.95217, Wisconsin, USA) ad libitum
which consisted of 18.8% protein, 41.4% carbohydrates
and 39.8% fat (expressed as % energy per 100 g). Group
three also received HFD ad libitum and was given
Sutherlandia frutescens plant extract in the drinking
water (HFD + S.f. group). All rats were housed in an
environmental room with controlled temperature (22 ±
2 °C) and a 12 h light–dark cycle.
Approval for the experiment was obtained by the
animal ethics committee at the Nelson Mandela Metro-
politan University. The animal experiment was conducted
in accordance to the UK Animal Scientiﬁc Procedures
Act 1986 and the associated EEC Directive of 1986
(86/609/EEC).
Medicinal dosage. A commercially available aqueous
extract of Sutherlandia frutescens (subsp. microphylla)
(Pinosundia®, Value Added Life Health Products (Pty)
Ltd, South Africa) was used in the experiment. The
extract was manufactured from the aerial parts of
S. frutescens, grown commercially in the Western Cape
in South Africa.
The dried powdered form of the medication was added
to the drinking water such that rats received a daily
dose of 50 mg/kg body weight (BW). Water consump-
tion was measured daily and the necessary amount of
extract adjusted according to the weights of the rats.
The dosage of 50 mg extract/kg BW was calculated
from a previous study on the antidiabetic effects of S.
frutescens (Chadwick et al., 2007), where 2.5 g leaves
were brewed in 100 mL of boiling water and left over-
night. The tea was given to the rats at a dose of 0.01 mL/
g BW. Extraction experiments showed that the typical
yield from S. frutescens leaves is 20% using this method
(data not shown). Therefore 2.5 g leaves yield 0.5 g
extract diluted in 100 mL water; hence rats received
0.05 g extract/kg BW.
Killing of animals and sampling. The animals were killed
on day 7 (week 1), day 14 (week 2) or day 84 (week 12).
Prior to killing, the animals were starved overnight and
anaesthetized by an intramuscular injection of 3 μL
ketamine/g BW. Blood was removed via heart punc-
ture with a 22 gauge needle without dissecting the animal.
The blood was collected in blood collection tubes con-
taining EDTA and centrifuged at 2000 × g for 20 min.
Plasma was removed and snap frozen in liquid nitrogen
and stored at −80 °C for further analysis. Each animal
was dissected and tissues were snap frozen in liquid
nitrogen and stored at −80 °C for further analysis.
Fasting plasma insulin levels. Insulin was determined
using a radio-labelled immunoassay for rat insulin (Linco,
USA), following the manufacturer’s instruction.
Fasting plasma glucose levels. Plasma glucose levels
were determined using a glucose oxidase assay (Bayer,
Sera-Pak, USA) according to the manufacturer’s
instructions.
Assessment of insulin resistance. To evaluate if the animals
were insulin resistant the quantitative insulin sensitiv-
ity check index (QUICKI) (Katz et al., 2000) and
homeostasis model assessment for insulin resistance
(HOMA–IR) (Matthews et al., 1985) were calculated.
Plasma free fatty acids. The total free fatty acid values in
the plasma were analysed using an enzymatic colorimetric
assay (Roche, Germany), according to the manufacturer’s
instructions.
Plasma lipid parameters. Triglycerides and total cho-
lesterol levels were analysed using enzymatic colorimetric
assays (KAT Medical, South Africa). High density lipo-
protein (HDL)-cholesterol was determined using the same
principle (Shanghai Rongsheng Biotech, China). Assays
were used according to the manufacturer’s instructions.
Low-density lipoprotein (LDL)-cholesterol was calculated
according to the equation of Friedewald et al. (1972).
Statistical analysis. Values are reported as mean ± SEM.
Comparisons between groups were analysed for statis-
tical signiﬁcance using the one-way analysis of variance
(Student’s t-test). Outliers were excluded using Grubbs
test. Values of p < 0.05 were considered signiﬁcant.
RESULTS
Body weight
There was no signiﬁcant weight difference at week 1
and week 2 between the three groups. At week 12 a
signiﬁcantly (p < 0.05) lower mean body weight was
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observed in the group on the normal diet (ND) and the
group medicated with Sutherlandia frutescens (HFD +
S.f.) compared with the high fat diet group (HFD) (data
not shown).
Plasma glucose values, insulin content and
assessment of insulin sensitivity
Fasting plasma glucose levels showed no signiﬁcant
differences between the three groups on all 3 days of
killing (Fig. 1a).
Fasting plasma insulin levels were not signiﬁcantly
different between the three groups at week 1. However,
at week 2 insulin levels were signiﬁcantly lower in the
group treated with S. frutescens compared with the HFD
group (p < 0.025), but not the ND group. No signiﬁcant
difference in blood insulin levels was observed between
the ND group and HFD group in the ﬁrst 2 weeks.
However, after 12 weeks on HFD, the rats showed
signiﬁcantly elevated insulin levels compared with the
ND group (p < 0.05). Rats in the HFD + S.f. group had
signiﬁcantly lower insulin levels than the HFD group
from week 2 (p < 0.025 at week 2 and p < 0.001 at week
12) (Fig. 1b). The rats medicated with S. frutescens did
not display hyperinsulinemia after 12 weeks on HFD,
in contrast to rats fed HFD only.
HOMA-IR and QUCKI were signiﬁcantly altered
in the HFD + S.f. group at week 2 (p < 0.025 for both)
and week 12 (p < 0.025 for HOMA-IR and p < 0.05 for
QUICKI) when compared with the HFD group (Fig. 1c,
d). Only rats in the HFD group displayed signiﬁcantly
decreased insulin sensitivity (elevated HOMA-IR,
lowered QUICK index) at week 12. Rats treated with
S. frutescens showed similar values for HOMA-IR
and QUICKI to the negative control rats (ND group)
(Fig. 1c,d), indicating that treating rats with S. frutescens
prevented high fat induced insulin resistance and main-
tained normal insulin responses.
Plasma free fatty acids
A signiﬁcant increase in plasma free fatty acid levels
was observed when comparing rats on ND and HFD at
week 2 (p < 0.05) and week 12 (p < 0.025), although no
signiﬁcant difference was noted between the ND and
HFD groups at week 1.
At all three time points a signiﬁcant decrease in free
fatty acid levels in the group treated with S. frutescens
was observed when compared with the group fed
HFD only (p < 0.05 at week 1, p < 0.025 at week 2, and
p < 0.025 at week 12) (Fig. 2a).
Plasma triglycerides
Plasma triglyceride (TG) levels in the HFD group were
only signiﬁcantly increased at week 1 in comparison
with the group fed ND (p < 0.05). Rats in the HFD +
Figure 1. Effect of high fat diet and S. frutescens extract on development and prevention of insulin resistance. (a) Fasting plasma
glucose levels. (b) Fasting plasma insulin levels. Assessment of insulin sensitivity by (c) homeostatic model assessment (HOMA-IR)
and (d) quantitative insulin sensitivity check index (QUICKI). ND, normal diet; HFD, high fat diet; HFD + S.f., high fat diet sup-
plemented with 50 mg/kg Sutherlandia frutescens extract. Values are expressed as mean ± SEM (n = 7 rats per group) * p < 0.05,
** p < 0.025, *** p < 0.001, y = vs HFD.
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Figure 2. Changes in blood lipid parameters at weeks 1, 2 and 12. Changes in (a) plasma free fatty acid levels (b) plasma triglycerides
(c) total cholesterol (d) LDL/HDL-cholesterol ratio. ND, normal diet; HFD, high fat diet; HFD + S.f., high fat diet supplemented with
50 mg/kg BW Sutherlandia frutescens extract. Values are expressed as mean ± SEM (n = 7 rats per group). * p < 0.05, ** p < 0.025,
*** p < 0.01, y = vs HFD, z = vs ND.
S.f. group showed a signiﬁcant increase in plasma TG
at all three time points compared with the ND (p < 0.05
at week 1, 2 and 12). However, there was no signiﬁcant
difference in the plasma TG levels between the HFD
group and the HFD + S.f. group (Fig. 2b).
Plasma cholesterol
No signiﬁcant difference in total cholesterol levels was
noted between the HFD group and the HFD + S.f. group
at week 1 and week 2. However, there was a signiﬁcant
decrease in total cholesterol at week 12 in the group
treated with S. frutescens, compared with the HFD
group (p < 0.05) (Fig. 2c).
At weeks 1 and 2 rats in the HFD + S.f. group showed
a signiﬁcantly elevated LDL/HDL-ratio compared with
the HFD group (p < 0.001 and p < 0.025, respectively)
(Fig. 2d). This ratio signiﬁcantly decreased at week
12 (p < 0.025) and also became signiﬁcantly lower than
the ratio of the ND group (p < 0.001). It appears that
long term treatment with S. frutescens decreased total
cholesterol levels and improved the LDL/HDL-ratio
towards HDL-cholesterol.
DISCUSSION
Several studies have conﬁrmed the link between high
caloric food intake, obesity and the development of
insulin resistance (Mlinar et al., 2007). Aqueous extracts
of Sutherlandia frutescens, a traditional South African
plant, have been successfully used to normalize the
symptoms of insulin resistance and the plant is thought
to be a promising treatment for DMT2 (Chadwick
et al., 2007). Very little is known as to the mechanism
of action of S. frutescens. There are no studies to our
knowledge that have established the preventative
effects of S. frutescens in regard to the development of
IR and DMT2. In the present study a commercially
available high fat diet was used to establish a model for
insulin resistance. Rats were killed at different times
during the feeding regime to gain insight into the
developmental progression of IR. Rats fed the high fat
diet with S. frutescens extract added to their drinking
water were compared with rats on the high fat diet
only, or the normal diet. This study evaluated whether
S. frutescens can prevent the negative metabolic effects
of high caloric food intake and the onset of insulin
resistance.
After 12 weeks of feeding, the rats on the HFD had
a signiﬁcantly higher weight compared with the two
other groups.
Normal fasting glucose levels (normoglycemia) are
displayed in healthy, as well as insulin resistant, indivi-
duals. The onset of insulin resistance can only be seen
when basal plasma insulin values are determined. To
maintain normoglycemia, the pancreas has to release
higher amounts of insulin to achieve the same glucose
uptake into tissues (Pirola et al., 2004). In agreement
with these ﬁndings, rats in all three groups showed
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be seen if those changes can be prevented by S.
frutescens.
Diabetic dyslipidemia is a typical pathophysiological
feature in DMT2. This includes high levels of TG and
low levels of HDL-cholesterol, while LDL-cholesterol stays
within normal levels. Insulin resistant patients already
show very similar lipid proﬁles to DMT2 patients (Ginsberg,
1991; Ginsberg, 2000). The present study found early
elevated levels of plasma TG in the HFD group and
HFD + S.f. group (week 1). This difference was reduced
as the feeding continued, and TG levels became similar
in the ND and HFD groups. Unexpectedly, rats on HFD
medicated with S. frutescens displayed higher TG levels
than rats on the ND (Fig. 2b). These ﬁndings suggest
that elevated plasma TG levels are not necessarily con-
nected with the development of insulin resistance in
rats. Further investigation is necessary to determine the
inﬂuence of plasma TG upon insulin resistance.
Total cholesterol levels were increased in rats fed
HFD and medicated with S. frutescens compared with
rats on ND at week 1. However, it appeared that chronic
medication with S. frutescens decreased cholesterol
levels signiﬁcantly by week 12, compared with the HFD
group (Fig. 2c).
Often in patients with DMT2 the LDL/HDL ratio is
lowered (Ginsberg, 1991). Surprisingly, the LDL/HDL-
ratio of the rats fed HFD and treated with S. frutescens
was elevated in the early stages (weeks 1 and 2) but
showed a signiﬁcant sharp decline at week 12 compared
with the HFD group (Fig. 2d). This may reﬂect the
time taken for the beneﬁcial action of S. frutescens to
stabilize the homeostatic controls for blood cholesterol.
Currently little is understood about how S. frutescens
modiﬁes pathways of fat metabolism and further re-
search is needed to study changes in gene expression
and enzyme activities. Ongoing PCR array analysis
of diabetes associated genes in an insulin resistant
human hepatocyte cell line has shown that S. frutescens
can modify a number of genes involved in fat metabo-
lism (Williams et al., 2008). Work is in progress to
determine if the same changes in gene expression
occur in the in vivo model.
CONCLUSION
S. frutescens can inhibit the development of high-fat
diet induced insulin resistance in rats. It is proposed
that S. frutescens is able to do so by averting the increase
in plasma free fatty acids that usually precedes IR. As
a consequence of the low levels of circulating FFA,
tissues do not develop insulin resistance and fasting
insulin levels stay within the normal range. In addition,
chronic S. frutescens treatment lowers total cholesterol
levels, and the LDL/HDL-ratio in high fat diet fed rats.
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stable fasting blood glucose levels at all three time points
(Fig. 1a). Analysis of fasting insulin levels in correspond-
ing plasma samples, gave higher values in the HFD
group compared with the ND group, with the insulin
level signiﬁcantly increased in the HFD group at week
12. Rats on HFD and treated with S. frutescens extract
exhibited signiﬁcantly decreased insulin values from
week 2. These levels were continuously depressed until
the end of the experiment (week 12) (Fig. 1b). Chadwick
et al. (2007) also observed decreasing insulin levels
in insulin resistant rats treated with S. frutescens. To
determine the onset of insulin resistance, fasting plasma
glucose and insulin values were used to calculate HOMA-
IR and QUICK-index (Katz et al., 2000, Matthews
et al., 1985). Both indices conﬁrmed that after 12 weeks
on HFD rats had become signiﬁcantly less insulin
sensitive compared with the rats on ND. Interestingly,
rats on HFD and treated with S. frutescens showed
an increase in insulin sensitivity already at week 2, com-
pared with the HFD group, with very similar insulin
sensitivity to that of rats on a normal diet (Fig. 1c, d).
Elevated circulating free fatty acid levels are the link
between high caloric food intake and the development
of insulin resistance (Kovacs and Stumvoll, 2005). The
present study focused on the effects of high fat diet and
S. frutescens on free fatty acid levels and other blood
lipid parameters.
High caloric food intake has been found to cause
an increase in visceral fat, which in turn releases free
fatty acids into the blood stream (Mlinar et al., 2007).
Alternatively the increased lipolysis of chylomicrons
by lipoprotein lipase (Bickerton et al., 2007) and the
increased expression of sterol regulatory element bind-
ing protein 1c (SREBP-1c) in the liver (Matsuzawa-
Nagata et al., 2008) can lead to an FFA-overspill into
the blood stream. The elevation of plasma FFA seems
to be the trigger for several metabolic changes leading
to insulin resistance. This process is very complex and
still not fully understood.
In our rat model there was an early elevation in FFA
(week 2) before the development of IR (week 12) in
the high fat diet rats. In addition, the increase of plasma
FFA in the HFD group was seen before an increase in
body weight. S. frutescens averts the elevation of free
fatty acids in the blood stream and thus prevents the
development of IR in peripheral tissues. The levels of
FFA after 12 weeks of treatment became signiﬁcantly
lower compared with the group fed with ND (Fig. 2a).
As a possible explanation for these ﬁndings we propose
that S. frutescens might act in the same way as thiazoli-
dinediones (TZDs) by binding to the peroxisome
proliferator-activated receptor (PPAR) γ, which reduces
adipogenic proliferation. This would modulate intracel-
lular FFA metabolism, and thus decrease the release of
FFA from visceral adipose tissue (Kovacs and Stumvoll,
2005).
However, TZDs are known to decrease plasma trigly-
ceride levels, which was not observed in the present study.
Currently studies are in progress to measure changes
in PPARγ in different fat deposits. These show that
young rats are especially sensitive to high fat diet
induced changes (Dealtry et al., 2008). It remains to
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